_
il de
200
100
199
ion in
, was fair half of fine pour hair
\$

FORM PTO-139 (P.EV. 9-2001)	90 U.S. DEPARTMENT OF COM	imerce patent and trademark office	ATTORNEY 'S DOCKET NUMBER					
TF	RANSMITTAL LETTER	REG 710-A-US						
	DESIGNATED/ELECT	U.S. APPLICATION NO. (If known, see 37 CFR 15						
1		NG UNDER 35 U.S.C. 371	пот 1 = 0 куби 0 0 9 8 5 2					
1	ATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE May 23, 2000	PRIORITY DATE CLAIMED June 8, 1999					
	WIND OF THE PROPERTY.							
AND METHODS OF MAKING AND USING THEREOF								
APPLICANT(S) FOR DO/EO/US								
Nicholas J. Papadopoulos, Samuel Davis, and George D. Yancopoulos Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include								
items (5), (6), (9) and (21) indicated below. 4. The US has been elected by the expiration of 19 months from the priority date (Article 31).								
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
a. is attached hereto (required only if not communicated by the International Bureau).								
b. has been communicated by the International Bureau.								
c. x is not required, as the application was filed in the United States Receiving Office (RO/US).								
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto.								
b. X has been previously submitted under 35 U.S.C. 154(d)(4).								
7. X Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3))								
a. are attached hereto (required only if not communicated by the International Bureau).								
b. have been communicated by the International Bureau.								
c. have not been made; however, the time limit for making such amendments has NOT expired.								
d.								
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).								
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
10. An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
Items 11 to 20 below concern document(s) or information included:								
11.	An Information Disclosure Statement	ent under 37 CFR 1.97 and 1.98.						
12.	An assignment document for recor	ding. A separate cover sheet in compliance	with 37 CFR 3.28 and 3.31 is included.					
13. X	A FIRST preliminary amendment.							
14.	A SECOND or SUBSEQUENT preliminary amendment.							
15.	A substitute specification.							
16.	A change of power of attorney and/or address letter.							
17. 🛚 🗙	A computer-readable form of the s	equence listing in accordance with PCT Rule	: 13ter.2 and 35 U.S.C. 1.821 - 1.825.					
18.	A second copy of the published in	ternational application under 35 U.S.C. 154(o	i)(4).					
19. 🗌	A second copy of the English lang	uage translation of the international applicati	on under 35 U.S.C. 154(d)(4).					
20. X	Other items or information: Express Mail Label No. ET712522493US dated December 6, 2001							

i i
100
THE ROLL STATE
I
FL
- 100
=

U.S. APPLICATION NO (IF LOOK	7009852	TERNATIONAL APPLICATION NO		ATTORNEY'S DO					
pr		REG 710-A-US CALCULATIONS PTO USE ONLY							
	ing fees are submitted:	CALCULATIONS	TIO OSE ONEI						
BASIC NATIONAL Neither internations									
nor international se	earch fee (37 CFR 1.445); earch Report not prepare								
International prelim USPTO but Interna	ninary examination fee (3 ational Search Report pre								
International prelim but international sea	ninary examination fee (3 arch fee (37 CFR 1.445(a								
International prelim	ninary examination fee (3 ot satisfy provisions of PC								
International prelim	ninary examination fee (3 fied provisions of PCT A								
ENTE	R APPROPRIATE	\$ 740.00							
Surcharge of \$130.0 months from the ear	0 for furnishing the oath liest claimed priority date	\$							
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$					
Total claims	154 - 20 =	134	x \$18.00	\$ 2,412.					
Independent claims	5 - 3 =	2	x \$84.00	\$ 168.					
MULTIPLE DEPEN	DENT CLAIM(S) (if app	plicable)	+ \$280.00	\$ 280.					
	TOTAL C	F ABOVE CALCU	LATIONS =	\$ 3,600					
Applicant claim are reduced by		e 37 CFR 1.27. The fees	indicated above +	\$					
		St	JBTOTAL =	\$ 3,600.					
Processing fee of \$1 months from the ear	30.00 for furnishing the liest claimed priority date	English translation later the (37 CFR 1.492(f)).	nan 20 30	\$					
		\$ 3,600.							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +									
		TOTAL FEES E	NCLOSED =	\$ 3,600.					
				Amount to be refunded:	\$				
				charged:	\$				
a. A check in the amount of \$ to cover the above fees is enclosed.									
b. X Please char A duplicate	b. X Please charge my Deposit Account No. 18-0650 in the amount of \$ 3,600. to cover the above fees. A duplicate copy of this sheet is enclosed.								
c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any									
overpayment to Deposit Account No. 18-0650 . A duplicate copy of this sheet is enclosed. d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card									
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.									
SEND ALL CORRESP	ONDENCE TO:		Al a of	an Australia	1				
Linda O. Palla			SIGNATIO	<u>a V. Jallas</u> RE	2/1/01				
Patent Agent	/ //	40101							
Regeneron Phan	rmaceuticals, Inc. ill River Road	<u>Linda 0</u> NAME	. Palladino						
Tarrytown, New	v York 10591								
			45,636	ATION NUMBER					
		ATION NOWBEK							

10/009852 AND RECYPTO 06 DEC 2001

Att. Docket No. REG 710-A-US

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, Washington, D.C. 20231.

XLIAD: / allaleno Linda O. Palladino

December 6, 2001

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of

Nicholas J. Papadopoulos, Samuel

Davis, and George D. Yancopoulos

USSN

:

Not Yet Known

Filed

Filed Herewith

Int'l File No.

•

PCT/US00/14142

Int'l File Date

May 23, 2000

For

MODIFIED CHIMERIC POLYPEPTIDES

WITH IMPROVED PHARMACOKINETIC

PROPERTIES AND METHODS OF MAKING AND USING THEREOF

December 6, 2001

Commissioner for Patents U.S. Patent and Trademark Office Washington, D.C. 20231

Att:

PRELIMINARY AMENDMENT

Sir:

This paper is submitted in connection with the above-identified application. Prior to examination of the application on the merits, please amend the specification as follows:

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

In the Claims:

Please replace Claim 9, starting on page 92, line 20, through page 93, line 10 with the following:

- 9. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding a modified Flt1 receptor fusion polypeptide, wherein the coding region of the nucleic acid molecule consists of a nucleotide sequence selected from the group consisting of:
- (a) the nucleotide sequence set forth in Figure 13A-13D (SEQ ID NOS: 3 and 4);
- (b) the nucleotide sequence set forth in Figure 14A-14C (SEQ ID NOS: 5 and 6);
- (c) the nucleotide sequence set forth in Figure 15A-15C (SEQ ID NOS: 7 and 8);
- (d) the nucleotide sequence set forth in Figure 16A-16D (SEQ ID NOS: 9 and 10);
- (e) the nucleotide sequence set forth in Figure 21A-21C (SEQ ID NOS: 11 and 12);
- (f) the nucleotide sequence set forth in Figure 22A-22C (SEQ ID NOS: 13 and 14);
- (g) the nucleotide sequence set forth in Figure 24A-24C (SEQ ID NOS: 15 and 16); and
- (h) a nucleotide sequence which, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a), (b), (c),

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

(d), (e), (f), or (g) and which encodes a fusion polypeptide molecule having the biological activity of the modified Flt1 receptor fusion polypeptide.

Please replace Claim 22, starting on page 95, line 1, with the following:

22. (Amended) A fusion polypeptide encoded by the nucleic acid sequence set forth in Figure 10A-10D (SEQ ID NOS: 1 and 2) or Figure 24A-24C (SEQ ID NOS: 15 and 16), which has been modified by acetylation or pegylation.

Please replace Claim 49, starting on page 98, line 24, through page 99, line 8, with the following:

- 49. (Amended) An fusion polypeptide comprising an amino acid sequence of a modified Flt1 receptor, wherein the amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence set forth in Figure 13A-13D (SEQ ID NOS: 3 and 4);
- (b) the amino acid sequence set forth in Figure 14A-14C (SEQ ID NOS: 5 and 6);
- (c) the amino acid sequence set forth in Figure 15A-15C (SEQ ID NOS: 7 and 8);
- (d) the amino acid sequence set forth in Figure 16A-16D (SEQ ID NOS: 9 and 10);
- (e) the amino acid sequence set forth in Figure 21A-21C (SEQ ID NOS: 11 and 12)

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

(f) the amino acid sequence set forth in Figure 22A-22C (SEQ ID NOS: 13 and 14); and

(g) the amino acid sequence set forth in Figure 24A-24C (SEQ ID

NOS: 15 and 16).

In the Specification:

Please replace the paragraph starting on page 1, line 5, with the following:

The application claims priority of International Application No. PCT/US00/14142, filed May 23, 2000, which claims priority of U.S. Provisional Application No. 60/138,133, filed on June 8, 1999. Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application.

Please replace the paragraph starting on page 11, line 15, through page 12, line 1, with the following:

Preferred embodiments include an isolated nucleic acid molecule comprising a nucleotide sequence encoding a modified Flt1 receptor fusion polypeptide, wherein the coding region of the nucleic acid molecule consists of a nucleotide sequence selected from the group consisting of (a) the nucleotide sequence set forth in Figure 13A-13D (SEQ ID NOS; 3 and 4);

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

- (b) the nucleotide sequence set forth in Figure 14A-14C (SEQ ID NOS: 5 and 6);
- (c) the nucleotide sequence set forth in Figure 15A-15C (SEQ ID NOS: 7 and 8);
- (d) the nucleotide sequence set forth in Figure 16A-16D (SEQ ID NOS: 9 and 10);
- (e) the nucleotide sequence set forth in Figure 21A-21C (SEQ ID NOS: 11 and 12);
- (f) the nucleotide sequence set forth in Figure 22A-22C (SEQ ID NOS: 13 and 14);
- (g) the nucleotide sequence set forth in Figure 24A-24C (SEQ ID NOS: 15 and 16); and
- (h) a nucleotide sequence which, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a), (b), (c), (d),
- (e), (f), or (g) and which encodes a fusion polypeptide molecule having the biological activity of the modified Flt1 receptor fusion polypeptide.

Please replace the paragraph starting on page 13, line 6, with the following:

Additional embodiments include a fusion polypeptide encoded by the nucleic acid sequence set forth in Figure 10A-10D (SEQ ID NOS: 1 and 2) or Figure 24A-24C (SEQ ID NOS: 15 and 16), which has been modified by acetylation or pegylation wherein the acetylation is accomplished with at least about a 100 fold molar excess of acetylation reagent or wherein

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

acetylation is accomplished with a molar excess of acetylation reagent ranging from at least about a 10 fold molar excess to about a 100 fold molar excess or wherein the pegylation is 10K or 20K PEG.

Please replace the paragraph starting on page 15, line 19, with the following:

Preferred embodiments include a fusion polypeptide comprising an amino acid sequence of a modified Flt1 receptor, wherein the amino acid sequence selected from the group consisting of (a) the amino acid sequence set forth in Figure 13A-13D (SEQ ID NOS: 3 and 4); (b) the amino acid sequence set forth in Figure 14A-14C (SEQ ID NOS: 5 and 6); (c) the amino acid sequence set forth in Figure 15A-15C (SEQ ID NOS: 7 and 8); (d) the amino acid sequence set forth in Figure 16A-16D (SEQ ID NOS 9 and 10); (e) the amino acid sequence set forth in Figure 21A-21C (SEQ ID NOS: 11 and 12); (f) the amino acid sequence set forth in Figure 22A-22C (SEQ ID NOS: 13 and 14) and (g) the amino acid sequence set forth in Figure 24A-24C (SEQ ID NOS: 15 and 16).

Please replace the paragraph starting on page 19, line 11, with the following:

Figure 10A-10D (SEQ ID NOS: 1 and 2). Nucleic acid (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO: 2) of Flt1(1-3)-Fc.

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

Please replace the paragraph starting on page 19, line 16, with the following:

Figure 13A-13D (SEQ ID NOS: 3 and 4). Nucleic acid (SEQ ID NO: 3) and deduced amino acid sequence (SEQ ID NO: 4) of Mut1: $Flt1(1-3_{AB})$ -Fc.

Please replace the paragraph starting on page 19, line 22, with the following:

Figure 14A-14 C (SEQ ID NOS: 5 and 6). Nucleic acid (SEQ ID NO: 5) and deduced amino acid sequence (SEQ ID NO: 6) of Mut2: Flt1(2- $3_{\Delta B}$)-Fc.

Please replace the paragraph starting on page 19, line 25, with the following:

Figure 15A-15C (SEQ ID NOS: 7 and 8). Nucleic acid (SEQ ID NO: 7) and deduced amino acid sequence (SEQ ID NO: 8) of Mut3: Flt1(2-3)-Fc.

Please replace the paragraph starting on page 20, line 1 with the following:

Figure 16A-16D (SEQ ID NOS. 9 and 10). Nucleic acid (SEQ ID NO: 9) and deduced amino acid sequence (SEQ ID NO: 10) of Mut4: Flt1(1-3_{R->N})-Fc.

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

Please replace the paragraph starting on page 21, line 16, with the following:

Figure 21A-21C (SEQ ID NOS: 11 and 12). Nucleotide (SEQ ID NO: 11) and deduced amino acid sequence (SEQ ID NO: 12) of the modified Flt1 receptor termed Flt1D2.Flk1D3.Fc△C1(a).

Please replace the paragraph starting on page 21, line 19, with the following:

Figure 22A-22C (SEQ ID NOS: 13 and 14). Nucleotide (SEQ ID NO: 13) and deduced amino acid sequence (SEQ ID NO: 14) of the modified Flt1 receptor termed Flt1D2.VEGFR3D3.FcΔC1(a).

Please replace the paragraph starting on page 22, line 1, with the following:

Figure 24A-24C (SEQ ID NOS: 15 and 16). Nucleotide (SEQ ID NO: 15) and deduced amino acid sequence (SEQ ID NO: 16) of the modified Flt1 receptor termed VEGFR1R2-FcΔC1(a).

Please replace the paragraph starting on page 25, line 18, with the following:

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

Figure 36 (SEQ ID NO: 17). Peptide mapping and glycosylation analysis. The disulfide structures and glycosylation sites in Flt1D2.Flk1D3.FcΔC1(a) were determined by a peptide mapping method. There are a total of ten cysteines in Flt1D2.Flk1D3.FcΔC1(a); six of them belong to the Fc region. Cys27 is disulfide bonded to Cys76. Cys121 is disulfide bonded to Cys 182. The first two cysteines in the Fc region (Cys211 and Cys214) form an intermolecular disulfide bond with the same two cysteines in another Fc chain. However, it can not be determined whether disulfide bonding is occurring between same cysteines (Cys211 to Cys211, for example) or between Cys211 and Cys214. Cys216 is disulfide bonded to Cys306. Cys 352 is disulfide bonded to Cys410. Please replace the paragraph starting on page 49, line 25, through page 51, line 12, with the following:

Based on the observation that acetylated Flt1(1-3)-Fc, which has a pl below 6, has much better pharmacokinetics than the highly positive unmodified Flt1(1-3)-Fc (pl > 9.3), it was asked whether the difference in pharmacokinetics could be attributed to the net charge of the protein, which made it stick to negatively charged extracellular matrix components, or whether there were perhaps specific locations on the surface of the Flt1(1-3)-Fc protein that constituted specific binding sites for extracellular matrix components. For example, many proteins are known to have heparin binding sites, often consisting of a cluster of basic residues. Sometimes these residues are found in a cluster on the primary sequence of the protein; some of the literature has identified "consensus"

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

sequences" for such heparin binding sites (see for example Hileman, et al., 1998, Bioessays 20(2):156-67). In other cases, the known crystal structure of a protein reveals a cluster of positively charged residues on the surface of a protein, but the residues come from different regions of the primary sequence and are only brought together when the protein folds into its tertiary structure. Thus it is difficult to deduce whether an isolated amino acid residue forms part of a cluster of basic residues on the surface of the protein. However, if there is a cluster of positively charged amino acid residues in the primary sequence, it is not unreasonable to surmise that the residues are spatially close to one another and might therefore be part of an extracellular matrix component binding site. Flt1 receptor has been studied extensively and various domains have been described (see for example Tanaka et al., 1997, Jpn. J. Cancer Res 88:867-876). Referring to the nucleic acid and amino acid sequence set forth in Figure 10A-10D (SEQ ID NOS: 1 and 2) of this application, one can identify the signal sequence for secretion which is located at the beginning of the sequence and extends to the glycine coded for by nucleotides 76-78. The mature protein begins with Ser-Lys-Leu-Lys (SEQ ID NO: 35), starting at nucleotide 79 of the nucleic acid sequence. Flt1 Ig domain 1 extends from nucleotide 79 to 393, ending with the amino acids Ser-Asp-Thr. Flt1 Ig domain 2 extends from nucleotide 394 to 687 (encoding Gly-Arg-Pro to Asn-Thr-Ile), and Flt1 Ig domain 3 extends from nucleotides 688 to 996 (encoding Ile-Asp-Val to Asp-Lys-Ala). There is a bridging amino acid sequence, Gly-Pro-Gly, encoded by nucleotides 997-1005, followed by the nucleotide sequence

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

encoding human Fc (nucleotides 1006-1701 or amino acids Glu-Pro-Lys to Pro-Gly-Lys-stop).

Please replace the paragraph starting on page 51, line 14, through page 52, line 16, with the following:

A more detailed analysis of the Flt1 amino acid sequence reveals that there is a cluster, namely, amino acid residues 272-281 (KNKRASVRR [SEQ ID NO: 36]) of Figure 10A-10D (SEQ ID NOS: 1 and 2), in which 6 out of 10 amino acid residues are basic. This sequence is located in Flt1 Ig domain 3 of the receptor (see Figure 11), which is not itself essential for binding of VEGF ligand, but which confers a higher affinity binding to ligand. An alignment of the sequence of Ig domain 3 with that of Ig domain 2 reveals that in this region, there is very poor alignment between the two Ig domains, and that there are about 10 additional amino acids in Ig domain 3. An analysis of the hydrophilicity profiles (MacVector computer software) of these two domains clearly indicates the presence of a hydrophilic region in the protein (Figure 12A-12B). These observations raised the possibility that the actual three dimensional conformation of Flt1 Ig domain 3 allowed for some type of protrusion that is not in Flt1 Ig domain 2. To test this hypothesis, the 10 additional amino acids were deleted and the resulting protein was tested to see whether the deletion would affect the pharmacokinetics favorably without seriously compromising the affinity of the receptor for VEGF. This DNA construct, which was constructed using standard molecular biology techniques (see

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

e.g., Molecular Cloning, A Laboratory Manual (Sambrook, et al., Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY) in the mammalian expression vector pMT21 (Genetics Institute, Inc., Cambridge, MA), is referred to as Mut1: Flt1(1-3 $_{\Delta B}$)-Fc. The Mut1: Flt1(1-3 $_{\Delta B}$)-Fc construct was derived from Flt1(1-3)-Fc by deletion of nucleotides 814-843 (set forth in Figure 10A-10D [SEQ ID NOS: 1 and 2]), which deletes the highly basic 10-amino acid residue sequence Lys-Asn-Lys-Arg-Ala-Ser-Val-Arg-Arg-Arg (SEQ ID NO: 32) from Flt1 Ig domain 3.

Please replace the paragraph starting on page 52, line 18, with the following:

The final DNA construct was sequence-verified using an ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, CA). The sequence of Mut1: Flt1(1-3 $_{\Delta B}$)-Fc is set forth in Figure 13A-13D (SEQ ID NOS: 3 and 4).

Please replace the paragraph starting on page 53, line 4, with the following:

A second deletion mutant construct, designated Mut2: Flt1($2-3_{\Delta B}$)-Fc, was derived from the Mut1: Flt1($1-3_{\Delta B}$)-Fc construct by deletion of Flt1 Ig domain 1 encoded by nucleotides 79-393 (see Figure 10A-10D [SEQ ID

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

NOS: 1 and 2]); for convenience, nucleotides 73-78 (TCA GGT) were changed to TCC GGA. This introduced a restriction site (BspE1) without altering the associated amino acid sequence, Ser-Gly. This DNA construct, which was constructed using standard molecular biology techniques (see e.g., Molecular Cloning, A Laboratory Manual (Sambrook, et al., Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY) in the mammalian expression vector pMT21 (Genetics Institute, Inc., Cambridge, MA), was also sequence-verified using an ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, CA). The sequence of Mut2: Flt1(2-3 $_{\Delta B}$)-Fc is set forth in Figure 14A-14C (SEQ ID NOS: 5 and 6).

Please replace the paragraph starting on page 53, line 23, through page 54, line 4, with the following:

A third deletion mutate construct, designated Mut3: Flt1(2-3)-Fc, was constructed the same way as the Mut2: Flt1(2-3 $_{\Delta B}$)-Fc construct, except that Flt1 Ig domain 3 was left intact (the basic region amino acids were not deleted). The construct was constructed using standard molecular biology techniques and the final construct was sequence-verified as described *supra*. The sequence of Mut3: Flt1(2-3)-Fc is set forth in Figure 15A-15C (SEQ ID NOS: 7 and 8).

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

Please replace the paragraph starting on page 54, line 9, with the following:

A final construct was made in which a N-glycosylation site was introduced into the middle of the basic region of Flt1 Ig domain 3. This construct was designated Mut4: Flt1(1-3 $_{R->N}$)-Fc and was made by changing nucleotides 824-825 from GA to AC, consequently changing the coded Arg residue (AGA) into an Asn residue (AAC) (see Figure 10A-10D [SEQ ID NOS: 1 and 2]). The resulting amino acid sequence is therefore changed from Arg-Ala-Ser to Asn-Ala-Ser, which matches the canonical signal (Asn-Xxx-Ser/Thr) for the addition of a N-glycosylation site at the Asn residue. The sequence of Mut4: Flt1(1-3 $_{R->N}$)-Fc is set forth in Figure 16A-16D (SEQ ID NOS: 9 and 10).

Please replace the paragraph starting on page 60, line 4, with the following:

5': bsp/flt1D2 (5'-GACTAGCAGTCCGGAGGTAGACCTTTCGTAGAGATG-3' [SEQ ID NO: 18])

Please replace the paragraph starting on page 60, line 6, with the

3': Flt1D2.VEGFR3D3.as(TTCCTGGGCAACAGCTGGATATCTATGATTGTA TTGGT [SEQ ID NO: 19])

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

Please replace the paragraph starting on page 60, line 8, with the following:

The 5' amplification primer encodes a BspE1 restriction enzyme site upstream of Ig domain 2 of Flt1, defined by the amino acid sequence GRPFVEM (SEQ ID NO: 20) (corresponding to amino acids 27-33 of Figure 21A-21C [SEQ ID NOS: 11 and 12]). The 3' primer encodes the reverse complement of the 3' end of Flt1 Ig domain 2 fused directly to the 5' beginning of Flk1 Ig domain 3, with the fusion point defined as TIID (SEQ ID NO: 37) of Flt1 (corresponding to amino acids 123-126 of Figure 21A-21C [SEQ ID NOS: 11 and 12]) and continuing into VVLS (SEQ ID NO: 38) (corresponding to amino acids 127-130 of Figure 21A-21C [SEQ ID NOS: 11 and 12]) of Flk1.

Please replace the paragraph starting on page 60, line 20, with the following:

5': Flt1D2-Flk1D3.s (5'-ACAATCATAGATGTGGTTCTGAGTCCGTCTCATG G-3' [SEQ ID NO: 21])

Please replace the paragraph starting on page 60, line 23, with the following:

3': Flk1D3/apa/srf.as (5'-GATAATGCCCGGGCCCTTTTCATGGACCCTGAC AAATG-3' [SEQ ID NO: 22])

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

Please replace the paragraph starting on page 61, line 1, with the following:

The 5' amplification primer encodes the end of Flt1 Ig domain 2 fused directly to the beginning of Flk1 Ig domain 3, as described above. The 3' amplification primer encodes the end of Flk1 Ig domain 3, defined by the amino acids VRVHEK (SEQ ID NO: 23) (corresponding to amino acids 223-228 of Figure 21A-21C [SEQ ID NOS: 11 and 12]), followed by a bridging sequence that includes a recognition sequence for the restriction enzyme Srf1, and encodes the amino acids GPG. The bridging sequence corresponds to amino acids 229-231 of Figure 21A-21C (SEQ ID NOS: 11 and 12).

Please replace the paragraph starting on page 61, line 10, with the following:

After a round of PCR amplification to produce the individual domains, the products were combined in a tube and subjected to a further round of PCR with the primers bsp/flt1D2 and Flk1D3/apa/srf.as (described *supra*) to produce the fusion product. This PCR product was subsequently digested with the restriction enzymes BspEl and Smal and the resulting 614bp fragment was subcloned into the BspEl to Srfl restriction sites of the vector pMT21/ΔB2.Fc, to create the plasmid pMT21/Flt1D2.Flk1D3.Fc. The nucleotide sequence of the Flt1D2-Flk1D3 gene fusion insert was verified by standard sequence analysis. This plasmid was then digested

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

with the restriction enzymes EcoRI and SrfI and the resulting 702bp fragment was transferred into the EcoRI to SrfI restriction sites of the plasmid pFlt1(1-3)B2-FcΔC1(a) to produce the plasmid pFlt1D2.Flk1D3.FcΔC1(a). The complete DNA and deduced amino acid sequences of the Flt1D2.Flk1D3.FcΔC1(a) chimeric molecule is set forth in Figure 21A-21C [SEQ ID NOS: 11 and 12].

Please replace the paragraph starting on page 62, line 13, with the following:

5': bsp/flt1D2 (5'-GACTAGCAGTCCGGAGGTAGACCTTTCGTAGAGATG-3' [SEQ ID NO: 24])

Please replace the paragraph starting on page 62, line 15, with the following:

3': Flt1D2.VEGFR3D3.as(TTCCTGGGCAACAGCTGGATATCTATGATTGTA TTGGT [SEQ ID NO: 25])

Please replace the paragraph starting on page 62, line 18, with the following:

The 5' amplification primer encodes a BspE1 restriction site upstream of Ig domain 2 of Flt1, defined by the amino acid sequence GRPFVEM (SEQ ID NO: 20) (corresponding to amino acids 27-33 of Figure 22A-22C [SEQ ID

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

NOS: 13 and 14]). The 3' amplification primer encodes the reverse complement of the end of Flt1 Ig domain 2 fused directly to the beginning of VEGFR3 Ig domain 3, with the fusion point defined as TIID (SEQ ID NO: 37) of Flt1 (corresponding to amino acids 123-126 of Figure 22A-22C [SEQ ID NOS: 13 and 14]) and continuing into IQLL (SEQ ID NO: 26) of VEGFR3 (corresponding to amino acids 127-130 of Figure 22A-22C [SEQ ID NOS: 13 and 14]).

Please replace the paragraph starting on page 63, line 5, with the following:

5': R3D3.s (ATCCAGCTGTTGCCCAGGAAGTCGCTGGAGCTGCTGGTA [SEQ ID NO: 27])

Please replace the paragraph starting on page 63, line 7, with the following:

3': R3D3.as (ATTTTCATGCACAATGACCTCGGTGCTCTCCCGAAATCG [SEQ ID NO: 28])

Please replace the paragraph starting on page 63, line 16, with the following:

5':Flt1D2.VEGFR3D3.s
(TCATAGATATCCAGCTGTTGCCCAGGAAGTCGCTGGAG [SEQ ID NO: 29])

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

Please replace the paragraph starting on page 63, line 19, with the following:

3': VEGFR3D3/srf.as

(GATAATGCCCGGGCCATTTTCATGCACAATGACCTCGGT [SEQ ID NO: 30])

Please replace the paragraph starting on page 63, line 22, through page 64, line 4, with the following:

The 5' amplification primer encodes the 3' end of Flt1 Ig domain 2 fused directly to the beginning (5' end) of VEGFR3 Ig domain 3, as described above. The 3' amplification primer encodes the 3' end of VEGFR3 Ig domain 3, defined by the amino acids VIVHEN (SEQ ID NO: 31) (corresponding to amino acids 221-226 of Figure 22A-22C [SEQ ID NOS: 13 and 14]), followed by a bridging sequence that includes a recognition sequence for Srf1, and encodes the amino acids GPG. The bridging sequence corresponds to amino acids 227-229 of Figure 22A-22C (SEQ ID NOS: 13 and 14).

Please replace the paragraph starting on page 64, line 6, with the following:

After one round (for Flt1 Ig domain 2) or two rounds (for Flt4 Ig domain 3) of PCR to produce the individual Ig domains, the PCR products were

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

combined in a tube and subjected to a further round of PCR amplification with the amplification primers bsp/flt1D2 and VEGFR3D3/srf.as described *supra*, to produce the fusion product. This PCR product was subsequently digested with the restriction enzymes BspEI and Smal and the resulting 625bp fragment was subcloned into the BspEI to SrfI restriction sites of the vector pMT21/Flt1ΔB2.Fc (described *supra*), to create the plasmid pMT21/Flt1D2.VEGFR3D3.Fc. The sequence of the Flt1D2-VEGFR3D3 gene fusion insert was verified by standard sequence analysis. This plasmid was then digested with the restriction enzymes EcoRI and SrfI and the resulting 693bp fragment was subcloned into the EcoRI to SrfI restriction sites of the plasmid pFlt1(1-3)ΔB2-FcΔC1(a) to produce the plasmid designated pFlt1D2.VEGFR3D3.FcΔC1(a). The complete DNA deduced amino acid sequence of the Flt1D2.VEGFR3D3.FcΔC1(a) chimeric molecule is set forth in Figure 22A-22C (SEQ ID NOS: 13 and 14).

Please replace the paragraph starting on page 67, line 7, with the following:

The pVEGFR1R2.FcΔC1(a) expression plasmid was constructed by insertion of DNA encoding amino acids SDT (corresponding to amino acids 27-29 of Figure 24A-24C [SEQ ID NOS: 15 and 16]) between Flt1d2-Flk1d3-FcΔC1(a) amino acids 26 and 27 of Figure 21A-21C (SEQ ID NOS: 11 and 12) (GG) and removal of DNA encoding amino acids GPG corresponding to amino acids 229-231 of Figure 21A-21C (SEQ ID NOS: 11 and 12). The SDT amino acid sequence is native to the Flt1 receptor and

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

was added back in to decrease the likelihood of heterogeneous N-terminal processing. The GPG (bridging sequence) was removed so that the Flt1 and Flk1 Ig domains were fused directly to one another. The complete DNA and deduced amino acid sequences of the pVEGFR1R2.FcΔC1(a) chimeric molecule is set forth in Figure 24A-24C (SEQ ID NOS: 15 and 16).

Please replace the paragraph starting on page 80, line 22, through page 81, line 6, with the following:

The disulfide structures and glycosylation sites in Flt1D2.Flk1D3.FcΔC1(a) were determined by a peptide mapping method. In this method, the protein was first cleaved with trypsin. Tryptic fragments were analyzed and identified by HPLC coupled with mass spectrometry, in addition to an N-terminal sequencing technique. Reduction of the tryptic digest was employed to help identify disulfide-bond-containing fragments. Treatment of the tryptic digest with PNGase F (Glyko, Novato, CA) was employed to help identify fragments with N-linked glycosylation sites. The results are summarized in the accompanying Figure 36 (SEQ ID NO: 17).

Please replace the paragraph starting on page 81, line 20, through page 82, line 2, with the following:

There are five possible N-linked glycosylation sites in Flt1D2.Flk1D3.Fc∆C1(a). All five of them are found to be glycosylated to varying degrees. Complete glycosylation was observed at Asn33 (amino

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

acid sequence NIT), Asn193 (amino acid sequence NST), and Asn282 (amino acid sequence NST). In addition, partial glycosylation isobserved on Asn65 and Asn120. Sites of glycosylation are highlighted by underline in the Figure 36 (SEQ ID NO: 17).

Please replace the paragraph starting on page 89, line 13, with the following:

10pM of VEGF165 was incubated overnight at room temperature with modified Flt1 receptor variants ranging from 160pM to 0.1pM. The modified Flt1 receptor variants used in this experiment were Flt1(1-3)-Fc, Flt1(1-3)-Fc (A40), transiently expressed Flt1D2Flk1D3.Fc△C1(a), transiently expressed Flt1D2VEFGFR3D3-Fc∆C1(a), Flt1-(1-3_{NAS})-Fc, Flt1(1-3_{R->C})-Fc and Tie2-Fc. Flt1(1-3_{NAS})-Fc is a modified version of Flt1(1-3)-Fc in which the highly basic amino acid sequence KNKRASVRRR (SEQ ID NO: 32) is replaced by NASVNGSR (SEQ ID NO: 33), resulting in the incorporation of two new glycosylation sites and a net reduction of five positive charges, both with the purpose of reducing the unfavorable effects of this sequence on PK. Flt1(1-3 _{R->C})-Fc is a modification in which a single arginine (R) residue within the same basic amino acid sequence is changed to a cysteine (C) (KNKRASVRRR (SEQ ID NO: 32) -> KNKCASVRRR [SEQ ID NO: 34]) to allow for pegylation at that residue, which could then shield the basic region from exerting its unfavorable effects on PK. After incubation the solution was transferred to a plate containing a capture antibody for VEGF165 (R&D). The amount of free

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

VEGF165 was then determined using an antibody to report free VEGF165. This showed that the modified Flt1 receptor variant with the highest affinity for VEGF165 (determined as the lowest amount of free VEGF165) was Flt1D2Flk1D3.Fc Δ C1(a), followed by Flt1(1-3)-Fc and Flt1(1-3)-Fc (A40) and then by Flt1(1-3_{R->C})-Fc, Flt1(1-3_{NAS})-Fc and Flt1D2VEFGFR3D3-Fc Δ C1(a). Tie2Fc has no affinity for VEGF165.

REMARKS

This Preliminary Amendment is made merely to insert the priority data and to add the sequence identifiers to the specification.

Applicants submit herewith as Exhibit A: Marked-Up Versions of pages 1, 11, 13, 15, 19, 20, 21, 22, 25, 49, 50, 51, 52, 53, 54, 60, 61, 62, 63, 64, 67, 80, 81, 82, 89, 90, 92, 93, 95, 98, and 99; Exhibit B: Sequence Listings in paper and computer readable forms.

I hereby state that the content of the paper readable and computer readable copy of the Sequence Listing submitted herewith and referred to herein in accordance with 37 C.F.R. § 1.821(g), contain no new subject matter.

Applicants direct the subject Sequence Listings submitted herewith be added to the specification.

USSN: Not Yet Known

US File Date: Filed Herewith Preliminary Amendment

No fee is deemed necessary for filing this paper. However, if any fees are deemed necessary, the Commissioner is hereby authorized to charge any such fees required by this paper to Deposit Account No. 18-0650.

Respectfully submitted,

Gail M. Kempler

Reg. No. 32,143

Joseph M. Sorrentino

Reg. No. 32,598

Attorneys for Applicants

Linda O. Palladino

Reg. No. 45,636

Patent Agent for Applicants

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400

JC13 Rec'd PCT/PTO 0 6 DEC 2001

MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES AND METHODS OF MAKING AND **USING THEREOF**

This application claims priority of International Application No. PCT/4500/14142 filed, may 23,2000, which

The application claims priority of U.S. Provisional Application No.

60/138,133, filed on June 8, 1999. Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application.

10

The time that the time that the time that the time

22

The tall the

15

5

INTRODUCTION

The field of this invention is modified polypeptides with improved pharmacokinetics. Specifically, the field of this invention relates to Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile. The field of this invention also relates to methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.

20

25

BACKGROUND

The ability of polypeptide ligands to bind to cells and thereby elicit a phenotypic response such as cell growth, survival, cell product secretion, or differentiation is often mediated through transmembrane receptors on the cells. The extracellular domain of such receptors (i.e. that portion of the receptor that is displayed on the surface of the cell) is generally the most distinctive portion of the molecule, as it provides the protein with its ligand binding characteristic. Binding of a ligand

5

MARKED-UP VERSION

In still another preferred embodiment, the nucleotide sequence encoding Ig domain 2 of the extracellular domain of the first VEGF receptor is downstream of the nucleotide sequence encoding Ig domain 3 of the extracellular domain of the second VEGF receptor.

In a preferred embodiment of the invention, the multimerizing component comprises an immunoglobulin domain.

10 In another embodiment, the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.

Preferred embodiments include an isolated nucleic acid molecule comprising a nucleotide sequence encoding a modified Flt1 receptor fusion polypeptide, wherein the coding region of the nucleic acid molecule consists of a nucleotide sequence selected from the group consisting of

- (a) the nucleotide sequence set forth in Figure 13A-13D;
- (b) the nucleotide sequence set forth in Figure 14A-14C; (Seq 10 Nos: 5 and 6) 20
 - (c) the nucleotide sequence set forth in Figure 15A-15C; (SEO 10 NOS) 7 and 8) (d) the nucleotide sequence set forth in Figure 16A-16D;

 - (e) the nucleotide sequence set forth in Figure 21A-21C; (SEQ 10 NOS) II AND 12)
 - (f) the nucleotide sequence set forth in Figure 22A-22C; (SEQ 18 NOS: 13 AND 14)
- (g) the nucleotide sequence set forth in Figure 24A-24C; and 25
 - (h) a nucleotide sequence which, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a), (b), (c), (d),
 - (e), (f), or (g) and which encodes a fusion polypeptide molecule having

MARKED-UP VERSION

Another embodiment of the invention is a method of producing a fusion polypeptide which comprises growing cells of the host-vector system under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.

5

10

Additional embodiments include a fusion polypeptide encoded by the (SEG) ID NOS: IRAND (SEG) ID NOS: IRAND (SEG) ID NOS: IRAND (SEG) ID NOS: ISTAND (SEG) ID

15 A

A preferred embodiment includes a method of decreasing or inhibiting plasma leakage in a mammal comprising administering to the mammal the fusion polypeptide described above, including embodiments wherein the mammal is a human, the fusion polypeptide is acetylated or the fusion polypeptide is pegylated.

20

A further embodiments is a fusion polypeptide which specifically binds the VEGF receptor ligand VEGF.

25 ves

A preferred embodiment of the invention is a method of blocking blood vessel growth in a human comprising administering an effective amount of the fusion polypeptide described above.

10

15

MARKED-UP VERSION

Still another embodiment of the fusion polypeptide is one in which the second VEGF receptor is Fit4.

Preferred embodiments include a fusion polypeptide wherein amino acid sequence of Ig domain 2 of the extracellular domain of the first VEGF receptor is upstream of the amino acid sequence of Ig domain 3 of the extracellular domain of the second VEGF receptor and a fusion polypeptide wherein the amino acid sequence of Ig domain 2 of the extracellular domain of the first VEGF receptor is downstream of the amino acid sequence of Ig domain 3 of the extracellular domain of the second VEGF receptor.

In yet another embodiment, the fusion polypeptide multimerizing component comprises an immunoglobulin domain including an embodiment wherein the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.

Preferred embodiments include a fusion polypeptide comprising an amino acid sequence of a modified Flt1 receptor, wherein the amino acid sequence selected from the group consisting of (a) the amino acid sequence set forth in Figure 13A-13D, (b) the amino acid sequence set [SEQ 1D NCS: 3 AND 4] forth in Figure 14A-14C, (c) the amino acid sequence set forth in Figure (SEQ 1D NCS: 7 and 8) 15A-15C; (d) the amino acid sequence set forth in Figure 16A-16D; (e) (SEQ 1D NCS: 11 and 12) the amino acid sequence set forth in Figure 21A-21C, (f) the amino acid sequence set forth in Figure 22A-22C; and (g) the amino acid sequence set forth in Figure 24A-24C.

MARKED-UP VERSION

unmodified, 10, 20 and 40 fold excess samples and 2 mice for 60 and 100 fold excess samples). The mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days and 3 days after injection. The sera were assayed in an ELISA-based assay designed to detect Flt1(1-3)-Fc. The T_{max} for all of the Flt1(1-3)-Fc proteins tested was at the 6 hour time point but the C_{max} was as follows: Unmodified Flt1(1-3)-Fc: $0.06\mu g/ml$; 10 fold excess sample: $-0.7\mu g/ml$, 20 fold excess sample $-2\mu g/ml$, 40 fold excess sample $-4\mu g/ml$, 60 fold excess sample $-2\mu g/ml$, 100 fold excess sample $-1\mu g/ml$.

10

5

(SEQ ID NOS: 1@ND 2) (SEQ ID NO:1) (SEQ ID NO:2)

Figure 10A-10D. Nucleic acid and deduced amino acid sequence of

Flt1(1-3)-Fc.

Figure 11. Schematic diagram of the structure of Flt1.

Figure 12A and 12B. Hydrophilicity analysis of the amino acid sequences of Ig domain 2 and Ig domain 3 of Flt1.

(SEQ 10 NOS: 3 AND 4) (SEQ 10 NO: 4)

Figure 13A-13D. Nucleic acid and deduced amino acid sequence of

20 Mut1: Flt1(1-3_{Δ B})-Fc.

(SEQ 10 NOS: 5 AND 6) (SEQ 10 NO: 5) (SEQ 10 NO: 6)

Figure 14A-14 C. Nucleic acid and deduced amino acid sequence of Mut2: $Flt1(2-3_{AB})$ -Fc.

(SEQ 10. NOS: 7 AND 8) (SEQ 10 NO: 7) (SEQ 10 NO: 8)

25 **Figure 15A-15C.** Nucleic acid and deduced amino acid sequence of Mut3: Flt1(2-3)-Fc.

MARKED-UP VERSION

(SEGIDNOS: 9 aND 10) (SEGIDNO: 9) (SEGIDNO: 10)

Figure 16A-16D. Nucleic acid and deduced amino acid sequence of Mut4: $Flt1(1-3_{B->N})$ -Fc.

Binding of unmodified Flt1(1-3)-Fc, basic region deletion Figure 17. mutant Flt1(1-3)-Fc, and Flt1(1-3) $_{\rm R->N}$ mutant proteins in a Biacorebased assay. At the sub-stoichiometric ratio (0.25 μg/ml Flt1(1-3)-Fc of unmodified, acetylated or genetically modified samples vs. 01. μg/ml VEGF), there is insufficient Flt1(1-3)-Fc protein to block binding of VEGF to the Flt1(1-3)-Fc immobilized on the Biacore chip. At 0.5 μg/ml of unmodified, acetylated or genetically modified Flt1(1-3)-Fc proteins, the stoichiometric ratio approximates 1:1 and there is an increased ability to block VEGF binding to the Biacore chip. At 1.0 μg/ml of unmodified, acetylated or genetically modified Flt1(1-3)-Fc proteins, which is approximately a 10:1 stoichiometric ratio, the Flt1(1-3)-Fc proteins are able to block binding of VEGF to the Biacore chip, but they are not equivalent. Unmodified, acetylated, and Mut1: FIt1(1-3 $_{\Delta B}$)-Fc are essentially equal in their ability to block VEGF binding, whereas Mut4: Flt1(1-3_{R->N})-Fc is somewhat less efficient at blocking binding

20

25

5

10

Figure 18. Binding of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3 $_{\Delta B}$)-Fc, Mut2: Flt1(2-3 $_{\Delta B}$)-Fc, and Flt1(2-3) mutant proteins to Matrigel® coated plates. Unmodified Flt1(1-3)-Fc protein binds avidly to these wells, the Mut3: Flt1(2-3)-Fc protein binds somewhat more weakly, the Mut1: Flt1(1-3 $_{\Delta B}$)-Fc protein binds more weakly still, and the Mut2: Flt1(2-3 $_{\Delta B}$)-Fc protein shows the best profile, binding more weakly than any of the other mutant proteins. The Mut4: Flt1(1-3 $_{R->N}$)-Fc

The state of the s

MARKED-UP VERSION

glycosylation mutant protein shows only marginal benefit on the Matrigel assay.

Figure 19. Binding of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1- $3_{\Delta B}$)-Fc, Mut2: Flt1(2- $3_{\Delta B}$)-Fc, and Flt1(2-3) mutant proteins in an ELISA-based assay. At the concentrations tested, unmodified Flt1(1-3)-Fc, Mut1: Flt1(1- $3_{\Delta B}$)-Fc, Mut2: Flt1(2- $3_{\Delta B}$)-Fc, and Flt1(2-3) mutant proteins bind VEGF similarly.

10 **Figure 20.** Pharmacokinetic profiles of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3_{ΔB})-Fc, Mut2: Flt1(2-3_{ΔB})-Fc, and Flt1(2-3) mutant proteins. the Cmax for these reagents was as follows: Unmodified Flt1(1-3)-Fc - 0.15μg/ml; 40 fold molar excess acetylated Flt1(1-3)-Fc - 1.5μg/ml; and Mut1: Flt1(1-3_{ΔB})-Fc - 0.7μg/ml.

(SEG ID NOS: 11 ano 12) (SEG IDNO: 12)

Figure 21A-21C. Nucleotide and deduced amino acid sequence of the modified Flt1 receptor termed Flt1D2.Flk1D3.Fc\(\Delta\C1(a)\).

(SEQ ID NOS. 13 AND 14) (SEQ ID NO: 13) (SEQ ID NO: 14)

Figure 22A-22C. Nucleotide and deduced amino acid sequence of the

20 modified Flt1 receptor termed Flt1D2.VEGFR3D3.Fc∆C1(a).

Figure 23. Extracellular Matrix (ECM) Assay. The results of this assay demonstrate that the Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a) proteins are considerably less sticky to the ECM as compared to the Flt1(1-3)-Fc protein.

25 ECM as compared to the Flt1(1-3)-Fc protein.

25

5

MARKED-UP VERSION

(SEG 10 HOS: 15 GNO 16)

(SEG 10 NO:15)

(SEQ 10 NO: 16)

Figure 24A-24C. Nucleotide and deduced amino acid sequence of the modified Flt1 receptor termed VEGFR1R2-Fc∆C1(a).

Figure 25A-25C. Phosphorylation assay. At a 1.5 molar excess of either Flt1(1-3)-Fc , Flt1(1-3)-Fc (A40) or transient Flt1D2Flk1D3.FcΔC1(a) there is complete blockage of receptor stimulation by these three modified Flt1 receptors as compared to control media challenge. In contrast, transient Flt1D2VEGFR3D3.FcΔC1(a) does not show significant blockage at this molar excess, as compared with VEGF positive control challenge. Similar results are seen in Figure 25B, where the modified Flt receptors are in a 3-fold molar excess to VEGF165 ligand. In Figure 25C, where the modified Flt1 receptors are in a 6-fold molar excess to VEGF165 ligand, transient Flt1D2VEGFR3D3.FcΔC1(a) can now be shown to be partially blocking VEGF165-induced stimulation of cell-surface receptors.

Figure 26A-26B. Phosphorylation assay. Detection by Western blot of tyrosine phosphorylated VEGFR2(Flk1) by VEGF165 ligand stimulation shows that cell-surface receptors are not phosphorylated by challenge samples which have VEGF165 preincubated with 1 and 2 fold molar excess (Figure 26A) or 3 and 4 fold molar excess (Figure 26B) of either transient Flt1D2Flk1D3.FcΔC1(a), stable Flt1D2Flk1D3.FcΔC1(a), or transient VEGFR1R2-FcΔC1(a). At all modified Flt1 receptor concentrations tested there is complete binding of VEGF165 ligand

25

5

MARKED-UP VERSION

Figure 33, Figure 34 and Figure 35. Size Exclusion

Chromatography (SEC) with On-Line Light Scattering. Size exclusion

chromatography column with a MiniDawn on-line light scattering

detector (Wyatt Technology, Santa Barbara, California) and refractive

index (RI) detectors (Shimadzu, Kyoto, Japan) was used to determine

the molecular weight (MW) of the receptor-ligand complex. As shown in

Figure 33, the elution profile shows two peaks. Peak #1 represents the

receptor-ligand complex and peak #2 represents the unbound VEGF165.

MW was calculated from LS and RI signals. The same procedure was

used to determine MW of the individual components of the receptor
ligand complex. The results of these determinations are as follows:

MW of the Flt1D2Flk1D3.FcAC1(a)/VEGF165 complex at the peak

position is 157 300 (Figure 33), the MW of VEGF165 at the peak

position is 44 390 (Figure 34) and the MW of R1R2 at the peak is 113

300 (Figure 35).

(SEG ID NO:17)

Figure 36. Peptide mapping and glycosylation analysis. The disulfide structures and glycosylation sites in Flt1D2.Flk1D3.FcΔC1(a) were determined by a peptide mapping method. There are a total of ten cysteines in Flt1D2.Flk1D3.FcΔC1(a); six of them belong to the Fc region. Cys27 is disulfide bonded to Cys76. Cys121 is disulfide bonded to Cys 182. The first two cysteines in the Fc region (Cys211 and Cys214) form an intermolecular disulfide bond with the same two cysteines in another Fc chain. However, it can not be determined

5

MARKED-UP VERSION

(d.) Pharmacokinetic analysis of step-acetylated Flt1(1-3)-Fc

In vivo experiments were designed to assess the pharmacokinetic profiles of unmodified Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc Balb/c mice (23-28g) were injected subcutaneously with 4mg/kg of unmodified or 10, 20, 40, 60 and 100 fold molar excess samples of step-acetylated Flt1(1-3)-Fc (3 mice for unmodified, 10, 20 and 40 fold molar excess samples and 2 mice for 60 and 100 fold molar excess samples). The mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days and 3 days after injection. The sera were assayed in an ELISA-based assay designed to detect Flt1(1-3)-Fc (described supra). Figure 9 details the results of this study. The Tmax for all of the Flt1(1-3)-Fc proteins tested was at the 6 hour time point but the Cmax was as follows: Unmodified Flt1(1-3)-Fc: 0.06µg/ml; 10 fold molar excess sample: - 0.7µg/ml, 20 fold molar excess sample - 2µg/ml, 40 fold molar excess sample - 4µg/ml, 60 fold molar excess sample - 2µg/ml, 100 fold molar excess sample - 1µg/ml. This results demonstrates that acetylation or pegylation of Flt1(1-3)-Fc significantly improves its pharmacokinetic profile.

Example 11: Construction of Flt1(1-3)-Fc basic region deletion mutant designated Mut1: Flt1(1-3 $_{\Lambda B}$)-Fc.

25 Based on the observation that acetylated Flt1(1-3)-Fc, which has a pl

15

20

MARKED-UP VERSION

below 6, has much better pharmacokinetics than the highly positive unmodified Flt1(1-3)-Fc (pl > 9.3), it was asked whether the difference in pharmacokinetics could be attributed to the net charge of the protein, which made it stick to negatively charged extracellular matrix components, or whether there were perhaps specific locations on the surface of the Flt1(1-3)-Fc protein that constituted specific binding sites for extracellular matrix components. For example, many proteins are known to have heparin binding sites, often consisting of a cluster of basic residues. Sometimes these residues are found in a cluster on the primary sequence of the protein; some of the literature has identified "consensus sequences" for such heparin binding sites (see for example Hileman, et al., 1998, Bioessays 20(2):156-67). In other cases, the known crystal structure of a protein reveals a cluster of positively charged residues on the surface of a protein, but the residues come from different regions of the primary sequence and are only brought together when the protein folds into its tertiary structure. Thus it is difficult to deduce whether an isolated amino acid residue forms part of a cluster of basic residues on the surface of the protein. However, if there is a cluster of positively charged amino acid residues in the primary sequence, it is not unreasonable to surmise that the residues are spatially close to one another and might therefore be part of an extracellular matrix component binding site. Flt1 receptor has been studied extensively and various domains have been described (see for example Tanaka et al., 1997, Jpn. J. Cancer Res 88:867-876). Referring

25 to the nucleic acid and amino acid sequence set forth in Figure 10A-10D ז (SEQ וס אכל: ו פאום 2)

10

15

20

25

MARKED-UP VERSION

of this application, one can identify the signal sequence for secretion which is located at the beginning of the sequence and extends to the glycine coded for by nucleotides 76-78. The mature protein begins with (SEQ ID NO.35)

Ser-Lys-Leu-Lys, starting at nucleotide 79 of the nucleic acid sequence. Flt1 lg domain 1 extends from nucleotide 79 to 393, ending with the amino acids Ser-Asp-Thr. Flt1 lg domain 2 extends from nucleotide 394 to 687 (encoding Gly-Arg-Pro to Asn-Thr-Ile), and Flt1 lg domain 3 extends from nucleotides 688 to 996 (encoding Ile-Asp-Val to Asp-Lys-Ala). There is a bridging amino acid sequence, Gly-Pro-Gly, encoded by nucleotides 997-1005, followed by the nucleotide sequence encoding human Fc (nucleotides 1006-1701 or amino acids Glu-Pro-Lys to Pro-Gly-Lys-stop).

A more detailed analysis of the Flt1 amino acid sequence reveals that there is a cluster, namely, amino acid residues 272-281 (KNKRASVRR) (SEQ 10 NCS: 1 Q NO)

of Figure 10A-10D, in which 6 out of 10 amino acid residues are basic.

This sequence is located in Flt1 Ig domain 3 of the receptor (see Figure 11), which is not itself essential for binding of VEGF ligand, but which confers a higher affinity binding to ligand. An alignment of the sequence of Ig domain 3 with that of Ig domain 2 reveals that in this region, there is very poor alignment between the two Ig domains, and that there are about 10 additional amino acids in Ig domain 3. An analysis of the hydrophilicity profiles (MacVector computer software) of these two domains clearly indicates the presence of a hydrophilic region in the protein (Figure 12A-12B). These observations raised the

10

15

MARKED-UP VERSION

possibility that the actual three dimensional conformation of Flt1 Ig domain 3 allowed for some type of protrusion that is not in Flt1 Ig domain 2. To test this hypothesis, the 10 additional amino acids were deleted and the resulting protein was tested to see whether the deletion would affect the pharmacokinetics favorably without seriously compromising the affinity of the receptor for VEGF. This DNA construct, which was constructed using standard molecular biology techniques (see e.g., Molecular Cloning, A Laboratory Manual (Sambrook, et al., Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY) in the mammalian expression vector pMT21 (Genetics Institute, Inc., Cambridge, MA), is referred to as Mut1: Flt1(1-3_{AB})-Fc. The Mut1: Fit1(1-3_{AB})-Fc construct was derived from Fit1(1-3)-Fc by deletion of nucleotides 814-843 (set forth in Figure 10A-10D), which deletes the highly basic 10-amino acid residue sequence Lys-Asn-Lys-Arg-Ala-(SEO 10 NO: 32) Ser-Val-Arg-Arg-Arg from Flt1 lg domain 3.

The final DNA construct was sequence-verified using an ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, CA). The sequence of Mut1: Flt1(1-3_{AB})-(SEQ ID NOS 3 CAB 4) Fc is set forth in Figure 13A-13D.

MARKED-UP VERSION

Example 12: Construction of Flt1(1-3)-Fc basic region deletion mutant designated Mut2: Flt1(2-3 $_{\Delta B}$)-Fc.

A second deletion mutant construct, designated Mut2: Flt1(2-3_{AB})-Fc, was derived from the Mut1: Flt1(1-3 AB)-Fc construct by deletion of Flt1 (SEG 10 NOS: 1 and 2) 5 Ig domain 1 encoded by nucleotides 79-393 (see Figure 10A-10D); for convenience, nucleotides 73-78 (TCA GGT) were changed to TCC GGA. This introduced a restriction site (BspE1) without altering the associated amino acid sequence, Ser-Gly. This DNA construct, which was constructed using standard molecular biology techniques (see e.g., 10 Molecular Cloning, A Laboratory Manual (Sambrook, et al., Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY) in the mammalian expression vector pMT21 (Genetics Institute, Inc., Cambridge, MA), was also sequence-verified using an ABI 373A DNA 15 sequencer and Tag Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, CA). The sequence of Mut2: Flt1(2-3 $_{\Delta B}$)-

20 Example 13: Construction of Flt1(1-3)-Fc deletion mutant designated Mut3: Flt1(2-3)-Fc.

Fc is set forth in Figure 14A-14C.

A third deletion mutate construct, designated Mut3: Flt1(2-3)-Fc, was constructed the same way as the Mut2: Flt1(2-3 $_{\Delta B}$)-Fc construct, except that Flt1 Ig domain 3 was left intact (the basic region amino

MARKED-UP VERSION

acids were not deleted). The construct was constructed using standard molecular biology techniques and the final construct was sequence-verified as described *supra*. The sequence of Mut3: Flt1(2-3)-Fc is set CSEQ ID NOS: 7 and 8) forth in Figure 15A-15C.

5

10

15

Example 14: Construction of Flt(1-3)-Fc basic region N-glycosylation mutant designated Mut4: Flt1(1-3 $_{R->N}$)-Fc.

A final construct was made in which a N-glycosylation site was introduced into the middle of the basic region of Flt1 Ig domain 3. This construct was designated Mut4: Flt1(1-3 $_{R->N}$)-Fc and was made by changing nucleotides 824-825 from GA to AC, consequently changing the coded Arg residue (AGA) into an Asn residue (AAC) (see Figure 10A- $_{L\leq EQ}$ 10 NOS 1 and 3) 10D). The resulting amino acid sequence is therefore changed from Arg-Ala-Ser to Asn-Ala-Ser, which matches the canonical signal (Asn-Xxx-Ser/Thr) for the addition of a N-glycosylation site at the Asn residue. The sequence of Mut4: Flt1(1-3 $_{R->N}$)-Fc is set forth in Figure 16A-16D.

Example 15: Characterization of acetylated Flt1(1-3)-Fc. Mut1: Flt1(1-3 $_{AB}$)-Fc, and Mut4: Flt1(1-3 $_{R->N}$)-Fc mutants.

(a.) Binding to extracellular matrix components

25 To determine whether the three modified proteins were more or less

MARKED-UP VERSION

single fragment. For Ig domain 2 of Flt1, the 5' and 3' amplification primers were as follows:

[SEG 10 NO: 18]

5': bsp/flt1D2 (5'-GACTAGCAGTCCGGAGGTAGACCTTTCGTAGAGATG-3')

5

10

15

[SEQ 10 NO:19]

3': Flt1D2-Flk1D3.as (5'-CGGACTCAGAACCACATCTATGATTGTATTGGT-3')

The 5' amplification primer encodes a BspE1 restriction enzyme site upstream of Ig domain 2 of Flt1, defined by the amino acid sequence [SEQ 10 NOS: 11 encola] GRPFVEM (corresponding to amino acids 27-33 of Figure 21A-21C). The 3' primer encodes the reverse complement of the 3' end of Flt1 Ig domain 2 fused directly to the 5' beginning of Flk1 Ig domain 3, with (SEQ 10 NOS: 11 encola) (SEQ 10 NOS: 38) 123-126 of Figure 21A-21C) and continuing into VVLS (corresponding [SEQ 10 NOS: 11 encola)] to amino acids 127-130 of Figure 21A-21C) of Flk1.

For Ig domain 3 of Flk1, the 5' and 3' amplification primers were as follows:

20 5': Flt1D2-Flk1D3.s (5'-ACAATCATAGATGTGGTTCTGAGTCCGTCTCATG

3': Flk1D3/apa/srf.as (5'-GATAATGCCCGGGCCCTTTTCATGGACCCTGAC

25

10

15

MARKED-UP VERSION

The 5' amplification primer encodes the end of Flt1 Ig domain 2 fused directly to the beginning of Flk1 Ig domain 3, as described above. The 3' amplification primer encodes the end of Flk1 Ig domain 3, defined by the amino acids VRVHEK (corresponding to amino acids 223-228 of Figure 21A-21C), followed by a bridging sequence that includes a recognition sequence for the restriction enzyme Srf1, and encodes the amino acids GPG. The bridging sequence corresponds to amino acids 229-231 of Figure 21A-21C.

After a round of PCR amplification to produce the individual domains, the products were combined in a tube and subjected to a further round of PCR with the primers bsp/flt1D2 and Flk1D3/apa/srf.as (described supra) to produce the fusion product. This PCR product was subsequently digested with the restriction enzymes BspEl and Smal and the resulting 614bp fragment was subcloned into the BspEl to Srfl restriction sites of the vector pMT21/\(\Delta\)B2.Fc, to create the plasmid pMT21/Flt1D2.Flk1D3.Fc. The nucleotide sequence of the Flt1D2-Flk1D3 gene fusion insert was verified by standard sequence analysis. This plasmid was then digested with the restriction enzymes EcoRI and Srfl and the resulting 702bp fragment was transferred into the EcoRI to Srfl restriction sites of the plasmid pFlt1(1-3)B2-Fc∆C1(a) to produce the plasmid pFlt1D2.Flk1D3.Fc∆C1(a). The complete DNA and deduced amino acid sequences of the Flt1D2.Flk1D3.Fc\(\Delta\)C1(a) chimeric molecule is set (SEQ 10 NOS: 11 and 12) forth in Figure 21A-210

20

10

MARKED-UP VERSION

Construction of the expression plasmid pFIt1D2VEGFR3D3Fc∆C1(a)

The expression plasmid pMT21.Flt1(1-3).Fc (6519bp) encodes ampicillin resistance and an Fc-tagged version of Iq domains 1-3 of human Flt1 receptor. This plasmid was used to produce a DNA fragment containing Ig domain 2 of Flt1 by PCR. RNA from the cell line HEL921.7 was used to produce Ig domain 3 of Flk1, using standard RT-PCR methodology. A further round of PCR amplification was used to achieve fusion of the two lg domains into a single fused fragment. For lg domain 2 of Flt1, the 5' and 3' amplification primers were as follows:

[SEQ 10 NO: 24] 5': bsp/flt1D2 (5'-GACTAGCAGTCCGGAGGTAGACCTTTCGTAGAGATG-3')

15 3': Flt1D2.VEGFR3D3.as(TTCCTGGGCAACAGCTGGATATCTATGATTGTA [SEQ 10 NO: 25] TTGGT

The 5' amplification primer encodes a BspE1 restriction site upstream (SEG 10 NO 20) of Ig domain 2 of Flt1, defined by the amino acid sequence GRPFVEM² [SEQ 10 NOS: 13 AND 14] 20 (corresponding to amino acids 27-33 of Figure 22A-22C). amplification primer encodes the reverse complement of the end of Flt1 Ig domain 2 fused directly to the beginning of VEGFR3 Ig domain 3, with the fusion point defined as TIID of Fit1 (corresponding to amino acids [SEQ 10 NOS: 13 and 14) (SEQ 10 NOS. 26) 123-126 of Figure 22A-22C) and continuing into IQLL of VEGFR3 [SEQ ID NOS: 13 aNO14]

(corresponding to amino acids 127-130 of Figure 22A-22C). 25

The state of the s

MARKED-UP VERSION

For Ig domain 3 of VEGFR3, the 5' and 3' primers used for RT-PCR were as follows:

[seq 10 no.27]

5 5: R3D3.s (ATCCAGCTGTTGCCCAGGAAGTCGCTGGAGCTGCTGGTA)

[SEQ 16 no. 28]

3': R3D3.as (ATTTTCATGCACAATGACCTCGGTGCTCTCCCGAAATCG)

Both the 5' and 3' amplification primers match the sequence of VEGFR3. The 296bp amplification product of this RT-PCR reaction was isolated by standard techniques and subjected to a second round of PCR to add suitable sequences to allow for fusion of the Flt1D2 with the Flk1D3 domains and fusion of the Flk1D3 and Fc domains via a GPG bridge (see below). The amplification primers were as follows:

15

25

10

5':Flt1D2.VEGFR3D3.s

[SEQ 10 NO: 29]

(TCATAGATATCCAGCTGTTGCCCAGGAAGTCGCTGGAG)

3': VEGFR3D3/srf.as

[SEQ 10 NO: 30]

20 (GATAATGCCCGGGCCATTTTCATGCACAATGACCTCGGT)

The 5' amplification primer encodes the 3' end of Flt1 Ig domain 2 fused directly to the beginning (5' end) of VEGFR3 Ig domain 3, as described above. The 3' amplification primer encodes the 3' end of (SEG ID NO: 31) VEGFR3 Ig domain 3, defined by the amino acids VIVHEN (corresponding

MARKED-UP VERSION

[SEG 10 NOS: 13 and 14]

to amino acids 221-226 of Figure 22A-22C), followed by a bridging sequence that includes a recognition sequence for Srf1, and encodes the amino acids GPG. The bridging sequence corresponds to amino acids (SEQ ID NOS: 13 and IH) 227-229 of Figure 22A-22C.

5

10

15

20

After one round (for Flt1 Ig domain 2) or two rounds (for Flt4 Ig domain 3) of PCR to produce the individual Ig domains, the PCR products were combined in a tube and subjected to a further round of PCR amplification with the amplification primers bsp/flt1D2 and VEGFR3D3/srf.as described *supra*, to produce the fusion product. This PCR product was subsequently digested with the restriction enzymes BspEl and Smal and the resulting 625bp fragment was subcloned into the BspEl to Srfl restriction sites of the vector pMT21/Flt1∆B2.Fc (described supra), to create the plasmid pMT21/Flt1D2.VEGFR3D3.Fc. The sequence of the Flt1D2-VEGFR3D3 gene fusion insert was verified by standard sequence analysis. This plasmid was then digested with the restriction enzymes EcoRI and Srfl and the resulting 693bp fragment was subcloned into the EcoRI to Srfl restriction sites of the plasmid pFlt1(1-3)∆B2-Fc∆C1(a) to produce the plasmid designated pFlt1D2.VEGFR3D3.Fc∆C1(a). The complete DNA deduced amino acid sequence of the Flt1D2.VEGFR3D3.Fc∆C1(a) chimeric molecule is set forth in Figure 22A-22C? (SEQ 10 NOS: 13 and 14)

15

MARKED-UP VERSION

cells. The supernatant was decanted into sterile 1L bottles and purification of the expressed protein was performed as described *infra*.

Example 20: Construction pVEGFR1R2-Fc∆C1(a) expression 5 vector

The pVEGFR1R2.Fc\(\Delta\C1(a)\) expression plasmid was constructed by insertion of DNA encoding amino acids SDT (corresponding to amino \(\left[LSEQ \colon \colo

Example 21: Cell Culture Process Used to Produce Modified 20 FIt1 Receptors

(a) Cell Culture Process Used to Produce Fit1D2.Fik1D3.Fc∆C1(a)

25 The process for production of Flt1D2.Flk1D3.FcΔC1(a) protein using the

10

15

25

MARKED-UP VERSION

(Pharmacia) equilibrated in PBS buffer and eluted with the same buffer at flow rate 0.5 ml/min. at room temperature. As shown in Figure 33, the elution profile shows two peaks. Peak #1 represents the receptor-ligand complex and peak #2 represents the unbound VEGF165. MW was calculated from LS and RI signals. The same procedure was used to determine MW of the individual components of the receptor-ligand complex. The results of these determinations are as follows: MW of the Flt1D2Flk1D3.FcΔC1(a)/VEGF165 complex at the peak position is 157 300 (Figure 33), the MW of VEGF165 at the peak position is 44 390 (Figure 34) and the MW of R1R2 at the peak is 113 300 (Figure 35).

These data indicated that the stoichiometry of the Flt1D2Flk1D3.FcΔC1(a)/VEGF complex is 1:1 as its corresponds to the sum of molecular weights for Flt1D2Flk1D3.FcΔC1(a) and VEGF165. Importantly, this method conclusively proved that the Flt1D2Flk1D3.FcΔC1(a)/VEGF165 complex was indeed composed of only one molecule of VEGF165 ligand and only one molecule of the Flt1D2Flk1D3.FcΔC1(a).

20 Example 28: Peptide Mapping of Flt1D2.Flk1D3.Fc△C1(a)

The disulfide structures and glycosylation sites in Flt1D2.Flk1D3.Fc\(\Delta\)C1(a) were determined by a peptide mapping method. In this method, the protein was first cleaved with trypsin. Tryptic fragments were analyzed and identified by HPLC coupled with mass

10

15

MARKED-UP VERSION

spectrometry, in addition to an N-terminal sequencing technique.

Reduction of the tryptic digest was employed to help identify disulfide-bond-containing fragments. Treatment of the tryptic digest with PNGase F (Glyko, Novato, CA) was employed to help identify fragments with N-linked glycosylation sites. The results are (SEQ ID NOVI) summarized in the accompanying Figure 36.1

There are a total of ten cysteines in Flt1D2.Flk1D3.Fc Δ C1(a); six of them belong to the Fc region. Cys27 has been confirmed to be disulfide bonded to Cys76. Cys121 is confirmed to be disulfide bonded to Cys 182. The first two cysteines in the Fc region (Cys211 and Cys214) form an intermolecular disulfide bond with the same two cysteines in another Fc chain. However, because these two cysteines can not be separated enzymatically from each other, it can not be determined whether disulfide bonding is occurring between same cysteines (Cys211 to Cys211, for example) or between Cys211 and Cys214. Cys216 is confirmed to be disulfide bonded to Cys306. Cys 352 is confirmed to be disulfide bonded to Cys410.

There are five possible N-linked glycosylation sites in Flt1D2.Flk1D3.FcΔC1(a). All five of them are found to be glycosylated to varying degrees. Complete glycosylation was observed at Asn33 (amino acid sequence NIT), Asn193 (amino acid sequence NST), and Asn282 (amino acid sequence NST). In addition, partial glycosylation is

MARKED-UP VERSION

observed on Asn65 and Asn120. Sites of glycosylation are highlighted (SEQ IDNO: 17) by underline in the Figure 36.

Example 29: Pharmacokinetic Analysis of Modified Flt
Receptors

(a) Pharmacokinetic analysis of Flt1(1-3)-Fc (A40). Flt1D2.Flk1D3.Fc△C1(a) and VEGFR1R2-Fc△C1(a)

Balb/c mice (25-30g) were injected subcutaneously with 4mg/kg of 10 Flt1(1-3)-Fc (A40), CHO transiently expressed Flt1D2.Flk1D3.FcΔC1(a), CHO stably expressed Flt1D2.Flk1D3.Fc∆C1(a), and CHO transiently expressed VEGFR1R2-Fc∆C1(a). The mice were tail bled at 1, 2, 4, 6, 24hrs, 2 days, 3 days and 6 days after injection. The sera were assayed in an ELISA designed to detect Flt1(1-3)-Fc (A40), 15 Flt1D2.Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a). The ELISA involves coating an ELISA plate with VEGF165, binding the detect Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.Fc∆C1(a) or VEGFR1R2-Fc∆C1(a) and reporting with an anti-Fc antibody linked to horse radish peroxidase. The results of this experiments are shown in Figure 37. The T_{max} for Flt1(1-3)-Fc 20 (A40) was at 6 hrs while the T_{max} for the transient and stable Fit1D2.Fik1D3.Fc∆C1(a) and the transient VEGFR1R2-Fc∆C1(a) was 24hrs. The C_{max} for Flt1(1-3)-Fc (A40) was $8\mu g/ml$. For both transients (Flt1D2.Flk1D3.Fc Δ C1(a) and VEGFR1R2-Fc Δ C1(a)) the C_{max}

20

25

5

MARKED-UP VERSION

Example 33: Pharmacokinetic Analysis of Flt1(1-3)-Fc (A40) and Pegylated Flt1(1-3)-Fc

Flt1(1-3)-Fc was PEGylated with either 10kD PEG or 20kD PEG and tested in balb/c mice for their pharmacokinetic profile. Both PEGylated forms of Flt1(1-3)-Fc were found to have much better PK profiles than Flt1(1-3)-Fc (A40), with the Tmax occurring at 24 hrs. for the PEGylated molecules as opposed to 6 hrs. for Flt1(1-3)-Fc (A40).

10 Example 34: VEGF165 ELISA to Test Affinity of Modified Flt1 Receptor Variants

10pM of VEGF165 was incubated overnight at room temperature with modified Flt1 receptor variants ranging from 160pM to 0.1pM. The modified Flt1 receptor variants used in this experiment were Flt1(1-3)-Fc, Flt1(1-3)-Fc (A40), transiently expressed Flt1D2VEFGFR3D3-FcΔC1(a), flt1-(1-3_{NAS})-Fc, Flt1(1-3_{R->C})-Fc and Tie2-Fc. Flt1(1-3 NAS)-Fc is a modified version of Flt1(1-3)-Fc in which the highly basic (SEG 16 NC:33) amino acid sequence KNKRASVRRR is replaced by NASVNGSR, resulting in the incorporation of two new glycosylation sites and a net reduction of five positive charges, both with the purpose of reducing the unfavorable effects of this sequence on PK. Flt1(1-3 R->C)-Fc is a modification in which a single arginine (R) residue within the same basic amino acid sequence is changed to a cysteine (C) (KNKRASVRRR -> 33)

MARKED-UP VERSION

[SEQ 10 NO: 34]

KNKCASVRRR) to allow for pegylation at that residue, which could then shield the basic region from exerting its unfavorable effects on PK. After incubation the solution was transferred to a plate containing a capture antibody for VEGF165 (R&D). The amount of free VEGF165 was then determined using an antibody to report free VEGF165. This showed that the modified Flt1 receptor variant with the highest affinity for VEGF165 (determined as the lowest amount of free VEGF165) was Flt1D2Flk1D3.Fc∆C1(a), followed by Flt1(1-3)-Fc and Flt1(1-3)-Fc (A40) and then by $Flt1(1-3_{R->C})$ -Fc, $Flt1(1-3_{NAS})$ -Fc and $Flt1D2VEFGFR3D3-Fc\Delta C1(a). \quad Tie2Fc \ has \ no \ affinity \ for \ VEGF165.$

10

10

15

MARKED-UP VERSION

- 5. The isolated nucleic acid molecule of claim 1, wherein the nucleotide sequence encoding Ig domain 2 of the extracellular domain of the first VEGF receptor is upstream of the nucleotide sequence encoding Ig domain 3 of the extracellular domain of the second VEGF receptor.
- 6. The isolated nucleic acid molecule of claim 1, wherein the nucleotide sequence encoding Ig domain 2 of the extracellular domain of the first VEGF receptor is downstream of the nucleotide sequence encoding Ig domain 3 of the extracellular domain of the second VEGF receptor.
- 7. The isolated nucleic acid molecule of claim 1, wherein the multimerizing component comprises an immunoglobulin domain.
- 8. The isolated nucleic acid molecule of claim 1, wherein the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.
- 9. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a modified Flt1 receptor fusion polypeptide, wherein the coding region of the nucleic acid molecule consists of a nucleotide sequence selected from the group consisting of:
 - (a) the nucleotide sequence set forth in Figure 13A-13D; (SEQ ID NOS 3 =NA 4)
- 25 (b) the nucleotide sequence set forth in Figure 14A-14C; SEQ ID NOS. SAND 6

10

MARKED-UP VERSION

- (c) the nucleotide sequence set forth in Figure 15A-15C; (SEC IDNOS; 7ANOLS)
- (d) the nucleotide sequence set forth in Figure 16A-16D; (SEQ 10 NOS: 9 and 10)
- (e) the nucleotide sequence set forth in Figure 21A-21C (SEG ID NOS: Now 13)
- (f) the nucleotide sequence set forth in Figure 22A-22C; (SEG 10 NOS: 13 ANDIU)
- (g) the nucleotide sequence set forth in Figure 24A-24C; and
- (h) a nucleotide sequence which, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a), (b), (c), (d), (e), (f), or (g) and which encodes a fusion polypeptide molecule having the biological activity of the modified Flt1 receptor fusion polypeptide.
- 10. A fusion polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, 3, 4 or 9.
- 15 11. A composition capable of binding a VEGF molecule to form a nonfunctional complex comprising a multimer of the fusion polypeptide of claim 10.
 - 12. The composition of claim 11, wherein the multimer is a dimer.
 - 13. The composition of claim 12 and a carrier.
 - 14. A vector which comprises the nucleic acid molecule of claim 1, 2,3, 4 or 9.

25

20

MARKED-UP VERSION

- 22. A fusion polypeptide encoded by the nucleic acid sequence set forth (SEQ 10 MOS) (SEQ 10 MOS
- 5 23. The fusion polypeptide of claim 22 wherein the modification is acetylation.

(AMENDED)

- 24. The fusion polypeptide of claim 22 wherein the modification is pegylation.
- 25. The fusion polypeptide of claim 23 wherein the acetylation is accomplished with at least about a 100 fold molar excess of acetylation reagent.
- 15 26. The fusion polypeptide of claim 23 wherein acetylation is accomplished with a molar excess of acetylation reagent ranging from at least about a 10 fold molar excess to about a 100 fold molar excess.
- 27. The fusion polypeptide of claim 24 wherein the pegylation is 10K 20 or 20K PEG.
 - 28. A method of decreasing or inhibiting plasma leakage in a mammal comprising administering to the mammal fusion polypeptide of claim 10.

25

15

MARKED-UP VERSION

- 43. The fusion polypeptide of claim 41 wherein the second VEGF receptor is Flk1.
- 44. The fusion polypeptide of claim 41 wherein the second VEGF receptor is Flt4.
 - 45. The fusion polypeptide claim 41, wherein amino acid sequence of Ig domain 2 of the extracellular domain of the first VEGF receptor is upstream of the amino acid sequence of Ig domain 3 of the extracellular domain of the second VEGF receptor.
 - 46. The fusion polypeptide of claim 41, wherein the amino acid sequence of Ig domain 2 of the extracellular domain of the first VEGF receptor is downstream of the amino acid sequence of Ig domain 3 of the extracellular domain of the second VEGF receptor.
 - 47. The fusion polypeptide of claim 41, wherein the multimerizing component comprises an immunoglobulin domain.
- 48. The fusion polypeptide of claim 41, wherein the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.

(AMENDOD)

49. An fusion polypeptide comprising an amino acid sequence of a modified Flt1 receptor, wherein the amino acid sequence selected from

5

MARKED-UP VERSION

the group consisting of:

(a) the amino acid sequence set forth in Figure 13A-13D;

(b) the amino acid sequence set forth in Figure 14A-14C;

(c) the amino acid sequence set forth in Figure 15A-15C;

(d) the amino acid sequence set forth in Figure 16A-16D; (e) the amino acid sequence set forth in Figure 21A-21C (SEG 10 NCS: 112WC 12)

(SEG 10 NOS: 13 AND 14)

(f) the amino acid sequence set forth in Figure 22A-22C; and (g) the amino acid sequence set forth in Figure 24A-24C.

10 A method of decreasing or inhibiting plasma leakage in a mammal comprising administering to the mammal fusion polypeptide of claim 41, 42, 43, 44 or 49.

A method of inhibiting VEGF receptor ligand activity in a mammal comprising administering to the mammal an effective amount of the fusion polypeptide of claim 41, 42, 43, 44 or 49.

MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES

The application claims priority of U.S. Provisional Application No. 60/138,133, filed on June 8, 1999. Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application.

10

5

INTRODUCTION

The field of this invention is modified polypeptides with improved pharmacokinetics. Specifically, the field of this invention relates to Fit1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile. The field of this invention also relates to methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.

20

25

15

BACKGROUND

The ability of polypeptide ligands to bind to cells and thereby elicit a phenotypic response such as cell growth, survival, cell product secretion, or differentiation is often mediated through transmembrane receptors on the cells. The extracellular domain of such receptors (i.e. that portion of the receptor that is displayed on the surface of the cell) is generally the most distinctive portion of the molecule, as it provides the protein with its ligand binding characteristic. Binding of a ligand

10

15

20

25

to the extracellular domain generally results in signal transduction which transmits a biological signal to intracellular targets. Often, this signal transduction acts via a catalytic intracellular domain. The particular array of sequence motifs of this catalytic intracellular domain determines its access to potential kinase substrates (Mohammadi, et al.,1990, Mol. Cell. Biol. 11:5068-5078; Fantl, et al., 1992, Cell 69:413-413). Examples of receptors that transduce signals via catalytic intracellular domains include the receptor tyrosine kinases (RTKs) such as the Trk family of receptors which are generally limited to cells of the nervous system, the cytokine family of receptors including the tripartate CNTF receptor complex (Stahl & Yancopoulos, 1994, J. Neurobio. 25:1454-1466) which is also generally limited to the cells of the nervous system, G-protein coupled receptors such as the β_2 -adrenergic receptor found on, for instance, cardiac muscle cells, and the multimeric IgE high affinity receptor FcERI which is localized, for the most part, on mast cells and basophils (Sutton & Gould, 1993, Nature <u>366</u>:421-428).

All receptors identified so far appear to undergo dimerization, multimerization, or some related conformational change following ligand binding (Schlessinger, J., 1988, Trend Biochem. Sci. 13:443-447; Ullrich & Schlessinger, 1990, Cell 61:203-212; Schlessinger & Ullrich, 1992, Neuron 9:383-391) and molecular interactions between dimerizing intracellular domains lead to activation of catalytic function. In some instances, such as platelet-derived growth factor (PDGF), the ligand is a dimer that binds two receptor molecules (Hart, et al., 1988, Science, 240:1529-1531; Heldin, 1989, J. Biol. Chem. 264:8905-8912) while, for example, in the case of epidermal growth

10

15

20

25

factor (EGF), the ligand is a monomer (Weber, et al., 1984, J. Biol. Chem. 259:14631-14636). In the case of the FcεRI receptor, the ligand, IgE, exists bound to FcεRI in a monomeric fashion and only becomes activated when antigen binds to the IgE/FcεRI complex and cross-links adjacent IgE molecules (Sutton & Gould, 1993, Nature 366:421-428).

Often, the tissue distribution of a particular receptor within higher organisms provides insight into the biological function of the receptor. The RTKs for some growth and differentiation factors, such as fibroblast growth factor (FGF), are widely expressed and therefore appear to play some general role in tissue growth and maintenance. Members of the Trk RTK family (Glass & Yancopoulos, 1993, Trends in Cell Biol. 3:262-268) of receptors are more generally limited to cells of the nervous system, and the Nerve Growth Factor family consisting of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5), which bind the Trk RTK family receptors, promote the differentiation of diverse groups of neurons in the brain and periphery (Lindsay, R. M, 1993, in Neurotrophic Factors, S.E. Loughlin & J.H. Fallon, eds., pp. 257-284, San Diego, CA, Academic Press). FceRI is localized to a very limited number of types of cells such as mast cells and basophils. Mast cells derive from bone marrow pluripotent hematopoietic stem cell lineage, but complete their maturation in the tissue following migration from the blood stream (See Janeway & Travers, 1996, in Immunobiology, 2d. Edition, M. Robertson & E. Lawrence, eds., pp. 1:3-1:4, Current Biology Ltd., London, UK, Publisher) and are involved in the allergic response.

Many studies have demonstrated that the extracellular domain of a receptor provides the specific ligand binding characteristic. Furthermore, the cellular environment in which a receptor is expressed may influence the biological response exhibited upon binding of a ligand to the receptor. For example, when a neuronal cell expressing a Trk receptor is exposed to a neurotrophin which binds to that receptor, neuronal survival and differentiation results. When the same receptor is expressed by a fibroblast, exposure to the neurotrophin results in proliferation of the fibroblast (Glass, et al., 1991, Cell 66:405-413).

10

15

5

A class of cell-derived dimeric mitogens with selectivity for vascular endothelial cells has been identified and designated vascular endothelial cell growth factor (VEGF). VEGF has been purified from conditioned growth media of rat glioma cells [Conn et al., (1990), Proc. Natl. Acad. Sci. U.S.A., 87. pp 2628-2632]; and conditioned growth media of bovine pituitary follicle stellate cells [Ferrara and Henzel, (1989), Biochem. Biophys. Res. Comm., 161, pp. 851-858; Gozpadorowicz et al., (1989), Proc. Natl. Acad. Sci. U.S.A., 86, pp. 7311-7315] and conditioned growth medium from human U937 cells [Connolly, D. T. et al. (1989),

Science, 246, pp. 1309-1312]. VEGF is a dimer with an apparent molecular mass of about 46 kDa with each subunit having an apparent molecular mass of about 23 kDa. VEGF has some structural similarities to platelet derived growth factor (PDGF), which is a mitogen for connective tissue cells but not mitogenic for vascular endothelial cells from large vessels.

The membrane-bound tyrosine kinase receptor, known as Flt, was shown to be a VEGF receptor [DeVries, C. et al., (1992), Science, 255, pp.989-

10

15

20

25

991]. The Fit receptor specifically binds VEGF which induces mitogenesis. Another form of the VEGF receptor, designated KDR, is also known to bind VEGF and induce mitogenesis. The partial cDNA sequence and nearly full length protein sequence of KDR is known as well [Terman, B. I. et al., (1991) Oncogene 6, pp. 1677-1683; Terman, B. I. et al., (1992) Biochem. Biophys. Res. Comm. 187, pp. 1579-1586].

Persistent angiogenesis may cause or exacerbate certain diseases such as psoriasis, rheumatoid arthritis, hemangiomas, angiofibromas, diabetic retinopathy and neovascular glaucoma. An inhibitor of VEGF activity would be useful as a treatment for such diseases and other VEGF-induced pathological angiogenesis and vascular permeability conditions, such as tumor vascularization. The present invention relates to a VEGF inhibitor that is based on the VEGF receptor Flt1.

Plasma leakage, a key component of inflammation, occurs in a distinct subset of microvessels. In particular, in most organs plasma leakage occurs specifically in the venules. Unlike arterioles and capillaries, venules become leaky in response to numerous inflammatory mediators including histamine, bradykinin, and serotonin. One characteristic of inflammation is the plasma leakage that results from intercellular gaps that form in the endothelium of venules. Most experimental models of inflammation indicate that these intercellular gaps occur between the endothelial cells of postcapillary and collecting venules (Baluk, P., et al., Am. J. Pathol. 1998 152:1463-76). It has been shown that certain lectins may be used to reveal features of focal sites of plasma leakage, endothelial gaps, and finger-like processes at endothelial cell borders in inflamed venules (Thurston, G., et al., Am. J.

10

15

Physiol, 1996, 271: H2547-62). In particular, plant lectins have been used to visualize morphological changes at endothelial cell borders in inflamed venules of, for example, the rat trachea. Lectins, such as conconavalin A and ricin, that bind focally to inflamed venules reveal regions of the subendothelial vessel wall exposed by gaps that correspond to sites of plasma leakage (Thurston, G., et al., Am J Physiol, 1996, 271: H2547-62).

The properties of the microvessels are dynamic. Chronic inflammatory diseases, for example, are associated with microvascular remodeling, including angiogenesis and microvessel enlargement. Microvessels can also remodel by acquiring abnormal phenotypic properties. In a murine model of chronic airway inflammation, airway capillaries acquire properties of venules, including widened vessel diameter, increased immunoreactivity for von Willebrand factor, and increased immunoreactivity for P-selectin. In addition, these remodeled vessels leak in response to inflammatory mediators, whereas vessels in the same position in the airways of normal mice do not.

20 Certain substances have been shown to decrease or inhibit vascular permeability and/or plasma leakage. For example, mystixins are synthetic polypeptides that have been reported to inhibit plasma leakage without blocking endothelial gap formation (Baluk, P., et al., J. Pharmacol. Exp. Ther., 1998, 284: 693-9). Also, the beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation (Baluk, P. and McDonald, D.M., Am. J. Physiol., 1994, 266:L461-8).

10

15

25

1

The angiopoietins and members of the vascular endothelial growth factor (VEGF) family are the only growth factors thought to be largely specific for vascular endothelial cells. Targeted gene inactivation studies in mice have shown that VEGF is necessary for the early stages of vascular development and that Ang-1 is required for later stages of vascular remodeling.

US Patent No. 6,011,003, issued January 4, 2000, in the name of Metris Therapeutics Limited, discloses an altered, soluble form of FLT polypeptide being capable of binding to VEGF and thereby exerting an inhibitory effect thereon, the polypeptide comprising five or fewer complete immunoglobulin domains.

US Patent No. 5,712,380, issued January 27, 1998 and assigned to Merck & Co., discloses vascular endothelial cell growth factor (VEGF) inhibitors that are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF.

Also assigned to Merck & Co. is PCT Publication No. WO 98/13071, published April 2, 1998, which discloses gene therapy methodology for inhibition of primary tumor growth and metastasis by gene transfer of a nucleotide sequence encoding a soluble receptor protein which binds to VEGF.

PCT Publication No. WO 97/44453, published November 27, 1997, in the name of Genentech, Inc., discloses novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular

endothelial growth factor (VEGF) receptors Flt1 and KDR, including the murine homologue to the human KDR receptor FLK1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof.

5

PCT Publication No. WO 97/13787, published April 17, 1997, in the name of Toa Gosei Co., LTD., discloses a low molecular weight VEGF inhibitor usable in the treatment of diseases accompanied by neovascularization such as solid tumors. A polypeptide containing the first immunoglobulin-like domain and the second immunoglobulin-like domain in the extracellular region of a VEGF receptor FLT but not containing the sixth immunoglobulin-like domain and the seventh immunoglobulin-like domain thereof shows a VEGF inhibitory activity.

10

15

20

Sharifi, J. et al., 1998, The Quarterly Jour. of Nucl. Med. 42:242-249, disclose that because monoclonal antibodies (MAbs) are basic, positively charged proteins, and mammalian cells are negatively charged, the electrostatic interactions between the two can create higher levels of background binding resulting in low tumor to normal organ ratios. To overcome this effect, the investigators attempted to improve MAb clearance by using various methods such as secondary agents as well as chemical and charge modifications of the MAb itself.

25

Jensen-Pippo, et al., 1996, Pharmaceutical Research 13:102-107, disclose that pegylation of a therapeutic protein, recombinant human granulocyte colony stimulating factor (PEG-G-CSF), results in an increase in stability and in retention of *in vivo* bioactivity when administered by the intraduodenal route.

10

15

20

25

Tsutsumi, et al., 1997, Thromb Haemost. 77:168-73, disclose experiments wherein the *in vivo* thrombopoietic activity of polyethylene glycol-modified interleukin-6 (MPEG-IL-6), in which 54% of the 14 lysine amino groups of IL-6 were coupled with PEG, was compared to that of native IL-6.

Yang, et al., 1995, Cancer 76:687-94, disclose that conjugation of polyethylene glycol to recombinant human interleukin-2 (IL-2) results in a compound, polyethylene glycol-modified IL-2 (PEG-IL-2) that retains the in vitro and in vivo activity of IL-2, but exhibits a markedly prolonged circulating half-life.

R. Duncan and F. Spreafico, Clin. Pharmacokinet. 27: 290-306, 296 (1994) review efforts to improve the plasma half-life of asparaginase by conjugating polyethylene glycol.

PCT International Publication No. WO 99/03996 published January 28, 1999 in the name of Regeneron Pharmaceuticals, Inc. and The Regents of The University of California describes modified human noggin polypeptides having deletions of regions of basic amino acids. The modified human noggin polypeptides are described as retaining biological activity while having reduced affinity for heparin and superior pharmacokinetics in animal sera as compared to the unmodified human noggin.

SUMMARY OF THE INVENTION

The present invention is directed to VEGF antagonists with improved pharmacokinetic properties. A preferred embodiment is an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a VEGF polypeptide comprising (a) a nucleotide sequence encoding a VEGF receptor component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the VEGF receptor component is the only VEGF receptor component of the fusion polypeptide and wherein the nucleotide sequence of (a) consists essentially of a nucleotide sequence encoding the amino acid sequence of Ig domain 2 of the extracellular domain of a first VEGF receptor and a nucleotide sequence encoding the amino acid sequence of Ig domain 3 of the extracellular domain of a second VEGF receptor.

15

10

5

In a further embodiment, the isolated nucleic acid of the first VEGF receptor is Flt1.

In a further embodiment, the isolated nucleic acid of the second VEGF 20 receptor is Flk1.

In yet another embodiment, the isolated nucleic acid of the second VEGF receptor is Flt4.

In another preferred embodiment, the nucleotide sequence encoding Ig domain 2 of the extracellular domain of the first VEGF receptor is upstream of the nucleotide sequence encoding Ig domain 3 of the extracellular domain of the second VEGF receptor.

5

In still another preferred embodiment, the nucleotide sequence encoding Ig domain 2 of the extracellular domain of the first VEGF receptor is downstream of the nucleotide sequence encoding Ig domain 3 of the extracellular domain of the second VEGF receptor.

In a preferred embodiment of the invention, the multimerizing component comprises an immunoglobulin domain.

In another embodiment, the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.

Preferred embodiments include an isolated nucleic acid molecule comprising a nucleotide sequence encoding a modified Flt1 receptor fusion polypeptide, wherein the coding region of the nucleic acid molecule consists of a nucleotide sequence selected from the group consisting of

- (a) the nucleotide sequence set forth in Figure 13A-13D;
- 20 (b) the nucleotide sequence set forth in Figure 14A-14C;
 - (c) the nucleotide sequence set forth in Figure 15A-15C;
 - (d) the nucleotide sequence set forth in Figure 16A-16D;
 - (e) the nucleotide sequence set forth in Figure 21A-21C;
 - (f) the nucleotide sequence set forth in Figure 22A-22C;
- 25 (g) the nucleotide sequence set forth in Figure 24A-24C; and
 - (h) a nucleotide sequence which, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a), (b), (c), (d),
 - (e), (f), or (g) and which encodes a fusion polypeptide molecule having

the biological activity of the modified Flt1 receptor fusion polypeptide.

In a further embodiment of the invention, a fusion polypeptide is encoded by the isolated nucleic acid molecules described above.

5

A preferred embodiment is a composition capable of binding a VEGF molecule to form a nonfunctional complex comprising a multimer of the fusion polypeptide.

10 Also preferred is a composition wherein the multimer is a dimer.

In yet another embodiment, the composition is in a carrier.

Another embodiment is a vector which comprises the nucleic acid

molecules described above, including an expression vector comprising a
the nucleic acid molecules described wherein the nucleic acid molecule
is operatively linked to an expression control sequence.

Other included embodiments are a host-vector system for the

production of a fusion polypeptide which comprises the expression vector, in a suitable host cell; the host-vector system wherein the suitable host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell; the host-vector system wherein the suitable host cell is <u>E. Coli</u>; the host-vector system wherein the suitable host cell is a

COS cell; the host-vector system wherein the suitable host cell is a CHO cell.

Another embodiment of the invention is a method of producing a fusion polypeptide which comprises growing cells of the host-vector system under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.

5

Additional embodiments include a fusion polypeptide encoded by the nucleic acid sequence set forth in Figure 10A-10D or Figure 24A-24C, which has been modified by acetylation or pegylation wherein the acetylation is accomplished with at least about a 100 fold molar excess of acetylation reagent or wherein acetylation is accomplished with a molar excess of acetylation reagent ranging from at least about a 10 fold molar excess to about a 100 fold molar excess or wherein the pegylation is 10K or 20K PEG.

10

15 A preferred embodiment includes a method of decreasing or inhibiting plasma leakage in a mammal comprising administering to the mammal the fusion polypeptide described above, including embodiments wherein the mammal is a human, the fusion polypeptide is acetylated or the fusion polypeptide is pegylated.

20

A further embodiments is a fusion polypeptide which specifically binds the VEGF receptor ligand VEGF.

A preferred embodiment of the invention is a method of blocking blood 25 vessel growth in a human comprising administering an effective amount of the fusion polypeptide described above.

15

20

25

WO 00/75319 PCT/US00/14142

Also preferred is a method of inhibiting VEGF receptor ligand activity in a mammal comprising administering to the mammal an effective amount of the fusion polypeptide described above.

5 Preferred embodiments of these methods are wherein the mammal is a human.

Further embodiments of the methods of the invention include attenuation or prevention of tumor growth in a human; attenuation or prevention of edema in a human, especially wherein the edema is brain edema; attenuation or prevention of ascites formation in a human, especially wherein the ascites is ovarian cancer-associated ascites.

Preferred embodiments of the invention include a fusion polypeptide capable of binding a VEGF polypeptide comprising (a) a VEGF receptor component operatively linked to (b) a multimerizing component, wherein the VEGF receptor component is the only VEGF receptor component in the fusion polypeptide and consists essentially of the amino acid sequence of Ig domain 2 of the extracellular domain of a first VEGF receptor and the amino acid sequence of Ig domain 3 of the extracellular domain of a second VEGF receptor.

In a further embodiment of the fusion polypeptide, the first VEGF receptor is Flt1.

In yet a further embodiment of the fusion polypeptide, the second VEGF receptor is Flk1.

10

15

20

25

Still another embodiment of the fusion polypeptide is one in which the second VEGF receptor is Flt4.

Preferred embodiments include a fusion polypeptide wherein amino acid sequence of Ig domain 2 of the extracellular domain of the first VEGF receptor is upstream of the amino acid sequence of Ig domain 3 of the extracellular domain of the second VEGF receptor and a fusion polypeptide wherein the amino acid sequence of Ig domain 2 of the extracellular domain of the first VEGF receptor is downstream of the amino acid sequence of Ig domain 3 of the extracellular domain of the second VEGF receptor.

In yet another embodiment, the fusion polypeptide multimerizing component comprises an immunoglobulin domain including an embodiment wherein the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.

Preferred embodiments include a fusion polypeptide comprising an amino acid sequence of a modified Flt1 receptor, wherein the amino acid sequence selected from the group consisting of (a) the amino acid sequence set forth in Figure 13A-13D; (b) the amino acid sequence set forth in Figure 14A-14C; (c) the amino acid sequence set forth in Figure 15A-15C; (d) the amino acid sequence set forth in Figure 21A-21C; (f) the amino acid sequence set forth in Figure 22A-22C; and (g) the amino acid sequence set forth in Figure 24A-24C.

Another preferred embodiment is a method of decreasing or inhibiting plasma leakage in a mammal comprising administering to the mammal the fusion polypeptide described above.

An alternative preferred embodiment is a method of inhibiting VEGF receptor ligand activity in a mammal comprising administering to the mammal an effective amount of the fusion polypeptide described above.

BRIEF DESCRIPTION OF THE FIGURES

10

Figure 1. IEF gel analysis of unmodified and acetylated Flt1(1-3)-Fc proteins. Unmodified Flt1(1-3)-Fc protein is unable to enter the gel due to its >9.3 pl, whereas acetylated Flt1(1-3)-Fc is able to enter the gel and equilibrate at pl 5.2.

15

Figure 2. Binding of unmodified Flt1(1-3)-Fc and acetylated Flt1(1-3)-Fc proteins to Matrigel® coated plates. Unmodified Flt1(1-3)-Fc proteins binds extensive to extracellular matrix components in Matrigel®, whereas acetylated Flt1(1-3)-Fc does not bind.

20

25

Figure 3. Binding of unmodified Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc, and pegylated Flt1(1-3)-Fc in a Biacore-based assay. Acetylated (columns 13-16), pegylated (columns 17-20), and heparin-treated Flt1(1-3)-Fc (columns 21-24) are each able to completely compete with the Biacore chip-bound Flt1(1-3)-Fc for VEGF binding as compared to control (columns 1-4) and irrelevant protein (columns 5-8). Unmodified Flt1(1-3)-Fc (columns 5-6) appears to only partially compete with Biacore chip-bound Flt1(1-3)-Fc for VEGF binding.

However, washing the bound samples with 0.5M NaCl (columns 7-8) results in a binding profile similar to the modified forms of Flt1(1-3)-Fc, indicating that the unmodified protein is exhibiting non-specific binding to the chip that can be eliminated by the salt wash.

5

Figure 4. Binding of unmodified Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc, and pegylated Flt1(1-3)-Fc to VEGF in an ELISA-based assay. Both pegylated and acetylated Flt1(1-3)-Fc proteins bind to VEGF with affinities approaching that of unmodified Flt1(1-3)-Fc.

10

15

Figure 5. Pharmacokinetic profiles of unmodified Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc, and pegylated Flt1(1-3)-Fc. Balb/c mice (23-28g) were injected subcutaneously with 4mg/kg of unmodified, acetylated, or pegylated Flt1(1-3)-Fc. The mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days, and 3 days after injection of protein and the sera were assayed in a standard ELISA-based assay designed to detect Flt1(1-3)-Fc protein. The T_{max} for all of the Flt1(1-3)-Fc proteins was between the 6 hour and 24 hour time points. The C_{max} for the different proteins was as follows: Unmodified: 0.06 μg/ml - 0.15 μg/ml; acetylated: 1.5 μg/ml - 4.0 μg/ml; and pegylated: approximately 5 μg/ml.

25

20

Figure 6A-6B. IEF gel analysis of unmodified and step-acetylated Flt1(1-3)-Fc proteins. Unmodified Flt1(1-3)-Fc protein is unable to enter the gel due to its >9.3 pl, whereas most of the step-acetylated Flt1(1-3)-Fc samples (30-100 fold excess samples) were able to migrate into the gel and equilibrate at pls ranging between 4.55 - 8.43, depending on the degree of acetylation.

Figure 7. Binding of unmodified Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc proteins to Matrigel® coated plates. As with the irrelevant control protein, rTie2-Fc, step-acetylated Flt1(1-3)-Fc (20 and 30 fold excess samples) does not exhibit any binding to the Matrigel coated plate, whereas the non-acetylated Flt1(1-3)-Fc protein exhibits significant binding. The 10 fold excess sample shows reduced binding, but the degree of acetylation is not enough to completely block binding to extracellular matrix components.

10

15

20

5

Figure 8. Binding of unmodified Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc in a Biacore-based assay. At a sub-stoichiometric ratio (0.5 μg/ml of either unmodified Flt1(1-3) or step-acetylated Flt1(1-3)-Fc vs. 0.2 μg/ml VEGF), there is not enough Flt1(1-3)-Fc (either unmodified or step-acetylated) in the solution to completely bind the VEGF. At 1.0 μg/ml, which approximates a 1:1 stoichiometric ratio, the both unmodified and step-acetylated Flt1(1-3)-Fc are better able to compete for VEGF binding, but there is still insufficient Flt1(1-3)-Fc protein (either unmodified or step-acetylated) to completely saturate the available VEGF. However, at 5.0 μg/ml, which is several times greater than a 1:1 stoichiometric ratio, both the Flt1(1-3)-Fc and the step-acetylated Flt1(1-3)-Fc proteins are able to saturate the VEGF, regardless of the degree of acetylation.

25 **Figure 9.** Pharmacokinetic profiles of unmodified Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc. Balb/c mice (23-28g) were injected subcutaneously with 4mg/kg of unmodified or 10, 20, 40, 60 and 100 fold excess samples of step-acetylated Flt1(1-3)-Fc (3 mice for

unmodified, 10, 20 and 40 fold excess samples and 2 mice for 60 and 100 fold excess samples). The mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days and 3 days after injection. The sera were assayed in an ELISA-based assay designed to detect Flt1(1-3)-Fc. The T_{max} for all of the Flt1(1-3)-Fc proteins tested was at the 6 hour time point but the C_{max} was as follows: Unmodified Flt1(1-3)-Fc: $0.06\mu g/ml$; 10 fold excess sample: $-0.7\mu g/ml$, 20 fold excess sample $-2\mu g/ml$, 40 fold excess sample $-4\mu g/ml$, 60 fold excess sample $-2\mu g/ml$, 100 fold excess sample $-1\mu g/ml$.

10

5

Figure 10A-10D. Nucleic acid and deduced amino acid sequence of Fit1(1-3)-Fc.

Figure 11. Schematic diagram of the structure of Flt1.

15

Figure 12A and 12B. Hydrophilicity analysis of the amino acid sequences of Ig domain 2 and Ig domain 3 of Flt1.

Figure 13A-13D. Nucleic acid and deduced amino acid sequence of Mut1: $Flt1(1-3_{AB})$ -Fc.

Figure 14A-14 C. Nucleic acid and deduced amino acid sequence of Mut2: $Flt1(2-3_{AB})$ -Fc.

25 **Figure 15A-15C.** Nucleic acid and deduced amino acid sequence of Mut3: Flt1(2-3)-Fc.

10

15

Figure 16A-16D. Nucleic acid and deduced amino acid sequence of Mut4: $Fit1(1-3_{R->N})$ -Fc.

Figure 17. Binding of unmodified Flt1(1-3)-Fc, basic region deletion mutant Flt1(1-3)-Fc, and Flt1(1-3)_{R->N} mutant proteins in a Biacorebased assay. At the sub-stoichiometric ratio (0.25 µg/ml Flt1(1-3)-Fc of unmodified, acetylated or genetically modified samples vs. 01. µg/ml VEGF), there is insufficient Flt1(1-3)-Fc protein to block binding of VEGF to the Flt1(1-3)-Fc immobilized on the Biacore chip. At 0.5 μg/ml of unmodified, acetylated or genetically modified Flt1(1-3)-Fc proteins, the stoichiometric ratio approximates 1:1 and there is an increased ability to block VEGF binding to the Biacore chip. At 1.0 ug/ml of unmodified, acetylated or genetically modified Flt1(1-3)-Fc proteins, which is approximately a 10:1 stoichiometric ratio, the Flt1(1-3)-Fc proteins are able to block binding of VEGF to the Biacore chip, but they are not equivalent. Unmodified, acetylated, and Mut1: FIt1(1-3 $_{\Delta B}$)-Fc are essentially equal in their ability to block VEGF binding, whereas Mut4: Flt1(1-3_{R->N})-Fc is somewhat less efficient at blocking binding

20

25

Figure 18. Binding of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1- 3_{AB})-Fc, Mut2: Flt1(2- 3_{AB})-Fc, and Flt1(2-3) mutant proteins to Matrigel® coated plates. Unmodified Flt1(1-3)-Fc protein binds avidly to these wells, the Mut3: Flt1(2-3)-Fc protein binds somewhat more weakly, the Mut1: Flt1(1- 3_{AB})-Fc protein binds more weakly still, and the Mut2: Flt1(2- 3_{AB})-Fc protein shows the best profile, binding more weakly than any of the other mutant proteins. The Mut4: Flt1(1- $3_{B->N}$)-Fc

25

glycosylation mutant protein shows only marginal benefit on the Matrigel assay.

- Figure 19. Binding of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3 $_{\Delta B}$)-Fc, Mut2: Flt1(2-3 $_{\Delta B}$)-Fc, and Flt1(2-3) mutant proteins in an ELISA-based assay. At the concentrations tested, unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3 $_{\Delta B}$)-Fc, Mut2: Flt1(2-3 $_{\Delta B}$)-Fc, and Flt1(2-3) mutant proteins bind VEGF similarly.
- 10 Figure 20. Pharmacokinetic profiles of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3 $_{\Delta B}$)-Fc, Mut2: Flt1(2-3 $_{\Delta B}$)-Fc, and Flt1(2-3) mutant proteins. the Cmax for these reagents was as follows: Unmodified Flt1(1-3)-Fc 0.15 μ g/ml; 40 fold molar excess acetylated Flt1(1-3)-Fc 1.5 μ g/ml; and Mut1: Flt1(1-3 $_{\Delta B}$)-Fc 0.7 μ g/ml.

Figure 21A-21C. Nucleotide and deduced amino acid sequence of the modified Flt1 receptor termed Flt1D2.Fik1D3.FcΔC1(a).

- Figure 22A-22C. Nucleotide and deduced amino acid sequence of the 20 modified Flt1 receptor termed Flt1D2.VEGFR3D3.FcΔC1(a).
 - Figure 23. Extracellular Matrix (ECM) Assay. The results of this assay demonstrate that the Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a) proteins are considerably less sticky to the ECM as compared to the Flt1(1-3)-Fc protein.

10

15

20

25

Figure 24A-24C. Nucleotide and deduced amino acid sequence of the modified Flt1 receptor termed VEGFR1R2-Fc∆C1(a).

Figure 25A-25C. Phosphorylation assay. At a 1.5 molar excess of either Flt1(1-3)-Fc , Flt1(1-3)-Fc (A40) or transient Flt1D2Flk1D3.FcΔC1(a) there is complete blockage of receptor stimulation by these three modified Flt1 receptors as compared to control media challenge. In contrast, transient Flt1D2VEGFR3D3.FcΔC1(a) does not show significant blockage at this molar excess, as compared with VEGF positive control challenge. Similar results are seen in Figure 25B, where the modified Flt receptors are in a 3-fold molar excess to VEGF165 ligand. In Figure 25C, where the modified Flt1 receptors are in a 6-fold molar excess to VEGF165 ligand, transient Flt1D2VEGFR3D3.FcΔC1(a) can now be shown to be partially blocking VEGF165-induced stimulation of cell-surface receptors.

Figure 26A-26B. Phosphorylation assay. Detection by Western blot of tyrosine phosphorylated VEGFR2(Flk1) by VEGF165 ligand stimulation shows that cell-surface receptors are not phosphorylated by challenge samples which have VEGF165 preincubated with 1 and 2 fold molar excess (Figure 26A) or 3 and 4 fold molar excess (Figure 26B) of either transient Flt1D2Flk1D3.FcΔC1(a), stable Flt1D2Flk1D3.FcΔC1(a), or transient VEGFR1R2-FcΔC1(a). At all modified Flt1 receptor concentrations tested there is complete binding of VEGF165 ligand

10

15

during the preincubation, resulting in no detectable stimulation of cellsurface receptors by unbound VEGF165 as compared to control media challenge.

Figure 27. MG/R2 Cell proliferation assay. The following modified Flt receptors Flt1(1-3)-Fc, Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a), plus an irrelevant receptor termed Tie2-Fc as a negative control, were titrated from 40nM to 20pM and incubated on the cells for 1hr at 37°C. Human recombinant VEGF165 in defined media was then added to all the wells at a concentration of 1.56nM. The negative control receptor Tie2-Fc does not block VEGF165-induced cell proliferation at any concentration whereas Flt1D2.Flk1D3.FcΔC1(a) blocks 1.56nM VEGF165 with a half maximal dose of 0.8nM. Flt1(1-3)-Fc and Flt1D2.VEGFR3D3.FcΔC1(a) are less effective in blocking VEGF165 in this assay with a half maximal dose of ~ 2nM. VEGF165 alone gives a reading of 1.2 absorbance units and the background is 0.38 absorbance units.

Figure 28. Biacore analysis of Binding Stoichiometry. Binding stoichiometry was calculated as a molar ratio of bound VEGF165 to the immobilized Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a), using the conversion factor of 1000 RU equivalent to 1 ng/ml. The results indicated binding stoichiometry of one VEGF165 dimeric molecule per one Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a) molecule.

Figure 29 and Figure 30. Size Exclusion Chromatography
Stoichiometry. Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a) at a concentration of 1nM (estimated to be 1000 times higher than the KD of the Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a)/VEGF165

- interaction) were mixed with varied concentrations of VEGF165. After incubation, concentrations of the free Flt1D2Flk1D3.FcΔC1(a) in solution were measured. The data shows that the addition of 1 nM VEGF165 into the Flt1D2Flk1D3.FcΔC1(a) solution completely blocks Flt1D2Flk1D3.FcΔC1(a) binding to the VEGF165 surface. This result suggested the binding stoichiometry of one VEGF165 molecule per one Flt1D2Flk1D3.FcΔC1(a) molecule.
 - Figure 31. Size Exclusion Chromatography (SEC) under native conditions. Peak #1 represents the Flt1D2Flk1D3.FcΔC1(a)/ VEGF165 complex and peak #2 represents unbound VEGF165. Fractions eluted between 1.1 and 1.2 ml were combined and guanidinium hydrochloride (GuHCl)was added to a final concentration 4.5M to dissociate the complex.
- Figure 32. Size Exclusion Chromatography (SEC) under dissociative conditions. To separate the components of the receptor-ligand complex and to determine their molar ratio, 50μl of dissociated complex was loaded onto a Superose 12 PC 3.2/30 equilibrated in 6M GuHCl and eluted. Peak #1 represents Flt1D2Flk1D3.FcΔC1(a) and peak #2 represents VEGF165.

10

15

20

25

Figure 33, Figure 34 and Figure 35. Size Exclusion
Chromatography (SEC) with On-Line Light Scattering. Size exclusion
chromatography column with a MiniDawn on-line light scattering
detector (Wyatt Technology, Santa Barbara, California) and refractive
index (RI) detectors (Shimadzu, Kyoto, Japan) was used to determine
the molecular weight (MW) of the receptor-ligand complex. As shown in
Figure 33, the elution profile shows two peaks. Peak #1 represents the
receptor-ligand complex and peak #2 represents the unbound VEGF165.
MW was calculated from LS and RI signals. The same procedure was
used to determine MW of the individual components of the receptorligand complex. The results of these determinations are as follows:
MW of the Flt1D2Flk1D3.FcΔC1(a)/VEGF165 complex at the peak
position is 157 300 (Figure 33), the MW of VEGF165 at the peak
position is 44 390 (Figure 34) and the MW of R1R2 at the peak is 113
300 (Figure 35).

Figure 36. Peptide mapping and glycosylation analysis. The disulfide structures and glycosylation sites in Flt1D2.Flk1D3.FcΔC1(a) were determined by a peptide mapping method. There are a total of ten cysteines in Flt1D2.Flk1D3.FcΔC1(a); six of them belong to the Fc region. Cys27 is disulfide bonded to Cys76. Cys121 is disulfide bonded to Cys 182. The first two cysteines in the Fc region (Cys211 and Cys214) form an intermolecular disulfide bond with the same two cysteines in another Fc chain. However, it can not be determined

whether disulfide bonding is occurring between same cysteines (Cys211 to Cys211, for example) or between Cys211 and Cys214. Cys216 is disulfide bonded to Cys306. Cys 352 is disulfide bonded to Cys410.

5

10

15

20

25

There are five possible N-linked glycosylation sites in Flt1D2.Flk1D3.Fc∆C1(a) and are found to be glycosylated to varying degrees. Complete glycosylation is observed at Asn33, Asn193, and Asn282. Partial glycosylation is observed on Asn65 and Asn120. Sites of glycosylation are highlighted by underline in the Figure.

Figure 37. Pharmacokinetics of Flt1(1-3)-Fc (A40),

Flt1D2.Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a). Balb/c mice were injected subcutaneously with 4mg/kg of Flt1(1-3)-Fc (A40), CHO transiently expressed Flt1D2.Flk1D3.FcΔC1(a), CHO stably expressed Flt1D2.Flk1D3.FcΔC1(a), and CHO transiently expressed VEGFR1R2-FcΔC1(a). The mice were tail bled at 1, 2, 4, 6, 24 hrs, 2 days, 3 days and 6 days after injection. The sera were assayed in an ELISA designed to detect Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) or VEGFR1R2-

FcΔC1(a). The Tmax for Flt1(1-3)-Fc (A40) was at 6 hrs while the Tmax for the transient and stable Flt1D2.Flk1D3.FcΔC1(a) and the transient VEGFR1R2-FcΔC1(a) was 24hrs. The Cmax for Flt1(1-3)-Fc (A40) was 8μg/ml, For both transients (Flt1D2.Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a)) the Cmax was 18μg/ml and the Cmax for the stable VEGFR1R2-FcΔC1(a) was 30μg/ml.

10

15

- Figure 38. Pharmacokinetics of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a). Balb/c mice were injected subcutaneously with 4mg/kg of Flt1(1-3)-Fc (A40), CHO transiently expressed Flt1D2.Flk1D3.FcΔC1(a) and CHO transiently expressed Flt1D2.VEGFR3D3.FcΔC1(a). The mice were tail bled at 1, 2, 5, 6, 7, 8, 12, 15 and 20 days after injection. The sera were assayed in an ELISA designed to detect Flt1(1-3)-Fc, Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a). Flt1(1-3)-Fc (A40) could no longer be detected in the serum after day 5 whereas Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a) were detectable for 15 days or more.
- Figure 39. The Ability of Flt1D2.Flk1D3.FcΔC1(a) to Inhibit HT-1080 Fibrosarcoma Tumor Growth In Vivo. Every other day or 2 times per week treatment of SCID mice with Flt1D2.Flk1D3.FcΔC1(a) at 25mg/Kg significantly decreases the growth of subcutaneous HT-1080 fibrosarcoma tumors.
- Figure 40. The Ability of Flt1D2.Flk1D3.Fc∆C1(a) to Inhibit C6 Glioma

 20 Tumor Growth In Vivo. Every other day or 2 times a week treatment of

 SCID mice with Flt1D2.Flk1D3.Fc∆C1(a) significantly decreases the

 growth of subcutaneous C6 glioma tumors at doses as low as 2.5mg/Kg.
- Figure 41. VEGF-Induced Uterine Hyperpermeability. PMSG injected subcutaneously (5 IU) to induce ovulation in prepubertal female rats

10

15

20

25

results in a surge of estradiol after 2 days which in turn causes an induction of VEGF in the uterus. This induction results in hyperpermeability of the uterus and an increase in uterine wet. Subcutaneous injection of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a) at 25mg/kg at 1hr after PMSG injection results in about a 50% inhibition of the increase in uterine wet weight.

Figure 42A-42B. Assessment of Corpus Luteum Angiogenesis Using Progesterone as a Readout. PMSG was injected subcutaneously (5 IU) to induce ovulation in prepubertal female rats, resulting in a fully functioning corpus luteum containing a dense network of blood vessels that secretes progesterone into the blood stream to prepare the uterus for implantation. The induction of angiogenesis in the corpus luteum requires VEGF. Resting levels of progesterone are about 5ng/ml and can be induced to 25-40ng/ml after PMSG. Subcutaneous injection of Flt1(1-3)-Fc (A40) or Flt1D2.Flk1D3.FcΔC1(a) at 25mg/kg or 5mg/kg at 1hr. after PMSG injection resulted in a complete inhibition of the progesterone induction on day 4.

DETAILED DESCRIPTION OF THE INVENTION

It has been a long standing problem in the art to produce a receptor based VEGF antagonist that has a pharmacokinetic profile that is appropriate for consideration of the antagonist as a therapeutic candidate. Applicants describe herein, for the first time, a chimeric

10

15

20

25

polypeptide molecule, capable of antagonizing VEGF activity, that exhibits improved pharmacokinetic properties as compared to other known receptor-based VEGF antagonists. The chimeric polypeptide molecules described herein thus provide for the first time appropriate molecules for use in therapies in which antagonism of VEGF is a desired result.

The present invention provides for novel chimeric polypeptide molecules formed by fusing a modified extracellular ligand binding domain of the Flt1 receptor to the Fc region of IgG.

The extracellular ligand binding domain is defined as the portion of a

receptor that, in its native conformation in the cell membrane, is oriented extracellularly where it can contact with its cognate ligand. The extracellular ligand binding domain does not include the hydrophobic amino acids associated with the receptor's transmembrane domain or any amino acids associated with the receptor's intracellular domain. Generally, the intracellular or cytoplasmic domain of a receptor is usually composed of positively charged or polar amino acids (i.e. lysine, arginine, histidine, glutamic acid, aspartic acid). The preceding 15-30, predominantly hydrophobic or apolar amino acids (i.e. leucine, valine, isoleucine, and phenylalanine) comprise the transmembrane domain. The extracellular domain comprises the amino acids that precede the hydrophobic transmembrane stretch of amino acids. Usually the transmembrane domain is flanked by positively

charged or polar amino acids such as lysine or arginine. von Heijne has published detailed rules that are commonly referred to by skilled artisans when determining which amino acids of a given receptor belong to the extracellular, transmembrane, or intracellular domains (See von Heijne, 1995, BioEssays 17:25-30). Alternatively, websites on the Internet, such as

http://ulrec3.unil.ch/software/TMPRED_form.html. have become available to provide protein chemists with information about making predictions about protein domains.

10

15

20

5

The present invention provides for the construction of nucleic acid molecules encoding chimeric polypeptide molecules that are inserted into a vector that is able to express the chimeric polypeptide molecules when introduced into an appropriate host cell. Appropriate host cells include, but are not limited to, bacterial cells, yeast cells, insect cells, and mammalian cells. Any of the methods known to one skilled in the art for the insertion of DNA fragments into a vector may be used to construct expression vectors encoding the chimeric polypeptide molecules under control of transcriptional/translational control signals. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinations (genetic recombination) (See Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory; Current Protocols in Molecular Biology, Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience,

13

10

15

20

25

Expression of nucleic acid molecules encoding the chimeric polypeptide molecules may be regulated by a second nucleic acid sequence so that the chimeric polypeptide molecule is expressed in a host transformed with the recombinant DNA molecule. For example, expression of the chimeric polypeptide molecules described herein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control expression of the chimeric polypeptide molecules include, but are not limited to, the long terminal repeat as described in Squinto et al., (1991, Cell 65:1-20); the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the CMV promoter, the M-MuLV 5' terminal repeat the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:144-1445), the regulatory sequences of the metallothionine gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the β-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25, see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADH (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and

10

15

20

· have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646: Ornitz et al., 1986. Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58); alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al. 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94); myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Shani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

10

15

20

25

Thus, according to the invention, expression vectors capable of being replicated in a bacterial or eukaryotic host comprising chimeric polypeptide molecule-encoding nucleic acid as described herein, are used to transfect the host and thereby direct expression of such nucleic acids to produce the chimeric polypeptide molecules, which may then be recovered in a biologically active form. As used herein, a biologically active form includes a form capable of binding to VEGF.

Expression vectors containing the chimeric nucleic acid molecules described herein can be identified by three general approaches: (a) DNA-DNA hybridization. (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising sequences that are homologous to the inserted chimeric polypeptide molecule sequences. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the chimeric polypeptide molecule DNA sequence is inserted within the marker gene sequence of the vector, recombinants containing the insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying

15

the foreign gene product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the chimeric polypeptide molecules.

5 Cells of the present invention may transiently or, preferably, constitutively and permanently express the chimeric polypeptide molecules.

The chimeric polypeptide molecules may be purified by any technique which allows for the subsequent formation of a stable, biologically active chimeric polypeptide molecule. For example, and not by way of limitation, the factors may be recovered from cells either as soluble proteins or as inclusion bodies, from which they may be extracted quantitatively by 8M guanidinium hydrochloride and dialysis (see, for example, Builder, et al., US Patent No. 5,663,304). In order to further purify the factors, conventional ion exchange chromatography, hydrophobic interaction chromatography, reverse phase chromatography or gel filtration may be used.

In one embodiment of the invention, the nucleotide sequence encoding the first component is upstream of the nucleotide sequence encoding the second component. In another embodiment of the invention, the nucleotide sequence encoding the first component is downstream of the nucleotide sequence encoding the second component. Further

25 embodiments of the invention may be prepared in which the order of the

10

15

20

25

first, second and third fusion polypeptide components are rearranged. For example, if the nucleotide sequence encoding the first component is designated 1, the nucleotide sequence encoding the second component is designated 2, and the nucleotide sequence of the third component is designated 3, then the order of the components in the isolated nucleic acid of the invention as read from 5' to 3' may be any of the following six combinations: 1,2,3; 1,3,2; 2,1,3; 2,3,1; 3,1,2; or 3,2,1.

The present invention also has diagnostic and therapeutic utilities. In particular embodiments of the invention, methods of detecting aberrancies in the function or expression of the chimeric polypeptide molecules described herein may be used in the diagnosis of disorders. In other embodiments, manipulation of the chimeric polypeptide molecules or agonists or antagonists which bind the chimeric polypeptide molecules may be used in the treatment of diseases. In further embodiments, the chimeric polypeptide molecule is utilized as an agent to block the binding of a binding agent to its target.

By way of example, but not limitation, the method of the invention may be useful in treating clinical conditions that are characterized by vascular permeability, edema or inflammation such as brain edema associated with injury, stroke or tumor; edema associated with inflammatory disorders such as psoriasis or arthritis, including rheumatoid arthritis; asthma; generalized edema associated with burns; ascites and pleural effusion associated with tumors, inflammation or

trauma; chronic airway inflammation; capillary leak syndrome; sepsis; kidney disease associated with increased leakage of protein; and eye disorders such as age related macular degeneration and diabetic retinopathy.

5

10

15

An amino acid sequence analysis of Flt1(1-3)-Fc revealed the presence of an unusually high number (46) of the basic amino acid residue lysine. An IEF analysis of Flt1(1-3)-Fc showed that this protein has pl greater than 9.3, confirming the prediction that the protein is very basic. It was hypothesized that the basic nature of Flt1(1-3)-Fc protein was causing it to bind to extracellular matrix components and that this interaction might be the cause of the extremely short detectable circulating serum half-life exhibited by Flt1(1-3)-Fc when injected into mice. In order to test this hypothesis, Flt1(1-3)-Fc protein was acetylated at the lysine residues to reduce the basic charge.

Acetylated Flt1(1-3)-Fc was then tested in the assays described *infra*.

The following examples are offered by way of illustration and not by way of limitation.

20

25

EXAMPLES

Example 1: Expression of FIt1(1-3)-Fc protein in CHO K1 cells.

Using standard molecular biology techniques (see e.g., Molecular Cloning, A Laboratory Manual (Sambrook, et al., Cold Spring Harbor

10

15

20

25

Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY), the gene encoding Flt1(1-3)-Fc was inserted into the expression vector pEE14.1 (Lonza Biologics, plc) at a multiple cloning site downstream of the CMV promoter. CHO K1 cells were transfected with the pEE14.1/Flt1(1-3)-Fc DNA construct using lipofectamine (Gaithersburg, MD). The transfected CHO K1 cells were grown in glutamine-free DMEM (JRH, Kansas City, MO) containing 25μM methionine sulfoximine (MSX) from Sigma Inc., St. Louis, MO, and high recombinant protein expressors were obtained by screening the CHO K1 cell supernatants from over 100 hand-picked colony isolates using a standard immunoassay which captures and detects human Fc. The selected hand-picked clone was amplified in the presence of 100 μM MSX followed by a second round of screening of the amplified clones. The highest producing clone had a specific productivity of recombinant Flt1(1-3)-Fc protein of 55 pg/cell/day.

The selected clone was expanded in 225cm² T-flasks (Corning, Acton, MA) and then into 8.5L roller bottles (Corning, Acton, MA) using the cell culture media described *supra*. Cells were removed from the roller bottles by standard trypsinization and put into 3.5L of suspension medium. The suspension medium is comprised of glutamine-free ISCHO medium (Irvine Scientific, Santa Ana, CA) containing 5% fetal bovine serum (FBS from Hyclone Labs, Logan, UT), 100µM MSX and GS supplement (JRH Scientific, Kansas City, MO) in a 5L Celligen bioreactor (New Brunswick Scientific, New Brunswick, NJ) at a density

10

25

of 0.3 x 10⁶ cells/mL. After the cells reached a density of 3.6 x 10⁶/mL and were adapted to suspension they were transferred to a 60L bioreactor (ABEC, Allentown, PA) at a density of 0.5 x 10⁶ cells/mL in 20L of ISCHO medium with 5% fetal bovine serum. After two days an additional 20L of ISCHO + 5% fetal bovine serum was added to the bioreactor. The cells were allowed to grow for an additional two days reaching a final density of 3.1 x 10⁶ cells/mL, and a final Flt1(1-3)-Fc concentration at harvest was 95 mg/L. At harvest the cells were removed by tangential flow filtration using 0.45µm Prostak Filters (Millipore, Inc., Bedford, MA).

<u>Example 2: Purification of Flt1(1-3)-Fc protein obtained</u> <u>from CHO K1 cells</u>

A Protein A column was used to bind, with high specificity, the Fc portion of the molecule. This affinity-purified protein was then concentrated and passed over a SEC column. The protein was then eluted into the formulation buffer. The following describes these procedures in detail.

Materials and Methods

All chemicals were obtained from J.T. Baker, Phillipsburg, NJ with the exception of PBS, which was obtained as a 10X concentrate from Life

Technologies, Gaithersburg, MD. Protein A Fast Flow and Superdex 200 preparation grade resins were obtained from Pharmacia, Piscataway, NJ. Equipment and membranes for protein concentration were obtained from Millipore, Bedford, MA.

5

10

15

Approximately 40L of 0.45µm-filtered CHO conditioned media containing Flt1(1-3)-Fc protein was applied to a 290mL Protein A Fast Flow column (10cm diameter) that had been equilibrated with PBS. The column was washed with PBS containing 350mM NaCl and 0.02% CHAPS and the bound protein was eluted with 20mM Citric Acid containing 10mM Na₂HPO₄. The single peak in the elution was collected and its pH was raised to neutrality with 1M NaOH. The eluate fractions was concentrated to approximately 9 mg/mL using 10K regenerated cellulose membranes by both tangential flow filtration and by stirred cell concentration. To remove aggregates and other contaminants, the concentrated protein was applied to a column packed with Superdex 200 preparation grade resin (10cm x 55cm) and run in PBS containing 5 % glycerol. The main peak fractions were pooled, sterile filtered, aliquoted and stored at -80°C.

20

25

Example 3: Acetylation of Flt1(1-3)-Fc protein.

Two milligrams of Flt1(1-3)-Fc protein were acetylated as described in the instruction manual provided with the sulfo-NHS-acetate modification kit (Pierce Chemical Co., Rockford, IL, Cat.#26777).

20

25

Example 4: Characterization of acetylated Flt1(1-3)-Fc protein.

5 (a.) IEF analysis: Flt1(1-3)-Fc and acetylated Flt1(1-3)-Fc were analyzed by standard IEF analysis. As shown in Figure 1, Flt1(1-3)-Fc protein is not able to migrate into the gel and therefore must have a pl greater than 9.3, the highest pl in the standard. However, acetylated Flt1(1-3)-Fc is able to migrate into the gel and equilibrate at a pl of approximately 5.2. This result demonstrates that acetylation reduces the net positive charge of the protein and therefore its pl considerably.

(b.) Binding to extracellular matrix components

To test for binding to extracellular matrix components, Flt1(1-3)-Fc and acetylated Flt1(1-3)-Fc where tested in an assay designed to mimic the interaction with extracellular matrix components. In this assay, 96-well tissue culture plates are coated with Matrigel (Biocoat MATRIGEL® matrix thin layer 96 well plate, Catalog #40607, Becton Dickinson Labware, Bedford, MA). The plates are incubated with varying concentrations of either Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc, or rTie2-Fc (an irrelevant control) protein are added to the wells. The plates are incubated for 1-2 hours at either room temperature or 37°C degrees and then detection of bound proteins is accomplished by adding a secondary alkaline phosphatase-conjugated anti-human Fc antibody to

the wells. Finally, alkaline phosphatase substrate is added to the wells and optical density is measured. Figure 2 shows the results of this assay. Like the irrelevant control protein rTie2-Fc, acetylated Flt1(1-3)-Fc does not exhibit any binding to the Matrigel coated plate, whereas the non-acetylated Flt1(1-3)-Fc protein exhibits significant binding. This result indicates that acetylation of basic amino acid residues is an effective way to interfere with the charge interactions that exist between positively charged proteins and the negatively charged extracellular matrix components they are exposed to *in vivo*.

10

15

20

25

5

Example 5: Pegylation of Flt1(1-3)-Fc protein.

Although pegylation (polyethylene glycol - PEG) of proteins has been shown to increase their *in vivo* potency by enhancing stability and bioavailability while minimizing immunogenicity (see references cited *supra*), it is counter-intuitive that pegylating molecules that are too large to be filtered by the kidney glomeruli would improve their pharmacokinetic properties. Without being bound by theory, Applicants postulated that pegylation of the Flt1(1-3)-Fc molecules could improve the pharmacokinetic properties, possibly not by altering the positive charge or by decreasing the pl of Flt1(1-3)-Fc, but rather by physically shielding the positive charges from interacting with the extracellular matrix. Applicants decided to attempt to improve the pharmacokinetic properties of Flt1(1-3)-Fc molecules by attaching strands of 20K PEGs as described *infra*.

10

15

20

25

Materials and Methods

Purified Flt1(1-3)-Fc derived from CHO cells (see *supra*) was used in the following pegylation experiments. Functionalized PEGs were obtained from Shearwater Polymers, Huntsville, AL; Bicine from Sigma, St Louis, MO; Superose 6 column from Pharmacia, Piscataway, NJ; PBS as a 10X concentrate from Life Technologies, Gaithersburg, MD; Glycerol from J.T. Baker, Phillipsburg, NJ; and Bis-Tris precast gels from Novex, CA.

20K PEG strands functionalized with amine-specific terminal moieties were used in small-scale reaction studies that were set-up to evaluate different reaction conditions in which the PEG:protein stoichiometry was varied. Based on these reactions and the analyses of samples on standard SDS-PAGE, Flt1(1-3)-Fc at a concentration of 1.5 mg/mL was reacted at pH 8.1 with 20K SPA-PEG (PEG succinimidyl propionate) molecules at a PEG-to-Fit1(1-3)-Fc monomer molar ratio of 1:6. The reaction was allowed to proceed at 8°C overnight. For initial purification, the reaction products were applied to a 10mm x 30cm Superose 6 column equilibrated with PBS containing 5% Glycerol. The column appeared to separate pegylated Flt1(1-3)-Fc molecules based on the extent of pegylation. Fractions corresponding to what appeared to be primarily mono-pegylated and di-pegylated dimeric Flt1(1-3)-Fc, as judged by banding patterns on reducing and non-reducing SDS-PAGE gels

15

20

25

were pooled. The protein concentration was determined by measuring absorbance at 280 nm. The pegylated Flt1(1-3)-Fc protein was sterile filtered, aliquoted and stored at -40°C.

5 Example 6: Binding of unmodified, acetylated, and pegylated
Flt1(1-3)-Fc in a Biacore-based assay.

Unmodified, acetylated, and pegylated Flt1(1-3)-Fc proteins were tested in a Biacore-based assay to evaluate their ability to bind to the Flt1 ligand, VEGF. In this assay, unmodified Flt1(1-3)-Fc protein was immobilized on the surface of a Biacore chip (see Biacore Instruction Manual, Pharmacia, Inc., Piscataway, NJ, for standard procedures) and a sample containing 0.2 µg/ml VEGF and either unmodified Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc or pegylated Flt1(1-3)-Fc (each at 25 µg/ml) was passed over the Flt1(1-3)-Fc-coated chip. To minimize the effects of non-specific binding, the bound samples were washed with a 0.5M NaCl wash. In one sample, unmodified Flt1(1-3)-Fc was mixed with heparin. Heparin is a negatively charged molecule and the Flt1(1-3)-Fc protein is a positively charged molecule, so when the two molecules are mixed together, they should interact through their respective This essentially neutralizes Flt1(1-3)-Fc's inherent positive charges. charge making the molecule behave as if it has been chemically or genetically modified so as to reduce its charge and its tendency to bind via charge interactions. As shown in Figure 3, acetylated (columns 13-16), pegylated (columns 17-20), and heparin-treated Flt1(1-3)-Fc

(columns 21-24) are each able to completely compete with the Biacore chip-bound Flt1(1-3)-Fc for VEGF binding as compared to control (columns 1-4) and irrelevant protein (columns 5-8). Unmodified Flt1(1-3)-Fc (columns 5-6) appeared to only partially compete with Biacore chip-bound Flt1(1-3)-Fc for VEGF binding. However, washing the bound samples with 0.5M NaCl (columns 7-8) resulted in a binding profile similar to the modified forms of Flt1(1-3)-Fc, indicating that the unmodified protein was exhibiting non-specific binding to the chip that could be eliminated by the salt wash.

10

15

5

Example 7: Binding of unmodified, acetylated, and pegylated FIt1(1-3)-Fc in an ELISA-based assay.

Unmodified, acetylated, and pegylated Flt1(1-3)-Fc proteins were tested in a standard ELISA-based assay to evaluate their ability to bind the Flt1 receptor ligand VEGF. As shown in Figure 4, both pegylated and acetylated Flt1(1-3)-Fc proteins are capable of binding to VEGF, demonstrating that modifying the protein either by pegylation or acetylation does not destroy its ability to bind its ligand.

20

Example 8: Pharmacokinetic analysis of unmodified Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc, and pegylated Flt1(1-3)-Fc.

In vivo experiments were designed to assess the pharmacokinetic profiles of unmodified Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc, and

10

20

pegylated Flt1(1-3)-Fc protein. Balb/c mice (23-28g; 3 mice/group) were injected subcutaneously with 4mg/kg of unmodified, acetylated, or pegylated Flt1(1-3)-Fc. The mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days, and 3 days after injection of protein. The sera were assayed in a standard ELISA-based assay designed to detect Flt1(1-3)-Fc protein. Briefly, the assay involves coating an ELISA plate with VEGF, binding the unmodified, acetylated, or pegylated Flt1(1-3)-Fc-containing sera, and reporting with an anti-Fc antibody linked to alkaline phosphatase. As shown in Figure 5, the Tmax for all of the Flt1(1-3)-Fc proteins was between the 6 hour and 24 hour time points. The Cmax for the different proteins was as follows: Unmodified: 0.06 μ /ml - 0.15 μ g/ml; acetylated: 1.5 μ g/ml - 4.0 μ g/ml; and pegylated: approximately 5 μ g/ml.

15 Example 9: Step-acetylation of Flt1(1-3)-Fc

To determine what minimal amount of acetylation is necessary to eliminate binding to extracellular matrix components, an experiment was designed that acetylated the Flt1(1-3)-Fc protein in a step-wise fashion by using increasing amounts of molar excess of acetylation reagent in the acetylation reaction mixture. The range of molar excess was as follows: 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 moles of acetylation reagent per 1 mole of Flt1(1-3)-Fc monomer. The reactions were performed as detailed in the instruction manual provided with the

15

25

sulfo-NHS-Acetate modification kit (Pierce Chemical Co., Rockford, IL, Cat.# 26777).

Example 10: Characterization of step-acetylated Flt1(1-3)
5 Fc.

(a.) IEF analysis Unmodified Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc proteins were analyzed by standard IEF analysis. As shown in Figure 6A-6B, unmodified Flt1(1-3)-Fc protein was not able to migrate into the gel due to its extremely high pl (greater than 9.3). However, most of the step-acetylated Flt1(1-3)-Fc samples (30-100 fold molar excess samples) were able to migrate into the gel and equilibrate at pls ranging between 4.55 - 8.43, depending on the degree of acetylation of the protein. This result demonstrates that acetylation can change the positive charge of the protein in a dosedependent manner and that reduction of the pl can be controlled by controlling the degree of acetylation.

(b.) Binding of step-acetylated Flt1(1-3)-Fc to extracellular 20 matrix components

To test for binding to extracellular matrix components, Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc where tested in the above-described assay designed to mimic the interaction with extracellular matrix components. Varying concentrations of either unmodified Flt1(1-3)-Fc,

10

15

20

step-acetylated Flt1(1-3)-Fc (10, 20, and 30 fold molar excess samples), or rTie2-Fc (an irrelevant control) protein were added to the wells. The plates were incubated for 1-2 hours at room temperature or 37°C and then detection of bound proteins was accomplished by adding a secondary alkaline phosphatase-conjugated anti-human Fc antibody to the wells. Alkaline phosphatase substrate was subsequently added to the wells and optical density measured. Figure 7 shows the results of this assay. Like the irrelevant control protein rTie2-Fc, stepacetylated Flt1(1-3)-Fc (20 and 30 fold molar excess samples) did not exhibit any significant binding to the Matrigel coated plate, whereas the non-acetylated Flt1(1-3)-Fc protein exhibited significant binding. The binding is saturable, indicating that the Flt1(1-3)-Fc protein may be binding to specific sites, rather than a more general chargemediated interaction that might not be saturable. The 10 fold molar excess sample showed reduced binding, but the degree of acetylation was not enough to completely block binding to extracellular matrix components. The 20 fold molar excess and higher samples displayed no detectable binding, despite the fact that by IEF analysis (Figure 6A and 6B) the lower molar excess samples still had a large net positive This result demonstrates that it is not necessary to completely acetylate all available basic amino acids in order to eliminate binding to extracellular matrix components.

10

15

20

25

(c.) Binding of step-acetylated Flt1(1-3)-Fc in a Biacorebased assay.

Unmodified and step-acetylated Flt1(1-3)-Fc proteins where tested in a Biacore-based assay to evaluate their ability to bind to the Flt1 ligand, VEGF. In this assay, unmodified Flt1(1-3)-Fc protein (0.5, 1.0, or 5.0 µg/ml) was immobilized on the surface of a Biacore chip (see Biacore Instruction Manual, Pharmacia, Inc., Piscataway, NJ, for standard procedures) and a solution containing 0.2 µg/ml VEGF and either unmodified Flt1(1-3)-Fc (at either 0.5, 1.0, or 5.0 µg/ml) or 10 different step-acetylated Flt1(1-3)-Fc samples (at 0.5, 1.0, or 5.0) μg/ml each) were passed over the Flt1(1-3)-Fc-coated chip. As shown in Figure 8, at a sub-stoichiometric ratio (0.5 µg/ml of either unmodified Flt1(1-3) or step-acetylated Flt1(1-3)-Fc vs. 0.2 µg/ml VEGF), there is not enough Flt1(1-3)-Fc (either unmodified or stepacetylated) in the solution to completely bind the VEGF. At 1.0 µg/ml, which approximates a 1:1 stoichiometric ratio, both unmodified and step-acetylated Flt1(1-3)-Fc are better able to compete for VEGF binding, but there is still insufficient Flt1(1-3)-Fc protein (either unmodified or step-acetylated) to completely bind the available VEGF. However, at 5.0 µg/ml, which is several times greater than a 1:1 stoichiometric ratio, both the Flt1(1-3)-Fc and the step-acetylated Flt1(1-3)-Fc proteins are able to bind the VEGF, regardless of the degree of acetylation. This clearly demonstrates that acetylation does not alter Flt1(1-3)-Fc's ability to bind VEGF.

10

15

20

(d.) Pharmacokinetic analysis of step-acetylated Flt1(1-3)-Fc

In vivo experiments were designed to assess the pharmacokinetic profiles of unmodified Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc protein. Balb/c mice (23-28g) were injected subcutaneously with 4mg/kg of unmodified or 10, 20, 40, 60 and 100 fold molar excess samples of step-acetylated Flt1(1-3)-Fc (3 mice for unmodified, 10, 20 and 40 fold molar excess samples and 2 mice for 60 and 100 fold molar excess samples). The mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days and 3 days after injection. The sera were assayed in an ELISA-based assay designed to detect Flt1(1-3)-Fc (described supra). Figure 9 details the results of this study. The Tmax for all of the Flt1(1-3)-Fc proteins tested was at the 6 hour time point but the Cmax was as follows: Unmodified Flt1(1-3)-Fc: 0.06µg/ml; 10 fold molar excess sample: - 0.7µg/ml, 20 fold molar excess sample - 2µg/ml, 40 fold molar excess sample - 4µg/ml, 60 fold molar excess sample - 2µg/ml, 100 fold molar excess sample - 1µg/ml. This results demonstrates that acetylation or pegylation of Flt1(1-3)-Fc significantly improves its pharmacokinetic profile.

Example 11: Construction of FIt1(1-3)-Fc basic region deletion mutant designated Mut1: FIt1(1-3 $_{\Delta B}$)-Fc.

25 Based on the observation that acetylated Flt1(1-3)-Fc, which has a pl

10

15

20

25

ξů.

below 6, has much better pharmacokinetics than the highly positive unmodified Flt1(1-3)-Fc (pl > 9.3), it was asked whether the difference in pharmacokinetics could be attributed to the net charge of the protein, which made it stick to negatively charged extracellular matrix components, or whether there were perhaps specific locations on the surface of the Flt1(1-3)-Fc protein that constituted specific binding sites for extracellular matrix components. For example, many proteins are known to have heparin binding sites, often consisting of a cluster of basic residues. Sometimes these residues are found in a cluster on the primary sequence of the protein; some of the literature has identified "consensus sequences" for such heparin binding sites (see for example Hileman, et al., 1998, Bioessays 20(2):156-67). In other cases, the known crystal structure of a protein reveals a cluster of positively charged residues on the surface of a protein, but the residues come from different regions of the primary sequence and are only brought together when the protein folds into its tertiary structure. difficult to deduce whether an isolated amino acid residue forms part of a cluster of basic residues on the surface of the protein. However, if there is a cluster of positively charged amino acid residues in the primary sequence, it is not unreasonable to surmise that the residues are spatially close to one another and might therefore be part of an extracellular matrix component binding site. Flt1 receptor has been studied extensively and various domains have been described (see for example Tanaka et al., 1997, Jpn. J. Cancer Res 88:867-876). Referring to the nucleic acid and amino acid sequence set forth in Figure 10A-10D

10

15

20

25

of this application, one can identify the signal sequence for secretion which is located at the beginning of the sequence and extends to the glycine coded for by nucleotides 76-78. The mature protein begins with Ser-Lys-Leu-Lys, starting at nucleotide 79 of the nucleic acid sequence. Flt1 Ig domain 1 extends from nucleotide 79 to 393, ending with the amino acids Ser-Asp-Thr. Flt1 Ig domain 2 extends from nucleotide 394 to 687 (encoding Gly-Arg-Pro to Asn-Thr-Ile), and Flt1 Ig domain 3 extends from nucleotides 688 to 996 (encoding Ile-Asp-Val to Asp-Lys-Ala). There is a bridging amino acid sequence, Gly-Pro-Gly, encoded by nucleotides 997-1005, followed by the nucleotide sequence encoding human Fc (nucleotides 1006-1701 or amino acids Glu-Pro-Lys to Pro-Gly-Lys-stop).

A more detailed analysis of the Flt1 amino acid sequence reveals that there is a cluster, namely, amino acid residues 272-281 (KNKRASVRR) of Figure 10A-10D, in which 6 out of 10 amino acid residues are basic. This sequence is located in Flt1 Ig domain 3 of the receptor (see Figure 11), which is not itself essential for binding of VEGF ligand, but which confers a higher affinity binding to ligand. An alignment of the sequence of Ig domain 3 with that of Ig domain 2 reveals that in this region, there is very poor alignment between the two Ig domains, and that there are about 10 additional amino acids in Ig domain 3. An analysis of the hydrophilicity profiles (MacVector computer software) of these two domains clearly indicates the presence of a hydrophilic region in the protein (Figure 12A-12B). These observations raised the

10

15

possibility that the actual three dimensional conformation of Flt1 Ig domain 3 allowed for some type of protrusion that is not in Flt1 Ig domain 2. To test this hypothesis, the 10 additional amino acids were deleted and the resulting protein was tested to see whether the deletion would affect the pharmacokinetics favorably without seriously compromising the affinity of the receptor for VEGF. This DNA construct, which was constructed using standard molecular biology techniques (see e.g., Molecular Cloning, A Laboratory Manual (Sambrook, et al., Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY) in the mammalian expression vector pMT21 (Genetics Institute, Inc., Cambridge, MA), is referred to as Mut1: Flt1(1-3 $_{AB}$)-Fc. The Mut1: FIt1(1-3_{AB})-Fc construct was derived from FIt1(1-3)-Fc by deletion of nucleotides 814-843 (set forth in Figure 10A-10D), which deletes the highly basic 10-amino acid residue sequence Lys-Asn-Lys-Arg-Ala-Ser-Val-Arg-Arg-Arg from Flt1 lg domain 3.

The final DNA construct was sequence-verified using an ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, CA). The sequence of Mut1: Flt1(1-3_{AB})-Fc is set forth in Figure 13A-13D.

10

15

25

WO 00/75319

Example 12: Construction of FIt1(1-3)-Fc basic region deletion mutant designated Mut2: FIt1(2-3 $_{\Delta B}$)-Fc.

A second deletion mutant construct, designated Mut2: $Flt1(2-3_{\Delta B})-Fc$, was derived from the Mut1: $Flt1(1-3_{\Delta B})-Fc$ construct by deletion of Flt1 lg domain 1 encoded by nucleotides 79-393 (see Figure 10A-10D); for convenience, nucleotides 73-78 (TCA GGT) were changed to TCC GGA. This introduced a restriction site (BspE1) without altering the associated amino acid sequence, Ser-Gly. This DNA construct, which was constructed using standard molecular biology techniques (see e.g., Molecular Cloning, A Laboratory Manual (Sambrook, et al., Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY) in the mammalian expression vector pMT21 (Genetics Institute, Inc., Cambridge, MA), was also sequence-verified using an ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, CA). The sequence of Mut2: $Flt1(2-3_{\Delta B})$ -Fc is set forth in Figure 14A-14C.

20 Example 13: Construction of Flt1(1-3)-Fc deletion mutant designated Mut3: Flt1(2-3)-Fc.

A third deletion mutate construct, designated Mut3: Flt1(2-3)-Fc, was constructed the same way as the Mut2: Flt1(2-3 $_{\Delta B}$)-Fc construct, except that Flt1 Ig domain 3 was left intact (the basic region amino

acids were not deleted). The construct was constructed using standard molecular biology techniques and the final construct was sequence-verified as described *supra*. The sequence of Mut3: Flt1(2-3)-Fc is set forth in Figure 15A-15C.

5

10

15

Example 14: Construction of FIt(1-3)-Fc basic region N-glycosylation mutant designated Mut4: FIt1(1-3 $_{R->N}$)-Fc.

A final construct was made in which a N-glycosylation site was introduced into the middle of the basic region of Flt1 lg domain 3. This construct was designated Mut4: Flt1(1-3 $_{R->N}$)-Fc and was made by changing nucleotides 824-825 from GA to AC, consequently changing the coded Arg residue (AGA) into an Asn residue (AAC) (see Figure 10A-10D). The resulting amino acid sequence is therefore changed from Arg-Ala-Ser to Asn-Ala-Ser, which matches the canonical signal (Asn-Xxx-Ser/Thr) for the addition of a N-glycosylation site at the Asn residue. The sequence of Mut4: Flt1(1-3 $_{R->N}$)-Fc is set forth in Figure 16A-16D.

Example 15: Characterization of acetylated Flt1(1-3)-Fc.

Mut1: Flt1(1-3_{Δ B})-Fc, and Mut4: Flt1(1-3_{B->N})-Fc mutants.

(a.) Binding to extracellular matrix components

25 To determine whether the three modified proteins were more or less

10

15

20

25

likely to have improved pharmacokinetic properties, Matrigel coated 96-well dishes (as described supra) were incubated with varying concentrations of the mutant proteins and detected with anti-human Fc/alkaline-phosphatase conjugated antibodies. As shown in Figure 18, this experiment showed that while the unmodified Flt1(1-3)-Fc protein could bind avidly to these wells, the Mut3: Flt1(2-3)-Fc protein bound somewhat more weakly, the Mut1: Flt1(1-3 $_{\Delta B}$)-Fc protein bound more weakly still, and the Mut2: Flt1(2-3 $_{\Delta B}$)-Fc protein showed the best profile, binding more weakly than any of the other mutant proteins. The Mut4: Flt1(1-3 $_{R->N}$)-Fc glycosylation mutant protein showed only marginal benefit on the Matrigel assay. These results confirm the hypothesis that a linear sequence of positive amino acids can be deleted from the primary sequence resulting in a decrease in charge interaction with extracellular matrix components.

(b.) Binding of Mut1: Flt1(1-3_{ΔB})-Fc and Mut4: Flt1(1-3_{R->N})-Fc in a Biacore-based assay.

Unmodified and acetylated Flt1(1-3)-Fc and genetically modified Mut1: Flt1(1-3 $_{AB}$)-Fc and Mut4: Flt1(1-3 $_{R->N}$)-Fc proteins where tested in a Biacore-based assay to evaluate their ability to bind to the Flt1 ligand, VEGF. In this assay, unmodified Flt1(1-3)-Fc protein (0.25, 0.5, or 1.0 μ g/ml) was immobilized on the surface of a Biacore chip (see Biacore Instruction Manual, Pharmacia, Inc., Piscataway, NJ, for standard procedures) and a solution containing 0.1 μ g/ml VEGF and either

10

15

purified or COS cell supernatant containing unmodified Flt1(1-3)-Fc (at approximately (0.25, 0.5, or 1.0 µg/ml), purified acetylated Flt1(1-3)-Fc (at (0.25, 0.5, or 1.0 µg/ml), COS cell supernatant containing Mut1: Flt1(1-3_{AB})-Fc (at approximately (0.25, 0.5, or 1.0 μ g/ml), or COS cell supernatant containing Mut4: Flt1(1-3_{R->N})-Fc (at approximately (0.25, 0.5, or 1.0 µg/ml) were passed over the Flt1(1-3)-Fc-coated chip. As shown in Figure 17, at the sub-stoichiometric ratio (0.25 µg/ml Flt1(1-3)-Fc of unmodified, acetylated or genetically modified samples vs. 01. ug/ml VEGF), there is insufficient Flt1(1-3)-Fc protein to block binding of VEGF to the Flt1(1-3)-Fc immobilized on the Biacore chip. At 0.5 ug/ml of unmodified, acetylated or genetically modified Flt1(1-3)-Fc proteins, the stoichiometric ratio approximates 1:1 and there is an increased ability to block VEGF binding to the Biacore chip. At 1.0 μg/ml of unmodified, acetylated or genetically modified Flt1(1-3)-Fc proteins, which is approximately a 10:1 stoichiometric ratio, the Flt1(1-3)-Fc proteins are able to block binding of VEGF to the Biacore chip, but they are not equivalent. Unmodified, acetylated, and Mut1: FIt1(1-3_{AB})-Fc are essentially equal in their ability to block VEGF binding, whereas Mut4: Flt1(1-3_{R->N})-Fc is somewhat less efficient at blocking binding. These results confirm the hypothesis that it is possible to reduce the non-specific binding of a positively charged molecule by genetically removing a linear sequence of predominantly negatively charged amino acids.

20

10

15

20

25

(c.) Binding of Mut1: Flt1(1-3_{AB})-Fc, Mut2: Flt1(2-3_{AB})-Fc, Mut3: Flt1(2-3)-Fc, and in an ELISA-based assay.

To determine whether the three mutant proteins could bind the Flt1 ligand VEGF, binding experiments were done in which 96-well plates coated with VEGF were incubated with varying concentrations of the respective mutant protein, and after washing, the amount bound was detected by incubating with an alkaline phosphatase conjugated anti-human Fc antibody and quantitated colorimetrically by the addition of an appropriate alkaline phosphatase substrate. As shown in Figure 19, this experiment showed that all the mutant proteins could bind VEGF similarly, at the concentrations tested.

Example 16: Pharmacokinetic analysis of acetylated FIt1(1-3)-Fc. Mut1: FIt1(1-3 $_{AB}$)-Fc. and unmodified FIt1(1-3)-Fc.

In vivo experiments were designed to assess the pharmacokinetic profiles of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3 $_{\Delta B}$)-Fc, and 40 fold molar excess acetylated Flt1(1-3)-Fc protein. Balb/c mice (25-30g) were injected subcutaneously with 4mg/kg of unmodified Flt1(1-3)-Fc, 40 fold molar excess acetylated Flt1(1-3)-Fc, and Mut1: Flt1(1-3 $_{\Delta B}$)-Fc proteins (4 mice each). These mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days, 3 days, and 5 days after injection. The sera were assayed in an ELISA designed to detect Flt1(1-3)-Fc protein which involves coating an ELISA plate with VEGF, binding the Flt1(1-3)-Fc and

reporting with an anti-Fc antibody linked to alkaline phosphatase. As shown in Figure 20, the Cmax for these reagents was as follows:

Unmodified Flt1(1-3)-Fc - 0.15μg/ml; 40 fold molar excess acetylated Flt1(1-3)-Fc - 1.5μg/ml; and Mut1: Flt1(1-3_{AB})-Fc - 0.7μg/ml.

5

10

15

20

25

Example 17: Modified Flt1 receptor vector construction

The rationale for constructing modified versions of the Flt1 receptor (also known as VEGFR1) was based on the observation that the protein sequence of Flt1 was highly basic, and was therefore likely to stick to extracellular matrix (ECM). The highly basic nature of Flt1 probably explains why unmodified Flt1(1-3)-Fc (described *supra*) has poor pharmacokinetics that make it difficult to use as a therapeutic agent. As described *supra*, the chemically modified form of 40 fold molar excess acetylated Flt1(1-3)-Fc, hereinafter termed A40, exhibited a greatly improved pharmacokinetic (PK) profile over the non-acetylated Flt1(1-3)-Fc. Therefore, attempts were made to engineer DNA molecules that could be used to recombinantly express modified forms of a Flt1 receptor molecule that would possess the improved PK profile exhibited by A40 and still maintain the ability to bind tightly to VEGF.

It is known in the literature that the first Ig domain of Flt1 (which has a net charge of +5 at neutral pH) is not essential for tight binding to VEGF, so this domain was deleted. The third Ig domain (having a net charge of +11) is not essential for binding, but confers higher affinity

10

20

for VEGF than the second Ig domain, so instead of deleting it entirely, it was replaced with the equivalent domains of the Flt1 receptor relatives Flk1 (also known as VEGFR2) and Flt4 (also known as VEGFR3). These chimeric molecules (denoted R1R2 (Flt1.D2.Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a) and R1R3 (Flt1D2.VEGFR3D3-FcΔC1(a) and VEGFR1R3-FcΔC1(a) respectively, wherein R1 and Flt1D2 = Ig domain 2 of Flt1 (VEGFR1); R2 and Flk1D3 = Ig domain 3 of Flk1 (VEGFR2); and R3 and VEGFR3D3 = Ig domain 3 of Flt4 (VEGFR3)) were much less sticky to ECM, as judged by an *in vitro* ECM binding assay as described *infra*, had greatly improved PK as described *infra*. In addition, these molecules were able to bind VEGF tightly as described *infra* and block phosphorylation of the native Flk1 receptor expressed in endothelial cells as described *infra*.

15 (a) Construction of the expression plasmid pFlt1D2.Flk1D3.Fc∆C1(a)

Expression plasmids pMT21.Flt1(1-3).Fc (6519bp) and pMT21.Flk-1(1-3).Fc (5230bp) are plasmids that encode ampicillin resistance and Fctagged versions of Ig domains 1-3 of human Flt1 and human Flk1, respectively. These plasmids were used to construct a DNA fragment consisting of a fusion of Ig domain 2 of Flt1 with Ig domain 3 of Flk1, using PCR amplification of the respective Ig domains followed by further rounds of PCR to achieve fusion of the two domains into a

single fragment. For Ig domain 2 of Flt1, the 5' and 3' amplification primers were as follows:

5': bsp/flt1D2 (5'-GACTAGCAGTCCGGAGGTAGACCTTTCGTAGAGATG-3')

5

10

15

3': Flt1D2-Flk1D3.as (5'-CGGACTCAGAACCACATCTATGATTGTATTGGT-3')

The 5' amplification primer encodes a BspE1 restriction enzyme site upstream of Ig domain 2 of Flt1, defined by the amino acid sequence GRPFVEM (corresponding to amino acids 27-33 of Figure 21A-21C). The 3' primer encodes the reverse complement of the 3' end of Flt1 Ig domain 2 fused directly to the 5' beginning of Flk1 Ig domain 3, with the fusion point defined as TIID of Flt1 (corresponding to amino acids 123-126 of Figure 21A-21C) and continuing into VVLS (corresponding to amino acids 127-130 of Figure 21A-21C) of Flk1.

For Ig domain 3 of Flk1, the 5' and 3' amplification primers were as follows:

20 5': Flt1D2-Flk1D3.s (5'-ACAATCATAGATGTGGTTCTGAGTCCGTCTCATG

3': Flk1D3/apa/srf.as (5'-GATAATGCCCGGGCCCTTTTCATGGACCCTGAC AAATG-3')

25

229-231 of Figure 21A-21C.

5

10

15

20

The 5' amplification primer encodes the end of Flt1 Ig domain 2 fused directly to the beginning of Flk1 Ig domain 3, as described above. The 3' amplification primer encodes the end of Flk1 Ig domain 3, defined by the amino acids VRVHEK (corresponding to amino acids 223-228 of Figure 21A-21C), followed by a bridging sequence that includes a recognition sequence for the restriction enzyme Srf1, and encodes the amino acids GPG. The bridging sequence corresponds to amino acids

After a round of PCR amplification to produce the individual domains, the products were combined in a tube and subjected to a further round of PCR with the primers bsp/flt1D2 and Flk1D3/apa/srf.as (described supra) to produce the fusion product. This PCR product was subsequently digested with the restriction enzymes BspEI and Smal and the resulting 614bp fragment was subcloned into the BspEI to SrfI restriction sites of the vector pMT21/ΔB2.Fc, to create the plasmid pMT21/Flt1D2.Flk1D3.Fc. The nucleotide sequence of the Flt1D2-Flk1D3 gene fusion insert was verified by standard sequence analysis. This plasmid was then digested with the restriction enzymes EcoRI and SrfI and the resulting 702bp fragment was transferred into the EcoRI to SrfI restriction sites of the plasmid pFlt1(1-3)B2-FcΔC1(a) to produce the plasmid pFlt1D2.Flk1D3.FcΔC1(a). The complete DNA and deduced amino acid sequences of the Flt1D2.Flk1D3.FcΔC1(a) chimeric molecule is set forth in Figure 21A-21C.

10

20

25

(b) Construction of the expression plasmid pFIt1D2VEGFR3D3Fc△C1(a)

The expression plasmid pMT21.Flt1(1-3).Fc (6519bp) encodes ampicillin resistance and an Fc-tagged version of Ig domains 1-3 of human Flt1 receptor. This plasmid was used to produce a DNA fragment containing Ig domain 2 of Flt1 by PCR. RNA from the cell line HEL921.7 was used to produce Ig domain 3 of Flk1, using standard RT-PCR methodology. A further round of PCR amplification was used to achieve fusion of the two Ig domains into a single fused fragment. For Ig domain 2 of Flt1, the 5' and 3' amplification primers were as follows:

5': bsp/flt1D2 (5'-GACTAGCAGTCCGGAGGTAGACCTTTCGTAGAGATG-3')

15 3': Flt1D2.VEGFR3D3.as(TTCCTGGGCAACAGCTGGATATCTATGATTGTA TTGGT)

The 5' amplification primer encodes a BspE1 restriction site upstream of Ig domain 2 of Flt1, defined by the amino acid sequence GRPFVEM (corresponding to amino acids 27-33 of Figure 22A-22C). The 3' amplification primer encodes the reverse complement of the end of Flt1 Ig domain 2 fused directly to the beginning of VEGFR3 Ig domain 3, with the fusion point defined as TIID of Flt1 (corresponding to amino acids 123-126 of Figure 22A-22C) and continuing into IQLL of VEGFR3 (corresponding to amino acids 127-130 of Figure 22A-22C).

For Ig domain 3 of VEGFR3, the 5' and 3' primers used for RT-PCR were as follows:

5 5': R3D3.s (ATCCAGCTGTTGCCCAGGAAGTCGCTGGAGCTGCTGGTA)

3': R3D3.as (ATTTTCATGCACAATGACCTCGGTGCTCTCCCGAAATCG)

Both the 5' and 3' amplification primers match the sequence of VEGFR3. The 296bp amplification product of this RT-PCR reaction was isolated by standard techniques and subjected to a second round of PCR to add suitable sequences to allow for fusion of the Flt1D2 with the Flk1D3 domains and fusion of the Flk1D3 and Fc domains via a GPG bridge (see below). The amplification primers were as follows:

15

25

10

5':Flt1D2.VEGFR3D3.s
(TCATAGATATCCAGCTGTTGCCCAGGAAGTCGCTGGAG)

3': VEGFR3D3/srf.as

20 (GATAATGCCCGGGCCATTTTCATGCACAATGACCTCGGT)

The 5' amplification primer encodes the 3' end of Flt1 Ig domain 2 fused directly to the beginning (5' end) of VEGFR3 Ig domain 3, as described above. The 3' amplification primer encodes the 3' end of VEGFR3 Ig domain 3, defined by the amino acids VIVHEN (corresponding

to amino acids 221-226 of Figure 22A-22C), followed by a bridging sequence that includes a recognition sequence for Srf1, and encodes the amino acids GPG. The bridging sequence corresponds to amino acids 227-229 of Figure 22A-22C.

5

10

15

20

After one round (for Flt1 Ig domain 2) or two rounds (for Flt4 Ig domain 3) of PCR to produce the individual Ig domains, the PCR products were combined in a tube and subjected to a further round of PCR amplification with the amplification primers bsp/flt1D2 and VEGFR3D3/srf.as described *supra*, to produce the fusion product. This PCR product was subsequently digested with the restriction enzymes BspEI and Smal and the resulting 625bp fragment was subcloned into the BspEl to Srfl restriction sites of the vector pMT21/Flt1 AB2. Fc (described supra), to create the plasmid pMT21/Flt1D2.VEGFR3D3.Fc. The sequence of the Flt1D2-VEGFR3D3 gene fusion insert was verified by standard sequence analysis. This plasmid was then digested with the restriction enzymes EcoRI and SrfI and the resulting 693bp fragment was subcloned into the EcoRl to Srfl restriction sites of the plasmid pFlt1(1-3)\DeltaB2-Fc\DeltaC1(a) to produce the plasmid designated pFlt1D2.VEGFR3D3.Fc\(\Delta\)C1(a). The complete DNA deduced amino acid sequence of the Flt1D2.VEGFR3D3.Fc\(\Delta\)C1(a) chimeric molecule is set forth in Figure 22A-22C.

ŝ

5

10

15

25

Example 18: Extracellular Matrix Binding (ECM) Binding Assay

ECM-coated plates (Becton Dickinson catalog # 35-4607) were rehydrated with warm DME supplemented with glutamine (2mM), 100U penicillin, 100U streptomycin, and 10% BCS for at least 1 hr. before adding samples. The plates were then incubated for 1 hr. at room temperature with varying concentrations of Flt1D2.Flk1D3.Fc\(\Delta\)C1(a) and Flt1D2.VEGFR3D3.Fc\(\Delta\)C1(a) starting at 10nM with subsequent 2-fold dilutions in PBS plus 10% BCS. The plates were then washed 3 times with PBS plus 0.1% Triton-X and incubated with alkaline phosphataseconjugated anti-human Fc antibody (Promega, 1:4000 in PBS plus 10% BCS) for 1 hr. at room temperature. The plates were then washed 4 times with PBS 0.1% Triton-X and alkaline phosphatase buffer/pNPP solution (Sigma) was added for color development. Plates were read at I = 405-570nm. The results of this experiment are shown in Figure 23 and demonstrate that the Flt1D2.Flk1D3.Fc∆C1(a) and Flt1D2.VEGFR3D3.Fc\(\Delta\)C1(a) proteins are considerably less sticky to the ECM as compared to the Flt1(1-3)-Fc protein.

20 Example 19: Transient expression of pFlt1D2.Flk1D3.Fc∆C1(a) in CHO-K1 (E1A) cells

A large scale (2L) culture of E. coli DH10B cells carrying the pFlt1D2.Flk1D3.FcΔC1(a) plasmid described *supra* in Example 17(a) was grown overnight in Terrific Broth (TB) plus 100μg/ml ampicillin. The

5

next day, the plasmid DNA was extracted using a QIAgen Endofree Megaprep kit following the manufacturer's protocol. The concentration of the purified plasmid DNA was determined by standard techniques using a UV spectrophotometer and fluorometer. The plasmid DNA was verified by standard restriction enzyme digestion of aliquots using the restriction enzymes EcoRI plus NotI and Asel. All restriction enzyme digest fragments corresponded to the predicted sizes when analyzed on a 1% agarose gel.

10 Forty 15 cm petri plates were seeded with CHO-K1/E1A cells at a density of 4 x 106 cells/plate. Plating media was Gibco Ham's F-12 supplemented with 10% Hyclone Fetal Bovine Serum (FBS), 100U penicillin/100U streptomycin and glutamine (2mM). The following day each plate of cells was transfected with 6 μg of the pFlt1D2.Flk1D3.FcΔC1(a) plasmid DNA using Gibco Optimem and Gibco

pFlt1D2.Flk1D3.FcΔC1(a) plasmid DNA using Gibco Optimem and Gibco Lipofectamine in 12 ml volume, following the manufacturer's protocol. Four hours after adding the transfection mix to the cells, 12 ml/plate of Optimem supplemented with 10% FBS was added. Plates were incubated at 37°C in a 5% CO2 incubator overnight. The following day the media was removed from each plate and 25 ml expression media (Gibco CHO-S-SFM II supplemented with glutamine (2mM) and 1mM sodium butyrate) was added. The plates were incubated at 37°C for 3 days. After 3 days of incubation, the media was aspirated from each plate and centrifuged at 400 rpm in a swinging bucket rotor to pellet

10

15

cells. The supernatant was decanted into sterile 1L bottles and purification of the expressed protein was performed as described *infra*.

Example 20: Construction pVEGFR1R2-Fc C1(a) expression vector

The pVEGFR1R2.FcΔC1(a) expression plasmid was constructed by insertion of DNA encoding amino acids SDT (corresponding to amino acids 27-29 of Figure 24A-24C) between Flt1d2-Flk1d3-FcΔC1(a) amino acids 26 and 27 of Figure 21A-21C (GG) and removal of DNA encoding amino acids GPG corresponding to amino acids 229-231 of Figure. The SDT amino acid sequence is native to the Flt1 receptor and was added back in to decrease the likelihood of heterogeneous N-terminal processing. The GPG (bridging sequence) was removed so that the Flt1 and Flk1 Ig domains were fused directly to one another. The complete DNA and deduced amino acid sequences of the pVEGFR1R2.FcΔC1(a) chimeric molecule is set forth in Figure 24A-24C.

Example 21: Cell Culture Process Used to Produce Modified 20 Flt1 Receptors

(a) Cell Culture Process Used to Produce FIt1D2.FIk1D3.Fc△C1(a)

25 The process for production of Flt1D2.Flk1D3.FcΔC1(a) protein using the

10

25

expression plasmid pFlt1D2.Flk1D3.Fc\(\Delta\)C1(a) described supra in Example 1 involves suspension culture of recombinant Chinese hamster ovary (CHO K1/E1A) cells which constitutively express the protein product. The cells are grown in bioreactors and the protein product is isolated and purified by affinity and size exclusion chromatography. The process is provided in greater detail below.

Cell Expansion

Two confluent T-225 cm² flasks containing the Flt1D2.Flk1D3.FcΔC1(a) expressing cell line were expanded by passaging cells into eight T-225 cm² flasks in medium (GMEM + 10% serum, GIBCO) and incubated at 37°C and 5% CO2. When the flasks approached confluence (approximately 3 to 4 days) the cells were detached using trypsin. Fresh medium was added to protect the cells from further exposure to the trypsin. The cells 15 were centrifuged and resuspended in fresh medium then transferred to eight 850 cm² roller bottles and incubated at 37°C and 5% CO2 until confluent.

20 Suspension Culture in Bioreactors

Cells grown in roller bottles were trypsinized to detach them from the surface and washed with suspension culture medium. The cells are aseptically transferred to a 5L bioreactor (New Brunswick Celligen Plus) where the cells are grown in 3.5L of suspension culture. The

10

20

suspension culture medium was a glutamine-free low glucose modification of IS-CHO (Irvine Scientific) to which 5% fetal bovine serum (Hyclone), GS supplement (Life Technologies) and 25 μM methionine sulfoximine (Sigma) was added. The pH was controlled at 7.2 by addition of carbon dioxide to the inlet gas or by addition of a liquid solution of sodium carbonate to the bioreactor. Dissolved oxygen level was maintained at 30% of saturation by addition of oxygen or nitrogen to the inlet gas and temperature controlled at 37°C. When a density of 4 x10⁶ cells/mL was reached the cells were transferred to a 40L bioreactor containing the same medium and setpoints for controlling the bioreactor. The temperature setpoint was reduced to 34°C to slow cell growth and increase the relative rate of protein expression.

15 (b) Cell Culture Process Used to Produce FIt1D2.VEGFR3D3.Fc∆C1(a)

The same methodologies as described *supra* for Flt1D2.Flk1D3.FcΔC1(a) were used to produce Flt1D2.VEGFR3D3.FcΔC1(a).

Example 22: Harvest and Purification of Modified Flt1
Receptors

10

15

20

25

(a) Harvest and Purification of Flt1D2.Flk1D3.Fc∆C1(a)

The product protein was aseptically harvested from the bioreactor while retaining cells using Millipore Prostak tangential-flow filtration modules and a low-shear mechanical pump (Fristam). Fresh medium was added to the bioreactor to replace that removed during the harvest filtration. Approximately 40L of harvest filtrate was then loaded onto a 400 mL column containing Protein A Sepharose resin (Amersham Pharmacia). After loading the resin was washed with buffer containing 10 mM sodium phosphate, 500 mM sodium chloride, pH 7.2 to remove any unbound contaminating proteins. Flt1D2.Flk1D3.Fc Δ C1(a) protein was eluted with a pH 3.0 citrate buffer. The eluted protein was neutralized by addition of Tris base and frozen at -20°C.

Several frozen lots of Flt1D2.Flk1D3.FcΔC1(a) protein from the Protein A step above were thawed, pooled and concentrated using a Millipore 30kD nominal molecular weight cutoff (NMWCO) tangential flow filtration membrane. The protein was transferred to a stirred cell concentrator (Millipore) and further concentrated to 30 mg/mL using a 30kD NMWCO membrane. The concentrated protein was loaded onto a size exclusion column packed with Superdex 200 resin (Amersham Pharmacia) that was equilibrated with phosphate buffered saline plus 5% glycerol. The same buffer was used to run the column. The fractions corresponding to Flt1D2.Flk1D3.FcΔC1(a) dimer were pooled, sterile filtered through a 0.22 micron filter, aliquoted and frozen.

15

20

25

(b) Harvest and Purification of Flt1D2.VEGFR3D3.Fc∆C1(a)

The same methodologies as described *supra* for Flt1D2.Flk1D3.FcΔC1(a) were used to harvest and purify Flt1D2.VEGFR3D3.FcΔC1(a).

Example 23: Phosphorylation Assay for Transiently Expressed VEGFR2

Primary human umbilical vein endothelial cells (HUVECs), passage 4-6, were starved for 2 hrs in serum-free DME high glucose media. Samples containing 40 ng/ml (1nM) human VEGF165, which is a ligand for the VEGF receptors Fit1. Fik1 and Fit4(VEGFR3) were prepared and were preincubated for 1 hr. at room temperature with varying amounts of the modified Flt1 receptors Flt1(1-3)-Fc, Flt1(1-3)-Fc (A40), Flt1D2Flk1D3.Fc\(\Delta\)C1(a) and Flt1D2VEGFR3D3.Fc\(\Delta\)C1(a) in serum-free DME-high glucose media containing 0.1% BSA. Cells were challenged for 5 minutes with the samples prepared above +/- VEGF165, followed by whole cell lysis using complete lysis buffer. Cell lysates were immunoprecipitated with an antibody directed against the C-terminus of VEGFR2 receptor. The immunoprecipitated lysates were loaded onto 4-12% SDS-PAGE Novex gel and then transferred to PVDF membrane using standard transfer methodologies. Detection of phosphorylated VEGFR2 was done by immunoblotting with the anti-phospho Tyrosine mAb called 4G10 (UBI) and developed using ECL-reagent (Amersham).

10

15

20

25

Figures 25A-25C and 26A-26B show the results of this experiment. Figure 25A-25C reveals that detection by Western blot of tyrosine phosphorylated VEGFR2(Flk1) by VEGF165 ligand stimulation shows that cell-surface receptors are phosphorylated to varying levels depending on which modified Flt1 receptor is used during the preincubations with VEGF. As is seen in Figure 25A, at a 1.5 molar excess of either Flt1(1-3)-Fc, Flt1(1-3)-Fc (A40) or transient Flt1D2Flk1D3.Fc∆C1(a) there is complete blockage of receptor stimulation by these three modified Flt1 receptors as compared to control media challenge. In contrast, transient Flt1D2VEGFR3D3.Fc∆C1(a) does not show significant blockage at this molar excess, as compared with VEGF positive control challenge. Similar results are seen in Figure 25B, where the modified Flt receptors are in a 3-fold molar excess to VEGF165 ligand. In Figure 25C, where the modified Flt1 receptors are in a 6-fold molar excess to VEGF165 ligand, transient Flt1D2VEGFR3D3.Fc∆C1(a) can now be shown to be partially blocking VEGF165-induced stimulation of cell-surface receptors.

In Figure 26A-26B, detection by Western blot of tyrosine phosphorylated VEGFR2(Flk1) by VEGF165 ligand stimulation shows that cell-surface receptors are not phosphorylated by challenge samples which have VEGF165 preincubated with 1 and 2 fold molar excess (Figure 26A) or 3 and 4 fold molar excess (Figure 26B) of either transient Flt1D2Flk1D3.FcΔC1(a), stable Flt1D2Flk1D3.FcΔC1(a), or transient VEGFR1R2-FcΔC1(a). At all modified Flt1 receptor

concentrations tested there is complete binding of VEGF165 ligand during the preincubation, resulting in no detectable stimulation of cell-surface receptors by unbound VEGF165 as compared to control media challenge.

5

10

15

20

25

Example 24: Cell Proliferation Bioassay

The test cell population is MG87 cells that have been stably transfected with a expression plasmid that contains a DNA insert encoding the VEGFR2(Flk1) extracellular domain fused to the TrkB intracellular kinase domain, thus producing a chimeric molecule. The reason the TrkB intracellular kinase domain was used rather than the native VEGFR2(Flk1) intracellular kinase domain is that the intracellular kinase domain of VEGFR2(Flk1) does not cause a strong proliferative response when stimulated by VEGF165 in these cells. It is known that MG87 cells containing full length TrkB receptor give a robust proliferative response when stimulated with BDNF, so the TrkB intracellular kinase domain was engineered to replace the intracellular kinase domain of VEGFR2(Flk1) to take advantage of this proliferative response capability.

5 x 10^3 cells/well were plated in a 96 well plate and allowed to settle for 2 hrs at 37° C. The following modified Flt receptors Flt1(1-3)-Fc, Flt1D2.Flk1D3.Fc Δ C1(a) and Flt1D2.VEGFR3D3.Fc Δ C1(a), plus an irrelevant receptor termed Tie2-Fc as a negative control, were titrated

10

from 40nM to 20pM and incubated on the cells for 1hr at 37°C. Human recombinant VEGF165 in defined media was then added to all the wells at a concentration of 1.56nM. The plates were incubated for 72 hrs at 37°C and then MTS (Owen's reagent, Promega) added and the plates were incubated for an additional for 4 hrs. Finally, the plates were read on a spectrophotometer at 450/570nm. The results of this experiment are shown in Figure 27. The control receptor Tie2-Fc does not block VEGF165-induced cell proliferation at any concentration whereas Flt1D2.Flk1D3.FcΔC1(a) blocks 1.56nM VEGF165 with a half maximal dose of 0.8nM. Flt1(1-3)-Fc and Flt1D2.VEGFR3D3.FcΔC1(a) are less effective in blocking VEGF165 in this assay with a half maximal dose of ~ 2nM. VEGF165 alone gives a reading of 1.2 absorbance units and the background is 0.38 absorbance units.

15 Example 25: Binding Stoichiometry of Modified Fit Receptors to VEGF165

(a) BIAcore Analysis

- The stoichiometry of Flt1D2Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a) interaction with human VEGF165 was determined by measuring either the level of VEGF saturation binding to the Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a) surfaces or measuring concentration of VEGF165 needed to completely prevent binding of Flt1D2Flk1D3.FcΔC1(a) or
- 25 VEGFR1R2-FcΔC1(a) to VEGF BlAcore chip surface.

10

15

20

25

Modified Flt receptors Flt1D2Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a), were captured with an anti-Fc specific antibody that was first immobilized on a Biacore chip (BIACORE) using amine-coupling chemistry. A blank antibody surface was used as a negative control. VEGF165 was injected at a concentration of 1 nM, 10 nM, and 50 nM over the Flt1D2Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a) surfaces at 10 μl/min for one hour. A real-time binding signal was recorded and saturation binding was achieved at the end of each injection. Binding stoichiometry was calculated as a molar ratio of bound VEGF165 to the immobilized Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a), using the conversion factor of 1000 RU equivalent to 1 ng/ml. The results indicated binding stoichiometry of one VEGF165 dimeric molecule per one Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a) molecule (Figure 28).

In solution, Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a) at a concentration of 1nM (estimated to be 1000 times higher than the KD of the Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a)/VEGF165 interaction) were mixed with varied concentrations of VEGF165. After one hour incubation, concentrations of the free Flt1D2Flk1D3.FcΔC1(a) in solution were measured as a binding signal to an amine-coupled VEGF165 surface. A calibration curve was used to convert the Flt1D2Flk1D3.FcΔC1(a) BlAcore binding signal to its molar concentration. The data showed that the addition of 1 nM VEGF165 into

10

15

20

25

the Flt1D2Flk1D3.FcΔC1(a) solution completely blocked Flt1D2Flk1D3.FcΔC1(a) binding to the VEGF165 surface. This result suggested the binding stoichiometry of one VEGF165 molecule per one Flt1D2Flk1D3.FcΔC1(a) molecule (Figure 29 and Figure 30). When the concentration of Flt1D2Flk1D3.FcΔC1(a) was plotted as a function of added concentration of VEGF165, the slope of the linear portion was -1.06 for Flt1D2Flk1D3.FcΔC1(a) and -1,07 for VEGFR1R2-FcΔC1(a). The magnitude of the slope, very close to negative one, was indicative that one molecule of VEGF165 bound to one molecule of either Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a).

(b) Size Exclusion Chromatography

Fit1D2Fik1D3.Fc\(\text{C1}(a)\) was mixed with a 3-fold excess of VEGF165 and the receptor-ligand complex was purified using a Pharmacia Superose 6 size exclusion chromatography column. The receptor-ligand complex was then incubated in a buffer containing 6M guanidine hydrochloride in order to dissociate it into its component proteins.

Fit1D2Fik1D3.FcΔC1(a) was separated from VEGF165 using Superose 6 size exclusion chromatography column run in 6M guanidium chloride. In order to determine complex stoichiometry, several injections of Fit1D2Fik1D3.FcΔC1(a) and VEGF165 were made and peak height or peak integrated intensity was plotted as a function of the concentration of injected protein. The calibration was done under condition identical to one used in separating components of Fit1D2Fik1D3.FcΔC1(a)/VEGF

complex. Quantification of the Flt1D2Flk1D3.FcΔC1(a)/VEGF complex composition was based on the calibration curves. The results of this experiment are set forth in Figure 28, which shows the ratio of VEGF165 to Flt1D2Flk1D3.FcΔC1(a) in a complex to be 1:1.

5

Example 26: Determination of the Binding Stoichiometry of FIt1D2FIk1D3.Fc\(\Delta\)C1(a)/VEGF165 Complex by Size Exclusion Chromatography

10 FIt1D2FIk1D3.Fc∆C1(a)/VEGF165 Complex Preparation

VEGF165 (concentration = 3.61 mg/ml) was mixed with CHO cell transiently expressed Flt1D2.Flk1D3.FcΔC1(a) (concentration = 0.9 mg/ml) in molar ratio of 3:1 (VEGF165:Flt1D2.Flk1D3.FcΔC1(a)) and incubated overnight at 4°C.

(a) Size Exclusion Chromatography (SEC) under native conditions

To separate the complex from excess of unbound VEGF165, 50 μl of the complex was loaded on a Pharmacia Superose 12 PC 3.2/30 which was equilibrated in PBS buffer. The sample was eluted with the same buffer at flow rate 40μl/min. at room temperature. The results of this SEC are shown in Figure 31. Peak #1 represents the complex and peak #2 represents unbound VEGF165. Fractions eluted between 1.1 and 1.2

20

25

ml were combined and guanidinium hydrochloride (GuHCl)was added to a final concentration 4.5M to dissociate the complex.

(b) Size Exclusion Chromatography (SEC) under dissociative 5 conditions

To separate the components of the receptor-ligand complex and to determine their molar ratio, 50μl of dissociated complex as described supra was loaded onto a Superose 12 PC 3.2/30 equilibrated in 6M GuHCl and eluted with the same solution at a flow rate 40μl/min. at room temperature. The results of this SEC are shown in Figure 32. Peak #1 represents Flt1D2Flk1D3.FcΔC1(a) and peak #2 represents VEGF165.

15 (c) Calculation of Fit1D2Fik1D3.Fc∆C1(a):VEGF165 Complex Stoichiometry

The stoichiometry of the receptor-ligand complex was determined from the peak area or the peak height of the components. Concentrations of VEGF165 and Flt1D2Flk1D3.FcΔC1(a) corresponding to the peak height or peak area, respectively, were obtained from the standard curves for VEGF165 and Flt1D2Flk1D3.FcΔC1(a). To obtain a standard curve, four different concentrations (0.04 mg/ml -0.3mg/ml) of either component were injected onto a Pharmacia Superose 12 PC 3.2/30 column equilibrated in 6M guanidinium chloride and eluted with the same

10

15

20

solution at flow rate 40μl/min. at room temperature. The standard curve was obtained by plotting peak area or peak height vs protein concentration. The molar ratio of VEGF165:Flt1D2Flk1D3.FcΔC1(a) determined from the peak area of the components was 1.16. The molar ratio of VEGF165:Flt1D2Flk1D3.FcΔC1(a) determined from the peak height of the components was 1.10.

Example 27: Determination of the Stoichiometry of the FIt1D2FIk1D3.Fc△C1(a)/VEGF165 Complex by Size Exclusion Chromatography with On-Line Light Scattering

Complex preparation

VEGF165 was mixed with CHO transiently expressed

Flt1D2.Flk1D3.FcΔC1(a) protein in molar ratio of 3:1

(VEGF165:Flt1D2Flk1D3.FcΔC1(a)) and incubated overnight at 4°C.

(a) Size Exclusion Chromatography (SEC) with On-Line Light Scattering

Size exclusion chromatography column with a MiniDawn on-line light scattering detector (Wyatt Technology, Santa Barbara, California) and refractive index (RI) detectors (Shimadzu, Kyoto, Japan) was used to determine the molecular weight (MW) of the receptor-ligand complex.

25 Samples were injected onto a Superose 12 HR 10/30 column

10

15

25

(Pharmacia) equilibrated in PBS buffer and eluted with the same buffer at flow rate 0.5 ml/min. at room temperature. As shown in Figure 33, the elution profile shows two peaks. Peak #1 represents the receptor-ligand complex and peak #2 represents the unbound VEGF165. MW was calculated from LS and RI signals. The same procedure was used to determine MW of the individual components of the receptor-ligand complex. The results of these determinations are as follows: MW of the Flt1D2Flk1D3.FcΔC1(a)/VEGF165 complex at the peak position is 157 300 (Figure 33), the MW of VEGF165 at the peak position is 44 390 (Figure 34) and the MW of R1R2 at the peak is 113 300 (Figure 35).

These data indicated that the stoichiometry of the Flt1D2Flk1D3.FcΔC1(a)/VEGF complex is 1:1 as its corresponds to the sum of molecular weights for Flt1D2Flk1D3.FcΔC1(a) and VEGF165. Importantly, this method conclusively proved that the Flt1D2Flk1D3.FcΔC1(a)/VEGF165 complex was indeed composed of only one molecule of VEGF165 ligand and only one molecule of the Flt1D2Flk1D3.FcΔC1(a).

20 Example 28: Peptide Mapping of Flt1D2.Flk1D3.Fc∆C1(a)

The disulfide structures and glycosylation sites in Flt1D2.Flk1D3.Fc\(\Delta\)C1(a) were determined by a peptide mapping method. In this method, the protein was first cleaved with trypsin. Tryptic fragments were analyzed and identified by HPLC coupled with mass

10

15

spectrometry, in addition to an N-terminal sequencing technique.

Reduction of the tryptic digest was employed to help identify disulfide-bond-containing fragments. Treatment of the tryptic digest with PNGase F (Glyko, Novato, CA) was employed to help identify fragments with N-linked glycosylation sites. The results are summarized in the accompanying Figure 36.

There are a total of ten cysteines in Flt1D2.Flk1D3.Fc Δ C1(a); six of them belong to the Fc region. Cys27 has been confirmed to be disulfide bonded to Cys76. Cys121 is confirmed to be disulfide bonded to Cys 182. The first two cysteines in the Fc region (Cys211 and Cys214) form an intermolecular disulfide bond with the same two cysteines in another Fc chain. However, because these two cysteines can not be separated enzymatically from each other, it can not be determined whether disulfide bonding is occurring between same cysteines (Cys211 to Cys211, for example) or between Cys211 and Cys214. Cys216 is confirmed to be disulfide bonded to Cys306. Cys 352 is confirmed to be disulfide bonded to Cys410.

There are five possible N-linked glycosylation sites in Flt1D2.Flk1D3.FcΔC1(a). All five of them are found to be glycosylated to varying degrees. Complete glycosylation was observed at Asn33 (amino acid sequence NIT), Asn193 (amino acid sequence NST), and Asn282 (amino acid sequence NST). In addition, partial glycosylation is

observed on Asn65 and Asn120. Sites of glycosylation are highlighted by underline in the Figure 36.

Example 29: Pharmacokinetic Analysis of Modified Flt Receptors

(a) Pharmacokinetic analysis of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.Fc\(\triangle C1(a)\) and VEGFR1R2-Fc\(\triangle C1(a)\)

Balb/c mice (25-30g) were injected subcutaneously with 4mg/kg of 10 Flt1(1-3)-Fc (A40), CHO transiently expressed Flt1D2.Flk1D3.Fc∆C1(a), CHO stably expressed Flt1D2.Flk1D3.Fc\(\Delta\)C1(a), and CHO transiently expressed VEGFR1R2-Fc\(\Delta\)C1(a). The mice were tail bled at 1, 2, 4, 6, 24hrs, 2 days, 3 days and 6 days after injection. The sera were assayed 15 in an ELISA designed to detect Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a). The ELISA involves coating an ELISA plate with VEGF165, binding the detect Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.Fc∆C1(a) or VEGFR1R2-Fc∆C1(a) and reporting with an anti-Fc antibody linked to horse radish peroxidase. The results of this experiments are shown in Figure 37. The T_{max} for Flt1(1-3)-Fc 20 (A40) was at 6 hrs while the T_{max} for the transient and stable Flt1D2.Flk1D3.Fc∆C1(a) and the transient VEGFR1R2-Fc∆C1(a) was 24hrs. The C_{max} for Flt1(1-3)-Fc (A40) was $8\mu\text{g/ml}$. For both transients (Flt1D2.Flk1D3.Fc Δ C1(a) and VEGFR1R2-Fc Δ C1(a)) the C_{max}

10

15

was 18µg/ml and the C_{max} for the stable VEGFR1R2-Fc Δ C1(a) was 30µg/ml.

(b) Pharmacokinetic analysis of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.Fc△C1(a) and Flt1D2.VEGFR3D3.Fc△C1(a)

Balb/c mice (25-30g) were injected subcutaneously with 4mg/kg of Fit1(1-3)-Fc (A40), CHO transiently expressed Fit1D2.Fik1D3.FcΔC1(a) and CHO transiently expressed Fit1D2.VEGFR3D3.FcΔC1(a). The mice were tail bled at 1, 2, 5, 6, 7, 8, 12, 15 and 20 days after injection. The sera were assayed in an ELISA designed to detect Fit1(1-3)-Fc, Fit1D2.Fik1D3.FcΔC1(a) and Fit1D2.VEGFR3D3.FcΔC1(a). The ELISA involves coating an ELISA plate with 165, binding the Fit1(1-3)-Fc, Fit1D2.Fik1D3.FcΔC1(a) or Fit1D2.VEGFR3D3.FcΔC1(a) and reporting with an anti-Fc antibody linked to horse radish peroxidase. Fit1(1-3)-Fc (A40) could no longer be detected in the serum after day 5 whereas , Fit1D2.Fik1D3.FcΔC1(a) and Fit1D2.VEGFR3D3.FcΔC1(a) were detectable for 15 days or more. The results of this experiment are shown in Figure 38.

20

Example 30: Evaluation of the Ability of Flt1D2.Flk1D3.Fc∆C1(a) to Inhibit Tumor Growth In Vivo

To evaluate the ability of Flt1D2.Flk1D3.Fc∆C1(a) to inhibit tumor

25 growth in vivo a model in which tumor cell suspensions are implanted

15

25

subcutaneously on the right flank of male severe combined immunodeficiency (SCID) mice was employed. Two cell lines, the human HT-1080 fibrosarcoma cell line (ATCC accession no. CCL-121) and the rat C6 glioma cell line (ATCC accession no. CCL-107), each of which exhibit distinctly different morphologies and growth characteristics, were used in the assay. The first dose of Flt1D2.Flk1D3.Fc∆C1(a) (at 25mg/Kg or as indicated in Figures 39 and 40) was given on the day of tumor implantation. Animals subsequently received subcutaneous injections of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.Fc\(\Delta\C1(a)\) or vehicle either every other day (EOD) or two times per week (2X/wk) for a period of 2 weeks. After 2 weeks, animals were perfused with fixative, tumors were removed and samples were blinded. Tumor volume was determined by measuring the length and width of visible subcutaneous tumors. Both of Flt1(1-3)-Fc (A40) and Flt1D2.Flk1D3.Fc∆C1(a) significantly reduced the growth of tumors formed by HT-1080 and C6 cells. The results of these

Example 31: The Effect of VEGF165 and Modified Flt 20 Receptors in Female Reproductive System

experiments are shown in Figure 39 and Figure 40.

The stereotypic pattern of vascular remodeling which occur in the uterus and ovary over the course of the reproductive cycle has been well characterized, making these tissues particularly well suited to the study of mechanisms which regulate angiogenesis, vascular

10

remodeling and vascular regression. Indeed, *in situ* hybridization studies in the reproductive tissues provided the first clear evidence that VEGF acts as a mediator of physiological angiogenesis in mature rodents, as well as humans and non-human primates (Phillips et al, 1990; Ravindranath et al, 1992; Shweiki et al, 1993; Kamat et al, 1995). As cyclic angiogenesis and vascular remodeling are prominent features of the normal ovary and uterus, it is not surprising that abnormal blood vessel growth and/or vascular dysfunction have been found to characterize many pathological conditions which affect these organs. Furthermore, these pathogenic vascular abnormalities are thought to be caused or perpetuated by the dysregulated expression of one or more angiogenic or anti-angiogenic factors, most prominently VEGF.

15 For example, abnormal angiogenesis is characteristic of polycystic ovary disease, endometriosis and endometrial carcinoma, and in each case VEGF is over expressed in the affected tissue (Kamat et al, 1995; Shifren et al, 1996; Guidi et al, 1996; Donnez et al, 1998).

Overexpression of VEGF is also thought to play a pathogenic role in the establishment of systemic vascular hyperpermeability in ovarian hyperstimulation syndrome (McClure et al, 1994; Levin et al, 1998) and preeclampsia (Baker et al, 1995; Sharkey et al, 1996). In addition, VEGF has been implicated as the permeability factor responsible for the production of ascites associated with ovarian carcinoma and other tumors (Senger et al, 1983; Boocock et al, 1995). Agents which effectively neutralize the biological actions of VEGF can reasonably be

10

15

anticipated to be of therapeutic benefit in the above and related conditions.

Angiogenesis and vascular remodeling are also hallmarks of blastocyst implantation and placental development (Findlay, 1986). VEGF is strongly expressed both in the maternal decidua and in embryonic trophoblasts, where it is thought to first stimulate expansion and hyperpermeability of the uterine vasculature during the peri-implantation period and subsequently mediate formation of both the maternal and embryonic components of the placental vasculature (Shweiki et al, 1993; Cullinan-Bove and Koos, 1993; Chakraborty et al, 1995; Das et al, 1997). VEGF is also required for luteal angiogenesis and associated progesterone secretion necessary to prepare the uterus for implantation (Ferrara et al, 1998). Thus, agents which inhibit the biological actions of VEGF may prove to be useful as contraceptive agents (by preventing implantation), or as an abortifacients in the early stages of gestation. The latter application might find particular use as a non-surgical intervention for the termination of ectopic pregnancies.

20 While the expression of VEGF receptors is largely confined to the vascular endothelium in normal reproductive tissues, Flt1 is also expressed by trophoblasts in the placenta in both humans and animals (Clark et al, 1996; He et al, 1999) where it has been proposed to play a role in trophoblast invasion. Interestingly, both Flt1 and KDR (Flk1) are expressed by choriocarcinoma cell line BeWo (Charnock-Jones et al, 1994), and VEGF has been shown to promote DNA synthesis and tyrosine phosphorylation of MAP kinase in these cells. Furthermore, primary and

metastatic ovarian carcinomas not only to express high levels of VEGF, but - in addition to the vascular endothelium - the tumor cells themselves express KDR and/ or Flt1 (Boocock et al, 1995). These findings suggest that VEGF may not only be critically involved in the generation and maintenance of tumor vasculature, but that at least in some tumors of reproductive origin VEGF may subserve an autocrine role, directly supporting the survival and proliferation of the tumor cells. Thus agents which block the actions of VEGF may have particularly beneficial applications to the treatment of tumors of reproductive origin.

Methods and Results

(a) Assessment of VEGF-Induced Uterine Hyperpermeability

15

20

25

10

Pregnant mare's serum gonadotrophin (PMSG) was injected subcutaneously (5 IU) to induce ovulation in prepubertal female rats. This results in a surge of estradiol after 2 days which in turn causes an induction of VEGF in the uterus. It is reported that this induction results in hyperpermeability of the uterus and an increase in uterine wet weight 6 hrs. later and, therefore, could potentially be blocked by the modified Flt receptors Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a). In this in vivo model, the normal weight of the rat uterus is about 50 mg and this can be induced to 300-350 mg by PMSG. Desiccation of the tissue reveals that this is all water weight. Subcutaneous injection of Flt1(1-3)-Fc (A40),

FIt1D2.FIk1D3.Fc\(\text{C1}(a)\) and FIt1D2.VEGFR3D3.Fc\(\text{C1}(a)\) at 25mg/kg at 1hr. after PMSG injection results in about a 50% inhibition of the increase in uterine wet weight. Increasing the dose of modified FIt receptor does not further reduce the increase in wet weight suggesting that there is a VEGF-independent component to this model. The results of this experiment are shown in Figure 41.

(a) Assessment of corpus luteum angiogenesis using progesterone as a readout

10

15

20

5

Pregnant mare's serum gonadotrophin (PMSG) is injected subcutaneously (5 IU) to induce ovulation in prepubertal female rats. This results in a fully functioning corpus luteum containing a dense network of blood vessels after 4 days that allows for the secretion of progesterone into the blood stream in order to prepare the uterus for implantation. The induction of angiogenesis in the corpus luteum requires VEGF; therefore, blocking VEGF would result in a lack of new blood vessels and thus a lack of progesterone secreted into the blood stream. In this in vivo model, resting levels of progesterone are about 5ng/ml and this can be induced to a level of 25-40ng/ml after PMSG. Subcutaneous injection of Flt1(1-3)-Fc (A40) or Flt1D2.Flk1D3.FcΔC1(a) at 25mg/kg or 5mg/kg at 1hr. after PMSG injection results in a complete inhibition of the progesterone induction on day 4. The results of this experiment are shown in Figure 42A-42B.

20

25

5

Example 33: Pharmacokinetic Analysis of Flt1(1-3)-Fc (A40) and Pegviated Flt1(1-3)-Fc

Flt1(1-3)-Fc was PEGylated with either 10kD PEG or 20kD PEG and tested in balb/c mice for their pharmacokinetic profile. Both PEGylated forms of Flt1(1-3)-Fc were found to have much better PK profiles than Flt1(1-3)-Fc (A40), with the Tmax occurring at 24 hrs. for the PEGylated molecules as opposed to 6 hrs. for Flt1(1-3)-Fc (A40).

10 Example 34: VEGF165 ELISA to Test Affinity of Modified Flt1 Receptor Variants

10pM of VEGF165 was incubated overnight at room temperature with modified Flt1 receptor variants ranging from 160pM to 0.1pM. The modified Flt1 receptor variants used in this experiment were Flt1(1-3)-Fc, Flt1(1-3)-Fc (A40), transiently expressed Flt1D2VEFGFR3D3-FcΔC1(a), transiently expressed Flt1D2VEFGFR3D3-FcΔC1(a), Flt1-(1-3_{NAS})-Fc, Flt1(1-3_{R->C})-Fc and Tie2-Fc. Flt1(1-3_{NAS})-Fc is a modified version of Flt1(1-3)-Fc in which the highly basic amino acid sequence KNKRASVRRR is replaced by NASVNGSR, resulting in the incorporation of two new glycosylation sites and a net reduction of five positive charges, both with the purpose of reducing the unfavorable effects of this sequence on PK. Flt1(1-3_{R->C})-Fc is a modification in which a single arginine (R) residue within the same basic amino acid sequence is changed to a cysteine (C) (KNKRASVRRR ->

10

KNKQASVRRR) to allow for pegylation at that residue, which could then shield the basic region from exerting its unfavorable effects on PK. After incubation the solution was transferred to a plate containing a capture antibody for VEGF165 (R&D). The amount of free VEGF165 was then determined using an antibody to report free VEGF165. This showed that the modified Flt1 receptor variant with the highest affinity for VEGF165 (determined as the lowest amount of free VEGF165) was Flt1D2Flk1D3.Fc Δ C1(a), followed by Flt1(1-3)-Fc and Flt1(1-3)-Fc (A40) and then by Flt1(1-3_{R->C})-Fc, Flt1(1-3_{NAS})-Fc and Flt1D2VEFGFR3D3-Fc Δ C1(a). Tie2Fc has no affinity for VEGF165.

WE CLAIM:

- 1. An isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a VEGF polypeptide comprising:
- (a) a nucleotide sequence encoding a VEGF receptor component operatively linked to
- (b) a nucleotide sequence encoding a multimerizing component, wherein the VEGF receptor component is the only VEGF receptor component of the fusion polypeptide and wherein the nucleotide sequence of (a) consists essentially of a nucleotide sequence encoding the amino acid sequence of Ig domain 2 of the extracellular domain of a first VEGF receptor and a nucleotide sequence encoding the amino acid sequence of Ig domain 3 of the extracellular domain of a second VEGF receptor.

15

5

- 2. The isolated nucleic acid of claim 1 wherein the first VEGF receptor is Flt1.
- 3. The isolated nucleic acid of claim 1 wherein the second VEGF 20 receptor is Flk1.
 - 4. The isolated nucleic acid of claim 1 wherein the second VEGF receptor is Flt4.

5. The isolated nucleic acid molecule of claim 1, wherein the nucleotide sequence encoding Ig domain 2 of the extracellular domain of the first VEGF receptor is upstream of the nucleotide sequence encoding Ig domain 3 of the extracellular domain of the second VEGF receptor.

5

6. The isolated nucleic acid molecule of claim 1, wherein the nucleotide sequence encoding Ig domain 2 of the extracellular domain of the first VEGF receptor is downstream of the nucleotide sequence encoding Ig domain 3 of the extracellular domain of the second VEGF receptor.

- 7. The isolated nucleic acid molecule of claim 1, wherein the multimerizing component comprises an immunoglobulin domain.
- 8. The isolated nucleic acid molecule of claim 1, wherein the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.
- An isolated nucleic acid molecule comprising a nucleotide sequence encoding a modified Flt1 receptor fusion polypeptide, wherein the coding region of the nucleic
 acid molecule consists essentially of a nucleotide sequence selected from the group consisting of:
 - (a) the nucleotide sequence set forth in Figure 21A-21C
 - (b) the nucleotide sequence set forth in Figure 22A-22C;
 - (c) the nucleotide sequence set forth in Figure 24A-24C; and
- 25 (d) a nucleotide sequence which, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a), (b) or (c) and which encodes a fusion polypeptide molecule having the biological activity of the modified Flt1 receptor fusion polypeptide.
- 30 10. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a modified Flt1 receptor fusion polypeptide, wherein the coding region of the nucleic

acid molecule consists essentially of a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence set forth in Figure 13A-13D;
- (b) the nucleotide sequence set forth in Figure 14A-14C;
- (c) the nucleotide sequence set forth in Figure 15A-15C;
 - (d) the nucleotide sequence set forth in Figure 16A-16D; and
- (e) a nucleotide sequence which as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a), (b), (c) or (d) and which encodes a fusion polypeptide molecule having the biological activity of the modified Flt1 receptor fusion polypeptide.
- 11. A fusion polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, 3, 4, 9 or 10.
- 15 12. A composition capable of binding a VEGF molecule to form a nonfunctional complex comprising a multimer of the fusion polypeptide of claim 10.
 - 13. The composition of claim 12, wherein the multimer is a dimer.
- 20 14. The composition of claim 13 and a carrier.
 - 15. A vector which comprises the nucleic acid molecule of claim 1, 2, 3, 4, 9 or 10.
- 25 16. An expression vector comprising a nucleic acid molecule of claim 1, 2, 3, 4, 9 or 10 wherein the nucleic acid molecule is operatively linked to an expression control sequence.
- 17. A host-vector system for the production of a fusion polypeptide which comprises the expression vector of claim 16, in a suitable host cell.

-94-

- 18. The host-vector system of claim 17, wherein the suitable host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell.
- 19. The host-vector system of claim 17, wherein the suitable host cell is <u>E. coli</u>.
- 20. The host-vector system of claim 17, wherein the suitable host cell is a COS cell or a CHO cell.
- 21. A method of producing a fusion polypeptide which comprises growing cells
 of the host-vector system of claim 17, under conditions permitting production of the
 fusion polypeptide and recovering the fusion polypeptide so produced.

- 22. A fusion polypeptide encoded by the nucleic acid sequence set forth Figure 10A-10D or Figure 24A-24C, which has been modified by acetylation or pegylation.
- 5 23. The fusion polypeptide of claim 22 wherein the modification is acetylation.
 - 24. The fusion polypeptide of claim 22 wherein the modification is pegylation.
 - 25. The fusion polypeptide of claim 23 wherein the acetylation is accomplished with at least about a 100 fold molar excess of acetylation reagent.
- 15 26. The fusion polypeptide of claim 23 wherein acetylation is accomplished with a molar excess of acetylation reagent ranging from at least about a 10 fold molar excess to about a 100 fold molar excess.
- 27. The fusion polypeptide of claim 24 wherein the pegylation is 10K20 or 20K PEG.
 - 28. A method of decreasing or inhibiting plasma leakage in a mammal comprising administering to the mammal fusion polypeptide of claim 10.

- 29. The method of claim 28, wherein the mammal is a human.
- 30. The method of claim 29, wherein the fusion polypeptide is acetylated.

31. The method of claim 29, wherein the fusion polypeptide is pegylated.

- 32. The fusion polypeptide of claims 10 which specifically binds the VEGF receptor ligand VEGF.
- 33. A method of blocking blood vessel growth in a human comprising administering an effective amount of the fusion polypeptide of claim 10.

15

10

- 34. A method of inhibiting VEGF receptor ligand activity in a mammal comprising administering to the mammal an effective amount of the fusion polypeptide of claim 10.
- 20 35. The method of claim 34, wherein the mammal is a human.
 - 36. The method of claim 34, used to attenuate or prevent tumor growth in a human.

15

- 37. The method of claim 34, used to attenuate or prevent edema in a human.
- 38. The method of claim 34, used to attenuate or prevent ascites formation in a human.
 - 39. The method of claim 37, wherein the edema is brain edema.
 - 40. The method of claim 38, wherein the ascites is ovarian cancer associated ascites.
 - 41. A fusion polypeptide capable of binding a VEGF polypeptide comprising:
 - (a a VEGF receptor component operatively linked to
 - (b) a multimerizing component, wherein the VEGF receptor component is the only VEGF receptor component in the fusion polypeptide and consists essentially of the amino acid sequence of Ig domain 2 of the extracellular domain of a first VEGF receptor and the amino acid sequence of Ig domain 3 of the extracellular domain of a second VEGF receptor.
 - 42. The fusion polypeptide of claim 41 wherein the first VEGF receptor is Flt1.

- The fusion polypeptide of claim 41 wherein the second VEGF receptor is Flk1.
- 44. The fusion polypeptide of claim 41 wherein the second VEGF receptor is 5 Flt4.
 - The fusion polypeptide claim 41, wherein amino acid sequence of Ig domain 2 of the extracellular domain of the first VEGF receptor is upstream of the amino acid sequence of Ig domain 3 of the extracellular domain of the second VEGF receptor.
 - The fusion polypeptide of claim 41, wherein the amino acid sequence of Ig domain 2 of the extracellular domain of the first VEGF receptor is downstream of the amino acid sequence of Ig domain 3 of the extracellular domain of the second VEGF receptor.
 - 47. The fusion polypeptide of claim 41, wherein the multimerizing component comprises an immunoglobulin domain.
- 20 48. The fusion polypeptide of claim 41, wherein the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.
 - 49. A fusion polypeptide consisting essentially of an amino acid sequence of a modified Flt1 receptor, wherein the amino acid sequence is selected from the group consisting of:
 - (a) the amino acid sequence set forth in Figure 21A-21C
 - (b) the amino acid sequence set forth in Figure 22A-22C; and
 - (c) the amino acid sequence set forth in Figure 24A-24C.


10


-99-

- 50. A fusion polypeptide comprising an amino acid sequence of a modified Flt1 receptor, wherein the amino acid sequence is selected from the group consisting of:
 - (a) the amino acid sequence set forth in Figure 13A-13D;
 - (b) the amino acid sequence set forth in Figure 14A-14C;
 - (c) the amino acid sequence set forth in Figure 15A-15C; and
 - (d) the amino acid sequence set forth in Figure 16A-16D;
- 51. A method of decreasing or inhibiting plasma leakage in a mammal comprising administering to the mammal fusion polypeptide of claim 41, 42, 43, 44, 49 or 50.
- 52. A method of inhibiting VEGF receptor ligand activity in a mammal comprising administering to the mammal an effective amount of the fusion polypeptide of claim 41, 42, 43, 44, 49 or 50.


1/55


Fig.1.






2/55





SUBSTITUTE SHEET (RULE 26)

4/55



SUBSTITUTE SHEET (RULE 26)

5/55

Fig.6A.






Fig.6B.



SUBSTITUTE SHEET (RULE 26)

6/55


Fig.7.




rTIE-2-Fc unmodified Flt-1(1-3)-Fc - acetylated Flt-1(1-3)-Fc (10X) ----- acetylated Flt-1(1-3)-Fc (20X)
----- acetylated Flt-1(1-3)-Fc (30X)

7/55

Fig.8.



8/55



SUBSTITUTE SHEET (RULE 26)

PROPERTY FIELD WE DEED CHET

9/55

Fig.10A.

9.					4.0
10	20	30	40	50	60 * *
* * *	* *	*	* *	•	-
ATG GTC AGC TAC TGG GAC	ACC GGG GTY	C CTG CTG	TGC GCG CIG	CAC AGC IGI CIG	GAA GAG
TAC CAG TCG ATG ACC CTG Met Val Ser Tyr Trp Asp	ומיר כיכו ויאו	2 (2AC (4AC	ALG CGC GGC	Otto 200 piges	
Met Val Ser Tyr Trp Asp	Thr Gly va	T rea nea	CAS WIG DOC		
70	80	90	100	110	120
	. *	*	* *	* *	* *
ACA GGA TCT AGT TCA GGT	TCA AAA TI	A AAA GAT	CCT GAA CTG	AGT TTA AAA GGC	ACC CAG
	. x ~ mmm m~ x x	אור) ושושוף יוד.	CALL USA	TON YEAR TOO OO.	
TGT CCT AGA TCA AGT CCA Thr Gly Ser Ser Ser Gly	Ser Lys Le	eu Lys Asp	Pro Glu Leu	Ser red ras gri	y 1111 Carr
			160	170	180
130	140	150 *	* *	* *	* *
CAC ATC ATG CAA GCA GGC	- 010 101 0	NG CAT CTC	CAA TGC AGG	GGG GAA GCA GC	C CAT AAA
	~ ~~~ ~~~	AP PURE 12018	I TOTAL TOTAL		-
GTG TAG TAC GTT CGT CCC His Ile Met Gln Ala Gly	v Gln Thr L	eu His Leu	Gln Cys Arg	Gly Glu Ala Al	a His Lys>
illo 110 oni oni	-				240
190	200	210	220	230	* *
* * *	* *	*	*	a acc ata act aa	A TCT GCC
TGG TCT TTG CCT GAA AT	G GTG AGT A	ag gaa ag Ma amm may	CAA AGG CX	TCG TAT TGA TI	T AGA CGG
ACC AGA AAC GGA CTT TA Trp Ser Leu Pro Glu Me	C CAC TCA T	re Glu Sei	colu Ara Lei	u Ser Ile Thr Ly	ys Ser Ala>
Trp Ser Leu Pro Glu Me	et var ser r	ys Gra DC.			
250	260	270	280	290	300
		*	* *	* *	
TGT GGA AGA AAT GGC AF	AA CAA TTC T	IGC AGT AC	T TTA ACC TT	G AAC ACA GCT C	TT CGT TTG
ACA CCT TCT TTA CCG TO Cys Gly Arg Asn Gly Ly	ys Gln Phe (Cys Ser In	r Leu Tin De	tu Abit III	
210	320	330	340	350	360
310 * * *			* *	* *	* *
CAC ACT GGC TTC TAC A	GC TGC AAA	TAT CTA GO	T GTA CCT AC	T TCA AAG AAG A	AG GAA ACA
GTG TGA CCG AAG ATG T His Thr Gly Phe Tyr S	er Cys Lys	Tyr Leu Al	la Val Pro T	nr ser Lys Lys 1	Dys Cae a
		390	400		420
370	380 *	+ *	* *	* *	* *
GAA TCT GCA ATC TAT A	TTA TTT AT	AGT GAT A	CA GGT AGA C	CT TTC GTA GAG	ATG TAC AGT
CTT AGA CGT TAG ATA T Glu Ser Ala Ile Tyr	Ile Phe Ile	Ser Asp T	hr Gly Arg P	ro Phe Val Giu	Wet TAI Ser>
			460	450	480
430	440	450 * *	* *	,	* * *
GAA ATC CCC GAA ATT		3 CM C33 C	KGA AGG GAG	OTC GTC ATT CCC	TGC CGG GTT
CTT TAG GGG CTT TAA	Ile His Met	Thr Glu	Sly Arg Glu I	Leu Val Ile Pro	Cys Arg Val>
314 110 110 014 110					540
490	500	510	52: *	0 530 * * *	* *
* * * * ACG TCA CCT AAC ATC	*	ממג מידים	ልልር ጥጥ CCA	CTT GAC ACT TIG	ATC CCT GAT
TGC AGT GGA TTG TAG Thr Ser Pro Asn Ile	Thr Val Th	Leu Lys	Lys Phe Pro	Leu Asp Thr Leu	Ile Pro Asp>
THE SEL PLO MON THE			T (RULE 26)		
	3003111		. (

10/55

Fig.10B.

			• •;	9 .	. •	.													
		5	50		,	560			570			58	30			590			600
	*		*	*		*		*	*		*		*	*		*		*	*
													ATA						
													TAT						
Gly	Lys	Arg	Ile	Ile	Trp	Asp	Ser	Arg	Lys	Gly	Phe	Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys>
		۰.	• •									_	4.0						
		6.	10 *		1	620 *			630		*	64	40 *		•	550 *		_	660
~ >>		~~~		*				*				~~~		~~~					
													CAT						
													GTA						
GIU	iie	GIĀ	reu	Leu	THE	Cys	GIU	Ala	THE	vaı	ASII	GIY	nis	Leu	TYL	гÃ2	THE	ASII	Tyr>
		۲.	70			con			600			70	١٥			710			720
	*	0	70 *		,	580 *		*	690		*	,,	00 *	*	•	, TO		*	/20 *
CITC		C A IT		מאם.	XCC		202			CAM		C3.3	ATA		ארא		CCC		
													TAT						
																			Val>
Deu	1111	urz	ALG	GIII	Tim	WPII	1111	TTE	TTG	wsp	vaı	GIH	116	SCL	1111	FIO	my	FIU	Val
		73	30			740			750			76	in.		7	770			780
	*	• •	*	*	•	*		*	*		*		*	*		*		*	*
AAA	TTA	Cdal	AGA	GGC	CAT	ACT	Chri	GTC	CTC	TAA	TGT	ACT	GCT	ACC	ACT	CCC	TTG	AAC	ACG
													CGA						
					-			_											Thr>
-2-			3	- _3															
		79	90		8	300			810			82	20		8	330			840
	*		*	*		*		*	*		*		*	*		*		*	*
AGA	GTT	CAA	ATG	ACC	TGG	AGT	TAC	CCT	GAT	GAA	AAA	AAT	AAG	AGA	GCT	TCC	GTA	AGG	CGA
TCT	CAA	GTT	TAC	TGG	ACC	TCA	ATG	GGA	CTA	CTT	TTT	TTA	TTC	TCT	CGA	AGG	CAT	TCC	GCT
Arg	Val	Gln	Met	Thr	Trp	Ser	Tyr	Pro	Asp	Glu	Lys	Asn	Lys	Arg	Ala	Ser	Va1	Arg	Arg>
		85	50		8	360			870			88	-		8	390			900
	*		*	*		*		*	*		*		*	*		*		*	*
													AGT						
													TCA						
Arg	Ile	Asp	Gln	Ser	Asn	Ser	His	Ala	Asn	Ile	Phe	Tyr	Ser	Val	Leu	Thr	Ile	Asp	Lys>
					_														000
		91	*		5	920 *		*	930			94	*	٠	3	950 *			960
3.000	~			~			~~~			man	~~~	CODS		^ ~~~	CC3	-	max.	mav-	222
													AGG TCC						
																			Lys>
1100	GIII	POII	nya	roħ.	Llys	GLY	Deu	171		C 3.3	3	102	9		U _3				
		97	70			980			990			100	00		10	010		1	L020
	*		*	*	•	*		*	*		*		*	*	_	*		*	*
TCT	GTT	AAC	ACC	TCA	GTG	CAT	ATA	TAT	GAT	AAA	GCA	GGC	CCG	GGC	GAG	CCC	AAA	TCT	TGT
													GGC						
																			Cys>
				·				_	_	-		-		_			-		-
		103	30		10	040		:	1050			100	50		1	070		:	1080
	*		*	*		*		*	*		*		*	*		*		*	*
													CTC						
													GAG						
Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val>

11/55

Fig.10C.

				1 1	y .	IU	U.	•												
			109	90		11	100		1	1110			112	0		11	.30		1	140
		*		*	*		*		*	*		*		*	*		*		*	*
								AAG												
								TTC												
Pr	ıe	Leu	Pne	Pro	Pro	Lys	Pro	ГÀЗ	Asp	Thr	Leu	Met	TTE	Ser	Arg	mr	Pro	GIU	vaı	Thr>
			119	50		11	160		1	L170			118	30		1.1	90		1	.200
		*		*	*		*		*	*		*		*	*		*		*	*
TC	3C	GTG	GTG	GTG	GAC	GTG	AGC	CAC	GAA	GAC	CCT	GAG	GTC	AAG	TTC	AAC	TGG	TAC	GTG	GAC
AC	CG	CAC	CAC	CAC	CTG	CAC	TCG	GTG	CTT	CTG	GGA	CTC	CAG	TTC	AAG	TTG	ACC	ATG	CAC	CTG
c7	/S	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp>
																				0.00
		*	12:	*	*	12	220 *		*	1230		*	124	* 10	*	12	250 *		* 1	.260
œ	30		CAC			ልልጥ		AAG			സ്ത		GMG			ጥልሮ		AGC		
								TTC												
																				Tyr>
	•							-		-						_				
			12			12	280			1290			130			13	310			320
		*		*	*		*		*	*		*		*	*		*	~~~	*	*
								GTC												
								CAG												Lys>
	-9	101	401	001	VUI	LCG	****	VU.	<u> </u>	11713						0_7	-3-		-3-	-10-
			133	30		13	40		1	L350			136	0		13	70		1	380
		*		*	*		*		*	*		*		*	*		*		*	*
								CTC												
								GAG												
C	/S	rys	vaı	ser	Asn	rys	ΑTG	Leu	Pro	ATA	Pro	TTE	GIU	гуѕ	THE	тте	ser	гàг	Ata	Lys>
			139	90		14	100		1	L410			142	20		14	130		3	440
		*		*	*		*		*	*		*		*	*		*		*	*
								GTG												
								CAC												
G)	ГĀ	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	GIU	Leu	Thr	Lys>
			149	50		14	160		1	L 47 0			148	30		14	190		1	500
		*		*	*		*		*	*		*		*	*		*		*	*
AA	/C	CAG	GTC	AGC	CTG	ACC	TGC	CTG	GTC	AAA	GGC	TTC	TAT	CCC	AGC	GAC	ATC	GCC	GTG	GAG
																				CTC
Αs	sn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu>
			15:	10		15	520			1530			154	10		1!	550		1	L560
		*		*	*		*		*	*		*		*	*		*		*	*
TC	3 G	GAG	AGC	AAT	GGG	CAG	CCG	GAG	AAC	AAC	TAC	AAG	ACC	ACG	CCT	CCC	GTG	CTG	GAC	TCC
								CTC												
Tı	æ	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser>
			15	70		11	580			1590			16	00		1	610		•	1620
		*		*	*		*		*	*		*	20	*	*	_	*		*	*
G.	AC	GGC	TCC	TTC	TTC	CTC	TAC	AGC	AAG	CTC	ACC	GTG	GAC	AAG	AGC	AGG	TGG	CAG	CAG	GGG
																				CCC
A:	sp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly>


12/55

Fig.10D.

1690 1700

CTC TCC CTG TCT CCG GGT AAA TGA GAG AGG GAC AGA GGC CCA TTT ACT Leu Ser Leu Ser Pro Gly Lys ***>

Fig. 11




SUBSTITUTE SHEET (RULE 26)

13/55

THE SHARE WE SHIP

14/55



SUBSTITUTE SHEET (RULE 26)

15/55

		15/55			
Fig.13	3 A .		A		60
10	20	30	40	50 * *	60 *
* * *	* *	* *	* *		
ATG GTC AGC TAC TGG GAC	ACC GGG GTC	CTG CTG TGC	C GCG CTG CTC A	GC TGT CTG CTT	CIC
	MCC CCC CAC	CAC GAC AU	ב לפל לבאל לאום ב	CO 11011 C110	_
Met Val Ser Tyr Trp Asp	Thr Gly Val	. Leu Leu Cy:	s Ala hed bed b		
70	80	90	100		120
	* *	* *	* *	**	
ACA GGA TCT AGT TCA GGT	TCA AAA TTA	AAA GAT CC	r gaa ctg agt i	TA AAA GGC ACC	CMC
	העע חששת אאו	אורים יושדשוי י	A CII GMC ICE A	M	
TGT CCT AGA TCA AGT CCA Thr Gly Ser Ser Ser Gly	Ser Lys Lev	ı Lys Asp Pr	o Glu Leu Ser I	eu Lys Gly THI	GIII>
		150	160	170	180
130	140	* *	* *	* *	*
CAC ATC ATG CAA GCA GGC		።	A TGC AGG GGG (BAA GCA GCC CAT	AAA
CAC ATC ATG CAA GCA GGC GTG TAG TAC GTT CGT CCC	CAG ACA CIG	CAL CIC CI	T ACC TCC CCC (CTT CGT CGG GTA	TTT
GTG TAG TAC GTT CGT CCC His Ile Met Gln Ala Gly	GIC TGT GA	. Uic Tau Gl	n Cvs Ara Gly	Glu Ala Ala His	Lys>
His Ile Met Gln Ala Gly	A GIU TUL De	u his bed Gi	ii cju img1		
	000	210	220	230	240
190	200	± *	* *	* *	*
* * * * TGG TCT TTG CCT GAA ATG	* *	C CNN NCC GI	A AGG CTG AGC	ATA ACT AAA TCT	GCC
TGG TCT TTG CCT GAA ATC ACC AGA AAC GGA CTT TA	G GTG AGT AA	G GAA AGC GF	TO THE GAC TOG	TAT TGA TTT AGA	CGG
ACC AGA AAC GGA CTT TA Trp Ser Leu Pro Glu Me	C CAC TCA TT	c Cly Ser G	lu Ara Leu Ser	Ile Thr Lys Ser	Ala>
Trp Ser Leu Pro Glu Me	f val ser by	S GIU SEL G.	.u .mg =	-	
050	260	270	280	290	300
250	260 * *	*	* * *	* *	*
	2 C22 MMC WC	ረር ልርጥ ACT T	TA ACC TTG AAC	ACA GCT CAA GCA	AAC
	- AMM 1817 18	א מבצוי מיצוי יצי	AT ILEG PARC 1+0		
ACA CCT TCT TTA CCG TI Cys Gly Arg Asn Gly Ly	ra Cla Phe C	s Ser Thr L	eu Thr Leu Asn	Thr Ala Gln Ala	Asn>
CAR GIA WIR WRU GIA DA	S GIN THE O				
310	320	330	340	350	360
	± ±	*	* * *	* *	*
	C TGC AAA TZ	AT CTA GCT G	TA CCT ACT TCA	AAG AAG AAG GA	A ACA
	200 MMM XI	וא מבאיר רעבט ני	AL CHAN TOW DOA	110	
GTG TGA CCG AAG ATG TC His Thr Gly Phe Tyr Se	er Cvs Ivs T	vr Leu Ala V	al Pro Thr Ser	Lys Lys Lys Gl	u Thr>
HIS THE GLY FILE 191 BO		-			
370	380	390	400	410	420 *
		*	* * *	* *	
GAA TCT GCA ATC TAT A	TA TTT ATT A	GT GAT ACA C	GT AGA CCT TTC	GTA GAG ATG TA	C AGT
CTT AGA CGT TAG ATA T Glu Ser Ala Ile Tyr I	le Phe Ile S	er Asp Thr (Bly Arg Pro Phe	Val Glu Met Ty	r Ser>
Gra ber man end eine					
430	440	450	460	470	480 *
	* *	* *	* * *	* *	
GAA ATC CCC GAA ATT A	TA CAC ATG A	CT GAA GGA	AGG GAG CTC GTC	ATT CCC TGC CG	O GIT
	እው <i>ተ</i> መረግ ጠሽሮ ባ	יויון) יויוויז מבע	ILL CIC GAG CAG	, 1122	
CTT TAG GGG CTT TAA T	le His Met T	thr Glu Gly	Arg Glu Leu Val	. Ile Pro Cys Ai	rg var>
_ _					540
490	500	510	520	530 * * *	
* * *	* 1	* *	* * * *	·-	ርጥ ርልጥ
ACG TCA CCT AAC ATC	ACT GTT ACT	ITA AAA AAG	TIT CCA CIT GAG	C WCT TIG WIC C	GA CTA
	የጣን ጣንን ጥርን	אובן יובושף יודע א.	AAA GGT GAM CT	2 TOW INTO TITE OF	
TGC AGT GGA TIG TAG	Thr Val Thr	Leu Lys Lys	Phe Pro Leu As	h um nen me E	-0 -100
		E ALIEET (DI			

SUBSTITUTE SHEET (RULE 26)

16/55

Fig.13B.

		55	50		5	60			570			58	0		5	90			600
	*		*	*		*		*	*		*		*	*		*		*	*
GGA	AAA	CCC	ATA	ATC	TGG	GAC	AGT	AGA	AAG	ĢGC	TTC	ATC	ATA	TCA	AAT	GCA	ACG	TAC	AAA
CCT	TTT	GCG	TAT	TAG	ACC	CTG	TCA	TCT	TTC	CCG	AAG	TAG	TAT	AGT	TTA	CGT	TGC	ATG	TTT
Gly	Lys	Arg	Ile	Ile	\mathtt{Trp}	Asp	Ser	Arg	Lys	Gly	Phe	Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys>
			_										_						
		61	LO.		•	520			630			64	10			550			660
~	*		*	*		*		*	*		*		*	*		*		*	*
												GGG							
												222							
GIU	116	GIĀ	Den	reu	THE	Cys	GIU	ATA	THE	vaı	ASII	Gly	nis	Leu	TÄT	цуs	1111	Wall	Tyr>
		6'	70			580			690			70	10			710			720
	*	•	*	*	`	*		*	*		*	•	*	*		*		*	*
CTC	ACA	CAT	CGA	CAA	ACC	ААТ	ACA	ATC	ል ምል	GAT	GTC	CAA	ATA	AGC	ACA	CCA	CGC	CCA	GTC
												GTT							
																			Val>
			_							-									
		7:	30		•	740			750			76	50		•	770			780
	*		*	*		*		*	*		*		*	*		*		*	*
AAA	TTA	CTT	AGA	GGC	CAT	ACT	CTT	GTC	CTC	AAT	TGT	ACT	GCT	ACC	ACT	CCC	TTG	AAC	ACG
												TGA							
Lys	Leu	Leu	Arg	Gly	His	Thr	Leu	Val	Leu	Asn	Cys	Thr	Ala	Thx	Thr	Pro	Leu	Asn	Thr>
		7:	90		;	800			810			8:	20			830			840
	*		*	*		*		*	*		*		*	*		*	03 m	*	*
												GAC							_
												CTG							
Arg	vaı	GIN	Met	THE	up	ser	TYL	PTO	Asp	GIU	TTE	Asp	GIN	Ser	ASII	Ser	uis	ALA	Asn>
		Q	50		4	860			870			R	80			890			900
	*	•	*	*	1	*		*	*		*	•	*	*		*		*	*
ATA	TTC	TAC	AGT	GTT	CTT	ACT	ATT	GAC	AAA	ATG	CAG	AAC	AAA	GAC	AAA	GGA	CTT	TAT	ACT
												TTG							
																_			Thr>
		_						_	_										
		9	10			920			930			9	40			950			960
	*		*	*		*		*	*		*		*	*		*		*	*
												AAC							
																			CTA
Cys	Arg	Vai	Arg	Ser	Gly	Pro	Ser	Phe	Lys	Ser	Val	Asn	Thr	Ser	Val	. His	TTE	Tyr	Asp>
		0	70			000			000			10	^^		1	.010			1020
	*	9	70 *	*		980		*	990		*	10	00 *	*		.010		*	*
ΔΔΔ		ccc		. כככ	GAG	**	222					ልሮጥ					רככי	י יוער	CCA
																			GGT
																			Pro>
-4 -				<u> </u>					-2-						-4.				
		10	30		1	040			1050)		10	60		1	L070			1080
	*		*	*		*		*	4	•	*		*	4	,	*		*	*
GCA	CCT	GAA	CTC	CTG	GGG	GGA	CCG	TCA	GTC	TTC	CTC	TTC	ccc	CCF	L AA	A CCC	AAC	GAC	ACC
																			g TGG
Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	· Val	Phe	. Lev	Phe	Pro	Pro	Ly:	Pro	Lys	: Asp	Thr>
						SUB	STIT	UTE	SHE	EET (RUL	E 26)						

17/55

Fig.13C.

			•																
		10	90		1:	100		:	1110			112	20		1:	130		:	1140
	*		*	*		*		*	*		*		*	*		*		*	*
CTC	ATG	ATC	TCC	CGG	ACC	ርርጥ	GAG	CTC	ACA	TCC	GTG	CTC	GTG	GAC	GTG	AGC	CAC	GAA	CAC
			AGG																
Leu	Mec	TIE	Ser	ALG	1111	PIO	GIU	vai	THE	Cys	Vai	vaı	Val	ASD	vai	ser	nıs	GIU	Asp>
		115	50		11	L60			1170			118			13	190			1200
	*		*	*		*		*	*		*		*	*		*		*	*
CCT	GAG	GTC	AAG	TTC	AAC	TGG	TAC	GTG	GAC	GGC	GTG	GAG	GTG	CAT	AAT	GCC	AAG	ACA	AAG
GGA	CTC	CAG	TTC	AAG	TTG	ACC	ATG	CAC	CTG	CCG	CAC	CTC	CAC	GTA	TTA	CGG	TTC	TGT	TTC
Pro	Glu	Val	Lys	Phe	Asn	Trp	Tvr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys>
			_			-	-		-	_							_		-
		12:	10		15	220		-	1230			124	10		13	250		-	1260
	*		*	*		*		*	*		*		*	*		*		*	*
CCC	ccc	CNC	GAG	CNG	ma.c	330	200	200	mac	COM	Catc	CITY	»CC	COC	CUIC	እርር	CTC	CINC	CAC
			CIC																
Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His>
		127	70		12	280		1	1290			130	00		13	310		1	1320
	*		*	*		*		*	*		*		*	*		*		*	*
CAG	GAC	TGG	CTG	AAT	GGC	AAG	GAG	TAC	AAG	TGC	AAG	GTC	TCC	AAC	AAA	GCC	CTC	CCA	GCC
GTC	CTG	ACC	GAC	TTA	CCG	TTC	CTC	ATG	TTC	ACG	TTC	CAG	AGG	TTG	TTT	CGG	GAG	GGT	CGG
																			Ala>
					2	-3 -		-1-	-2-	-3-	-2-								
		133	RA		17	340			1350			136	50		3:	370			1380
	*	10.	*	*	Ι.	*			*		*	100	*	*		*		*	*
~~~	3.000	~~~		3.00						~~~	<b>~</b>	~~~		03.3	~~		OTTO	ma 🔿	
			AAA																
			TTT																
Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr>
		139	90		14	100		:	1410			142	20		14	130		:	1440
	*		*	*		*		*	*		*		*	*		*		*	*
CTG	CCC	CCA	TCC	CGG	GAT	GAG	CTG	ACC	AAG	AAC	CAG	GTC	AGC	CTG	ACC	TGC	CTG	GTC	AAA
GAC	GGG	GGT	AGG	GCC	CTA	CTC	GAC	TGG	TTC	TIG	GTC	CAG	TCG	GAC	TGG	ACG	GAC	CAG	TTT
																			Lys>
				_	_				•							_			_
		149	50		14	160		4	1470			148	30		14	190		-	1500
	*		*	*		*		*	*		*		*	*		*		*	*
ccc	mm~	mam	ccc		CNC		000		CIC	m/c	CNC	አርር	יחתת	CCC	CAG	CCC	GNG	220	NAC.
			GGG																
GIA	Pne	TYT	Pro	Ser	Asp	11e	Ala	Val	GIU	Trp	GIU	ser	Asn	GTĀ	Gin	PIO	GIU	ASN	Asn>
			_																
		151	LO		15	20		1	1530			154			15	550		•	1560
	*		*	*		*		*	*		*		*	*		*		*	*
TAC	AAG	ACC	ACG	CCT	CCC	GTG	CTG	GAC	TCC	GAC	GGC	TCC	TTC	TTC	CTC	TAC	AGC	AAG	CTC
ATG	TTC	TGG	TGC	GGA	GGG	CAC	GAC	CTG	AGG	CTG	CCG	AGG	AAG	AAG	GAG	ATG	TCG	TTC	GAG
Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu>
		157	0		15	80		3	1590			160	00		16	510		:	1620
	*		*	*		*		*	*		*		*	*		*		*	*
ACC	GTG	GAC	AAG	AGC	AGG	TGG	CAG	CAG	GGG	AAC	GTC	TTC	TCA	TGC	TCC	GTG	ATG	CAT	GAG
																			CTC
																			Glu>
4114	ACT	rap.	-ys	a⊄r	wid	TP	GTII	GTII	GTĀ	wall	AGT	FIRE	PET	CYS	2CT	AGT	1446	****	-u-u-

18/55

## Fig.13D.

		16:	30		16	540		1	L650			166	50		16	570	
	*		*	*		*		*	*		*		*	*		*	
GCT	CIG	CAC	AAC	CAC	TAC	ACG	CAG	AAG	AGC	CTC	TCC	CTG	TCT	CCG	GGT	AAA	TGA
CGA	GAC	GTG	TTG	GTG	ATG	TGC	GTC	TTC	TCG	GAG	AGG	GAC	AGA	GGC	CCA	TTT	ACT
Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	***>

#### 19/55

### Fig.14A.

1.5

			•	<b>J</b> .	• •														
			10			20			30			•	40			50			60
	*		*	*	~~	*	~~~	*	*	omo.	*	~~~	*	*		*		*	*
					GAC														
					CTG														Leu>
nec	Val	per	ıyı	ııp	rsp	1111	GIŞ	VOI	Beu	Deu	Cys	ALG	пец	Deu	oer.	Cys	Deu	Dea	Deu>
			70			80			90			10	00		1	110			120
	*		*	*		*		*	*		*		*	*		*		*	*
ACA	GGA	TCT	AGT	TCC	GGA	GGT	AGA	CCT	TTC	GTA	GAG	ATG	TAC	AGT	GAA	ATC	ccc	GAA	ATT
TGT	CCT	AGA	TCA	AGG	CCT	CCA	TCT	GGA	AAG	CAT	CTC	TAC	ATG	TCA	CTT	TAG	GGG	CTT	TAA
Thr	Gly	Ser	Ser	Ser	Gly	Gly	Arg	Pro	Phe	Val	Glu	Met	Tyr	Ser	Glu	Ile	Pro	Glu	Ile>
												_							
	*	1.	30 *	*	-	140 *		*	150		*	16	50 *	*	]	L70 ★		*	180
አመአ		300			003		<b>C</b> 2C			3.000		maa			100		ccm		
					GGA CCT														
																			Ile>
	*****	1200	1114	Giu	Gry	лy	Gra	nea	Val	110	110	CYD	149	V W.		-	110	12011	
		19	90		:	200			210			22	20		2	230			240
	*		*	*		*		*	*		*		*	*		*		*	*
ACT	GTT	ACT	TTA	AAA	AAG	TTT	CCA	CTT	GAC	ACT	TTG	ATC	CCT	GAT	GGA	AAA	CGC	ATA	ATC
TGA	CAA	TGA	AAT	TTT	TTC	AAA	GGT	GAA	CTG	TGA	AAC	TAG	GGA	CTA	CCT	TTT	GCG	TAT	TAG
Thr	Val	Thr	Leu	Lys	Lys	Phe	Pro	Leu	Asp	Thr	Leu	Ile	Pro	Asp	Gly	Lys	Arg	Ile	Ile>
		25	50		2	260			270			28			2	290			300
<b>***</b>	*		*	*		*		*	*		*	- ~~	*	*	~	*	~~~	*	*
					GGC														
					CCG														Leu>
ırp	vaħ	SEL	wg	nys	Gry	PHE	116	TTE	Ser	Poli	Ma	1111	ıyı	БУЗ	GIU	TTE	GIĀ	nea	Leu>
		31	LO		3	320			330			34	10		3	50			360
	*		*	*		*		*	*		*		*	*		*		*	*
ACC	TGT	GAA	GCA	ACA	GTC	AAT	GGG	CAT	TTG	TAT	AAG	ACA	AAC	TAT	CTC	ACA	CAT	CGA	CAA
TGG	ACA	CTT	CGT	TGT	CAG	TTA	CCC	GTA	AAC	ATA	TTC	TGT	TTG	ATA	GAG	TGT	GTA	GCT	GTT
Thr	Cys	Glu	Ala	Thr	Val	Asn	Gly	His	Leu	Tyr	Lys	Thr	Asn	Tyr	Leu	Thr	His	Arg	Gln>
					_							4.							400
	*	37	/U *		2	380 *		*	390		*	4(	*	*	4	110 *		*	420 *
እሮር		מיים		גיינה	GAT		C A A			እሮአ		CCC			አአአ		Custr		
					CTA														
																			Gly>
												3							
		4:	30		4	140			450			4	50			470			480
	*		*	*		*		*	*		*		*	*		*		*	*
					AAT														
					TTA														
His	Thr	Leu	Val	Leu	Asn	Суѕ	Thr	Ala	Thr	Thr	Pro	Leu	Asn	Thr	Arg	Val	Gln	Met	Thr>
		49	20			500			510			5.	20			520			540
	*	4.	*	*	-	*		*	310		*	J.	*	*	•	530 *		*	540 *
TGG	AGT	TAC	CCT	GAT	GAA	ATT	GAC	CAA	AGC	ААТ	TCC	САТ	GCC	AAC	ATA	TTC	TAC	AGT	GTT
					CTT														
																			Val>
				•	SUBS	STITE	JTF	SHF	FT (	2()  F	= 261								
							- <b></b>	IN	-· /·		,								

#### 20/55

### Fig.14B.

				J															
		5	50		!	560			570			58	30		9	590			600
	*		*	*		*		*	*		*		*	*		*		*	*
CTT	ACT	ATT	GAC	AAA	ATG	CAG	AAC	AAA	GAC	AAA	GGA	CTT	TAT	ACT	TGT	CGT	GTA	AGG	AGT
GAA	TGA	TAA	CTG	TTT	TAC	GTC	TTG	TTT	CTG	TTT	CCT	GAA	ATA	TGA	ACA	GCA	CAT	TCC	TCA
																			Ser>
				-2-		·		-20		_,_			-1-		~1_		,	5	
		6	10			620			630			6.	40			550			660
		0.	*			*		*	450		*	0.	*	*	,	*		*	*
003	-	max			mom					~~~		3.003					000		
												ATA							
												TAT							
GIA	Pro	Ser	Phe	Lys	Ser	Val	Asn	Thr	Ser	Val	His	Ile	Tyr	Asp	Lys	Ala	Gly	Pro	Gly>
		6	70		- (	680			690			70	00		•	710			720
	*		*	*		*		*	*		*		*	*		*		*	*
GAG	CCC	AAA	TCT	TGT	GAC	AAA	ACT	CAC	ACA	TGC	CCA	CCG	TGC	CCA	GCA	CCT	GAA	CTC	CTG
CTC	GGG	TTT	AGA	ACA	CTG	TTT	TGA	GTG	TGT	ACG	GGT	GGC	ACG	GGT	CGT	GGA	CTT	GAG	GAC
G1u	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu>
		_		_	_	_				_			_						
		73	30		•	740			750			76	50		•	770			780
	*		*	*		*		*	*		*		*	*		*		*	*
GGG	GGA	CCG	TCA	GTC	יארי	CTC	مكلمك	CCC	CCA	AAA	CCC	AAG	GAC	ACC	CTC	ATG	ATC	TCC	CGG
												TTC							
																			Arg>
GLY	GLY	FIO	Ser	vaı	FILE	Deu	FILE	FLO	FIO	nys	FLO	цуз	A3D	1111	Dea	Mec	116	Der	mgz
		79	30			300			810			82	20		•	330			840
			*	*	•	*		*	*		*	02	*	*	`	*		*	*
እርር	COM	CNC			mcc		COC					CAC			~~m		CITC		mm>
												GTG							
THE	PIO	GIU	vaı	Thr	Cys	vaı	vai	vaı	ASD	vaı	ser	HIS	GIU	ASP	PIO	GIU	vai	гÃг	Phe>
																300			000
	_	85	*		ŧ	360			870			88	*	_	8	390 *		*	900
				*		*		*											
												AAG							
												TTC							
Asn	$\operatorname{Trp}$	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln>
		91			9	920			930			94	10		,	950			960
	*		*	*		*		*	*		*		*	*		*		*	*
												GTC							
												CAG							
Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	$\operatorname{Trp}$	Leu	Asn>
		97	70		9	980			990			100	00		1	010		:	1020
	*		*	*		*		*	*		*		*	*		*		*	*
GGC	AAG	GAG	TAC	AAG	TGC	AAG	GTC	TCC	AAC	AAA	GCC	CTC	CCA	GCC	CCC	ATC	GAG	AAA	ACC
CCG	TTC	CTC	ATG	TTC	ACG	TTC	CAG	AGG	TTG	TTT	CGG	GAG	GGT	CGG	GGG	TAG	CTC	TTT	TGG
																			Thr>
		103	30		10	040		1	L050			106	50		1	070		:	1080
	*		*	*		*		*	*		*		*	*		*		*	*
ATC	TCC	AAA	GCC	AAA	GGG	CAG	CCC	CGA	GAA	CCA	CAG	GTG	TAC	ACC	CTG	CCC	CCA	TCC	CGG
TAG	AGG	TTT	CGG	TTT	CCC	GTC	GGG	GCT	CTT	GGT	GTC	CAC	ATG	TGG	GAC	GGG	GGT	AGG	GCC
Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg>
				-				_					-						_

Fig.14C.

21/55

				J															
		109	10		11	00		1	110			112	:0		11	.30			140
			-	*		_		*	*		*		*	*		*		*	*
~> m	*	CITYC			אאר	~~	GTC	AGC	CTG	ACC	TGC	CTG	GTC	AAA	GGC	TTC	TAT	CCC	AGC
CTA	CTC	GAC	166	TIC	116	G1C	UAG	Cor	Leu	Thr	Cvs	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser>
Asp	Glu	Leu	Thr	Lys	ASN	GIN	AGT	Ser	Deu	****	<b>-</b> 2			_					
									170			111	80		1:	190		1	200
		11:	50		13	.60			*		*		*	*		*		*	*
	*		*	*		*		*					አአሮ	አአሮ	ጥልሮ	AAG	ACC	ACG	CCT
GAC	ATC	GCC	GTG	GAG	TGG	GAG	AGC	AAT	GGG	CAG	CCG	CAC	MAC	WWC.	אתעב	אואני	TYCG	TGC	GGA
Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	ASN	ASII	TYL	пуз	1111	****	Pro>
																			1260
		12	10		1:	220			1230			12	40			250			*
									*		*		*	*		*		*	-
				*		*		*	*										
	*		*		GAC		TCC	mmo	ייייי	CTC	TAC	AGC	AAG	CTC	ACC	GTG	GAC	AAG	AGC
		CTG	* GAC	TCC		GGC		TTC	TTC		TAC	AGC	AAG		ACC				AGC TCG
		CTG	* GAC	TCC		GGC		TTC	TTC		TAC	AGC	AAG		ACC				
		CTG	* GAC	TCC		GGC		TTC	TTC		TAC	AGC	AAG		ACC				AGC TCG Ser>
		GAC Lev	* GAC CTG Asp	TCC	CTG Asp	GGC CCG Gly		TTC AAG Phe	TTC AAG Phe	Leu	TAC	AGC TCC Ser	AAG TTC		ACC TGC			Lys	
		GAC Lev	* GAC	TCC	CTG Asp	GGC CCG Gly 280		TTC AAG Phe	TTC AAG Phe	Leu	TAC ATG	AGC TCC Ser	AAG		ACC TGC Thr	. Val		Lys	Ser>
GGG	CAC Val	GAC Leu	* GAC CTG Asp	TCC AGG Ser	CTG Asp	GGC CCG Gly 280	AGG Ser	TTC AAG Phe	TTC AAG Phe 1290	Lev	TAC ATG Tyr	AGC TCG Ser	AAG TTC Lys	Leu	ACC TGC Thr	.310	Asp	Lys *	Ser> 1320 *
GGG	CAC Val	GAC	* GAC CTG Asp	TCC AGG Ser	CTG Asp	GGC CCG Gly 280	AGG Ser	TTC AAG Phe	AAG Phe 1290	Lev	TAC ATG Tyr	AGC FOO Ser 13	AAG TTC Lys	Leu *	ACC TGC Thr	Val	Asp CAC	tys *	Ser> 1320     * CAC
Pro	CAC Val  * TGG	CTG GAC Leu	* GAC CTG Asp 70 * CAG	TCC AGG Ser *	Asp 1	GGC CCG Gly 280	AGG	TTC	TTC AAG Phe 1290 *	Lev TCC	TAC ATG Tyr *	AGC TCG Ser 13	AAG TTC Lys	Lev * GAG	ACC TGG Thr	Val	Asp CAC	* AAC	Ser> 1320  * CAC GTG
Pro	CAC Val  * TGG	CTG GAC Leu	* GAC CTG Asp 70 * CAG	TCC AGG Ser *	Asp 1	GGC CCG Gly 280	AGG	TTC	TTC AAG Phe 1290 *	Lev TCC	TAC ATG Tyr *	AGC TCG Ser 13	AAG TTC Lys	Lev * GAG	ACC TGG Thr	Val	Asp CAC	* AAC	Ser> 1320  * CAC GTG
Pro	CAC Val  * TGG	CTG GAC Leu	* GAC CTG Asp 70 * CAG	TCC AGG Ser *	Asp 1	GGC CCG Gly 280	AGG	TTC	TTC AAG Phe 1290 *	Lev TCC	TAC ATG Tyr *	AGC TCG Ser 13	AAG TTC Lys	Lev * GAG	ACC TGG Thr	Val	Asp CAC	* AAC	Ser> 1320     * CAC

TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT AAA TGA ATG TGC GTC TTC TCG GAG AGG GAC AGA GGC CCA TTT ACT Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys ***>

1340

#### 22/55

### Fig.15A.

			1	10			20			30			4	l0			50			60
		*		*	*		*		*	*		*		*	*		*		*	*
											CTG									
											GAC									
Me	t	VaI	Ser	Tyr	Trp	Asp	Thr	Gly	Val	Leu	Leu	Cys	Ala	Leu	Leu	Ser	Cys	Leu	Leu	Leu>
			-	70			00										110			120
		*	•	70 *			80 *			90			10	*	•	1	110		*	120
20	Δ.	CC A	et/ver		TCC -	CCN		אכא	CCT		GTA	GNG.	አጥር	ጥእር	ልርጥ	(Z) )	አጥጥ	CCC	GNN.	
											CAT									
																				Ile>
		2				1	2	3						-4-						
			13	30		1	40			150			16	50		1	170			180
		*		*	*		*		*	*		*		*	*		*		*	*
ΓA	'A	CAC	ATG	ACT	GAA	GGA	AGG	GAG	CTC	GTC	ATT	CCC	TGC	CGG	GTT	ACG	TCA	CCT	AAC	ATC
T	T	GTG	TAC	TGA	CTT	CCT	TCC	CTC	GAG	CAG	TAA	GGG	ACG	GCC	CAA	TGC	AGT	GGA	TTG	TAG
IJ	e	His	Met	Thr	Glu	Gly	Arg	Glu	Leu	Val	Ile	Pro	Cys	Arg	Val	Thr	Ser	Pro	Asn	Ile>
		_	19	90 *		2	200			210			22	20 *			230			240
20	·m	~ ~	3.00		**	***		<b>~~</b>	×			mm~	2000		~~~	001		~~~	2002	
											ACT TGA									
_		_																		Ile>
	_	141		<u>u</u> cu	цуs	ay s	riic	110	Deu	nap	1111	neu	110	110	- GC	OLY	y.5	-mg	***	110
			2	50		:	260			270			28	30		:	290			300
		*		*	*		*		*	*		*		*	*		*		*	*
T	G	GAC	AGT	AGA	AAG	GGC	TTC	ATC	ATA	TCA	AAT	GCA	ACG	TAC	AAA	GAA	ATA	GGG	CTT	CTG
											TTA									
Ti	q.	Asp	Ser	Arg	Lys	Gly	Phe	Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys	Glu	Ile	Gly	Leu	Leu>
			٦.										_				250			260
		*	۵.	10 *	*	•	320		*	330		*	34	40 ★	*	,	350 *		*	360 *
AC	÷	ጥርም	GAA			CTC		ccc			TAT		ልሮል		ጥልጥ	כיזיכי		ርልጥ	CGA	
											ATA									
																				Gln>
		•						-			-	-			-				_	
			3'	70			380			390			4	00			410			420
		*		*	*		*		*	*		*		*	*		*		*	*
AC	C	AAT									ACA								AGA	GGC
_																				CCG
11	ш	ASN	inr	iie	TTE	Asp	Val	Gin	TTE	ser	inr	Pro	Arg	Pro	Val	гÀг	Leu	Leu	Arg	Gly>
			4	30			440			450			4	60			470			480
		*	<b>TE</b> .	*	*		*		*	*		*	•	*	*		*		*	*
CZ	Υ	ACT	CTT	GTC	CTC	ААТ	TGT	ACT	GCT	ACC	ACT	CCC	TTG	AAC	ACG	AGA	GTT	CAA	ATG	ACC
																				TGG
H:	İs	Thr	Leu	Val	Leu	Asn	Cys	Thr	Ala	Thr	Thr	Pro	Leu	Asn	Thr	Arg	Val	Gln	Met	Thr>
			4	90			500			510		-	5	20			530			540
m	~	*	m*~	* . ~~~	*	~**	*	* * *	*	*		*	~~~	*	*	~~-	*	. ~	* . ~~-	*
																				AGC
																				TCG Ser>
	٠,	-UL	- YL		, rap									wra		- ALG	, ,,,,	, nap		- OCT >
						51	ו כםי	וטוו	E S	HEE	Γ (RL	ILE 2	26)							

#### 23/55

### Fig.15B.

	*	55	50 *	*	5	60 *		*	570		*	58	30 *	*	5	590 *		*	600
AAT	TCC	CAT	GCC	AAC	ATA	TTC	TAC			CTT	ACT	ATT		AAA	ATG		AAC		
														TTT					
Asn	Ser	His	Ala	Asn	Ile	Phe	Tyr	Ser	Val	Leu	Thr	Ile	Asp	Lys	Met	Gln	Asn	Lys	Asp>
		61	LO			20			630			64	10			550			660
	*	0.	*	*	•	*		*	*		*	04	*	*	`	*		*	*
AAA	GGA	CTT	TAT	ACT	TGT	CGT	GTA	AGG	AGT	GGA	CCA	TCA	TTC	AAA	TCT	GTT	AAC	ACC	TCA
														TTT					
Lys	Gly	Leu	Tyr	Thr	Cys	Arg	Val	Arg	Ser	Gly	Pro	Ser	Phe	Lys	Ser	Val	Asn	Thr	Ser>
		6'	70		,	80			690			76	00		•	710			720
	*	•	*	*	Ì	*		*	*		*		*	*		*		*	*
GTG	CAT	ATA	TAT	GAT	AAA	GCA	GGC	CCG	GGC	GAG	ccc	AAA	TCT	TGT	GAC	AAA	ACT	CAC	ACA
														ACA				_	_
Val	His	Ile	Tyr	Asp	Lys	Ala	Gly	Pro	Gly	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr>
		7:	30		•	740			750			70	50		,	770			780
	*		*	*		*		*	*		*		*	*		*		*	*
														GTC					
														CAG					
Cys	Pro	Pro	Cys	Pro	ALA	Pro	GIU	Leu	Leu	GIÀ	GIY	Pro	ser	vaı	Pne	rea	Pne	Pro	Pro>
		7	90		1	300			810			8:	20			830			840
	*		*	*		*		*	*		*		*	*		*		*	*
														ACA					
														TGT					Asp>
y3	FIO	шys	η	1111	Leu	Mec	116	SEL	nr.g	2111	FIG	GIU	VOL	****	Cys	141	741	•••	·mp·
		8	50		1	860			870			8	80			890			900
	*		*	*		*		*	*		*		*	*		*		*	*
														GAC					
								. –	_	-				CTG		_	_	_	His>
vaa	561	****	GLU	nap	210	GIU	VAL	БyЗ	2116	11311	***	-3-	142	ıwp	CLJ	742			1120-
		9	10			920			930			9	40			950			960
	*		*	*		*		*	*		*		*	*		*		*	*
														TAC					CAG
																			Val>
		-		-		_				•				_					
		9	70			980			990			10	00		1	.010		4	1020
CAC	300	Carc	~uv:	*	CNC	*	ance:	× Carc	* ************************************	CCC	, yyc.	CAC	* : ጥልቦ	ממי	ביוער	* * 330	carc	, 44.7.	. AAC
																			TTG
																			: Asn>
			20		_														
	*	10	30 *	*	1	040		*	1050	) :	*	10	160 *			L070 *		*	1080
AAA	GCC	CTC	CCA	GCC	ccc	ATC	GAG	AAA	ACC	: ATC	: TCC	: AAA	GCC	. AAZ	GGC	G CAC	3 CC	: CG2	A GAA
																			CTT
Lys	Ala	Leu	Pro	Ala				_					: Ala	Lys	Gly	/ Glr	Pro	Arg	Glu>
					SI	JBST	TITU'	TE S	HEE	T (R	ULE	26)							

PCT/US00/14142

24/55

### Fig.15C.

1090 1100 1130 1140 1110 1120 CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG GGT GTC CAC ATG TGG GAC GGG GGT AGG GCC CTA CTC GAC TGG TTC TTG GTC CAG TCG GAC Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu> 1160 1170 1180 ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG TGG ACG GAC CAG TTT CCG AAG ATA GGG TCG CTG TAG CGG CAC CTC ACC CTC TCG TTA CCC Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly> 1210 1250 1260 1220 1230 1240 CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC GGC TCC TTC TTC GTC GGC CTC TTG TTG ATG TTC TGG TGC GGA GGG CAC GAC CTG AGG CTG CCG AGG AAG AAG Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe> 1320 1270 1280 1290 1300 1310 CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC TCA TGC GAG ATG TCG TTC GAG TGG CAC CTG TTC TCG TCC ACC GTC CCC TTG CAG AAG AGT ACG Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys> 1380 1330 1360 1370 TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG AGG CAC TAC GTA CTC CGA GAC GTG TTG GTG ATG TGC GTC TTC TCG GAG AGG GAC AGA GGC Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro>

GGT AAA TGA CCA TTT ACT Gly Lys ***>

PCT/US00/14142

### 25/55

# Fig.16A.

		1	10			20			30			4	10			50			60
	*		*	*		*		*	*		*		*	*		*		*	*
											TGC ACG								
											Cys								
			_	_	_		_				_								
		7	70			80			90			10			1	10			120
מימ	(CC)	m~m	*	* ∧י∨ח	CCM	* ~~~	***	₩.	*	Cam	* CCT	CAA	*	* ውጥ	ans y	* **	ccc	* acc	* C)C
											GGA								
											Pro								
									-										
		13	30 ·		1	.40 *			150		*	16	50 *	*	1	L70 ★		*	180
ርኔሮ	אחירי	ATV3		GC.V	ccc		a~a	* CTC		حىر	CAA	ጥርር			GAA		GCC		_
											GTT								
																			Lys>
																			- 40
	*	13	90	*	7	200			210		*	22	20 *	*	•	230		*	240 *
TGG		TTG	CCT	GAA	ATG		AGT			AGC	GAA	AGG	CTG	AGC	ATA	ACT	AAA	TCT	GCC
											CTT								
Trp	Ser	Leu	Pro	Glu	Met	Val	Ser	Lys	Glu	Ser	Glu	Arg	Leu	Ser	Ile	Thr	Lys	Ser	Ala>
		21	50						270			20	90			290			300
	*	4:	50 *	*	•	260 *		*	270		*	20	80 *	*	•	*		*	*
TGT	GGA	AGA	AAT	GGC	AAA	CAA	TTC	TGC	AGT	ACT	TTA	ACC	TTG	AAC	ACA	GCT	CAA	GCA	AAC
											AAT								
Cys	Gly	Arg	Asn	Gly	Lys	Gln	Phe	Cys	Ser	Thr	Leu	Thr	Leu	Asn	Thr	Ala	Gln	Ala	Asn>
		3	10			320			330			34	40			350			360
	*	-	*	*	•	*		*	*		*		*	*	•	*		*	*
											GTA								
											CAT								
His	Thr	Gly	Phe	Tyr	Ser	Cys	Lys	Tyr	Leu	Ala	Val	Pro	Thr	Ser	Lys	rys	Lys	GIU	Thr>
		3	70			380			390			4	00			410			420
	*		*	*		*		*	*		*		*	*		*		*	*
			ATC								GGT								
																			TCA Ser>
Gra	Ser	VIO	116	TAT	116	File	116	Ser	qan	1111	GLY	ντä	110	1110	V4.1	0.0	1100	-1-	002
		4	30			440			450			4	60			470			480
	*		*	*		*		*	*		*		*	*		•*		*	*
											AGG								CAA
																			Val>
	_									-	-						-	_	
		4	90	-		500			510			5	20			530			540
ארכ	* ፈረጉ	CCm	* አአሶ	* ንጥል	ልረግጥ	ريس. *	<b>a</b> cm	* መግ	* 444		* TTT	רירים.	ئەلىك *	* CAC		. ብህሊ *	: ልባሃገ	* '	* ייעב
																			CTA
																			Asp>

**SUBSTITUTE SHEET (RULE 26)** 

# Fig.16B.

		55	50		5	60			570			58	30		5	590			600
	*		*	*		*		*	*		*		*	*		*		*	*
													ATA TAT						
													Ile						
_	_				_	-		_	-	-								_	_
		61			€	520			630			64			6	550			660
C2 2	* * * * * * * * * * * * * * * * * * *	000	*	~~~	200	*	<b>~</b> 333	*	*	~	*	000	* ~~m	* ~mm~	mam.	*	B (* B	*	mam *
													CAT GTA						
_													His						
						_						_			_	-			_
		67	70		6	80			690			70	00	-	7	710		_	720
CTC	* 202	ሮኔጥ	*	<b>~</b>	NCC.	*	እሮአ	* ****	* «m«	CNT	~ ~	C22	* ATA	» »	ልሮል	* ~~	CCC	~ *	
													TAT						
																			Val>
	_	73	30 *	4	7	740			750		_	76	50	4	•	770		_	780 *
ממג	עידייני "	لبليات		GCC.	_ር አጥ	yCu.	للملك	ж *		አልጥ	ጥርም	ልርጥ	GCT	200	س⊃ھ	ссс. _	באנינה	* *	
													CGA						
																			Thr>
												_							
	*	79	90 *		8	300 *		*	810		*	8:	20 *			B30 *			840
AGA		CAA		ACC	<b>TGG</b>		ጥልሮ			GAA		ААТ	AAG	AAC	GCT		GTA	AGG	
													TTC						
																			Arg>
		_										_							
	*	8:	50 *	*	1	860		*	870		*	8	80 ★	*	,	890 *		*	900 *
CGA	ATT	GAC		AGC	AAT		CAT	GCC		ATA		TAC	AGT	GTT	CTT		ATT	GAC	
GCT	TAA	CTG	GTT	TCG	TTA	AGG	GTA	CGG	TTG	TAT	AAG	ATG	TCA	CAA	GAA	TGA	TAA	CIG	TTT
Arg	Ile	Asp	Gln	Ser	Asn	Ser	His	Ala	Asn	Ile	Phe	Tyr	Ser	Val	Leu	Thr	Ile	Asp	Lys>
		^	10			222			020			٥	40			950			960
	*	9	10 *	*	-	920 *		*	930		*	<b>9</b>	40 *	*		*		*	*
ATG	CAG	AAC	AAA	GAC	AAA	GGA	CTT	TAT	ACT	TGT	CGT	GTA	AGG	AGT	GGA	CCA	TCA	TTC	AAA
													TCC						
Met	Gln	Asn	Lys	Asp	Lys	Gly	Leu	Tyr	Thr	Cys	Arg	Val	Arg	Ser	Gly	Pro	Ser	Phe	Lys>
		9	70			980			990			10	00		1	010			1020
	*	_	*	*		*		*	*		*		*	*	_	*		*	*
													CCG						
													GGC						
ser	val	ASN	ınr	ser	val	H1S	пте	ŢŢŢ	Asp	Lys	ATA	GIY	Pro	GTĀ	GIU	Pro	Lys	ser	Cys>
		10	30		1	040			1050			10	60		1	.070			1080
	*		*	*		*		*	*		*		*	*		*		*	*
													CTC						
													GAG			_			
usb	nys	LILL	пıs	1111	cys	PLO	FLO	cys	PEC	wrg	FLO	GIU	Lueu	Let	. GL	GIY	PIC	s ser	Val>

SUBSTITUTE SHEET (RULE 26)

PCT/US00/14142

### 27/55

# Fig.16C.

		9	<del>-</del> -		
1090	1100	1110	1120	1130	1140
TTC CTC TTC CCC CCA	AAA CCC AAG		ATG ATC TCC CGG	ACC CCT GAG	STC ACA
AAG GAG AAG GGG GGT					
Phe Leu Phe Pro Pro	Lys Pro Lys	Asp Thr Leu	Met Ile Ser Arg	Thr Pro Glu V	/al Thr>
1150	1160	1170	1180	1190	1200
* * *	* *	* *	* * *		* *
TGC GTG GTG GTG GAC					
ACG CAC CAC CTG					
Cys Val Val Val Asp	Val Ser His	Glu Asp Pro	GIU Val Lys Phe	Asn Trp Tyr \	Val Asp>
1210	1220	1230	1240	1250	1260
* * *		* *	* * *		* *
GGC GTG GAG GTG CAT CCG CAC CTC CAC GTA					
Gly Val Glu Val His					
Giy vai Giu vai nis	ASII AIG LYS	THE HYS FLO	Ang Gru Gru Gru	Tyl Abn bel .	in iyir
1270	1280	1290 * *	1300	1310	1320 * *
OGT GTG GTC AGC GTC	CTC ACC GTC	CTG CAC CAG	GAC TGG CTG AAT	GGC AAG GAG '	TAC AAG
GCA CAC CAG TCG CAG					
Arg Val Val Ser Val					
1330	1340	1350	1360	1370	1380
* * *	*	* *	* * *		* *
TGC AAG GTC TCC AAC	AAA GCC CTC	CCA GCC CCC	ATC GAG AAA ACC	ATC TCC AAA	GCC AAA
ACG TTC CAG AGG TTG	TTT CGG GAG	GGT CGG GGG	TAG CTC TTT TGG	TAG AGG TTT	CGG TTT
Cys Lys Val Ser Asn	Lys Ala Leu	Pro Ala Pro	Ile Glu Lys Thr	Ile Ser Lys	Ala Lys>
1390	1400	1410	1420	1430	1440
* * *	r <b>*</b>	* *	* * *	*	* *
GGG CAG CCC CGA GAA					
CCC GTC GGG GCT CTT					
Gly Gln Pro Arg Glu	Pro Gln Val	Tyr Thr Leu	Pro Pro Ser Arg	Asp Glu Leu	Thr Lys>
1450	1460	1470	1480	1490	1500
* * 1	* *	* *	* * *	•	* *
AAC CAG GTC AGC CTC					
TIG GTC CAG TCG GAG Asn Gln Val Ser Lev					
ASH GIH VAI SEL LEG	THE CYS Let	var bys Gry	rue lyl rio sei	ASP IIE AIG	var diu
1510	1520	1530	1540	1550	1560
* * * 1	* *	* *	* * * *		* *
TGG GAG AGC AAT GGC					
ACC CTC TCG TTA CCC Trp Glu Ser Asn Gly					
1570 * *	1580 * *	1590 * *	1600	1610	1620
GAC GGC TCC TTC TT			י כידוכ כאר אאה ארי	TAGG TIGG CAG	CAG GGG
CTG CCG AGG AAG AAG					
Asp Gly Ser Phe Phe					

WO 00/75319

PCT/US00/14142


#### 28/55


## Fig.16D.


1690 1700

CTC TCC CTG TCT CCG GGT AAA TGA GAG AGG GAC AGA GGC CCA TTT ACT Leu Ser Leu Ser Pro Gly Lys ***>

Fig.17.










	Fig	j.21A	•		>EcoR	I_site		
	10	20	30	40	50	60	70	80
						- GAATTCGCAAC		
TTCG	iAACCCGACG1	rccagctagc	TGAGATCTCC	PAGCTAGGGG	CCGCTCGAG	CTTAAGCGTTG	GTGGTACCA M V	
							1	7 S Y>
								>
						>BspEI_brid	dge	
	90	100	110	120	130	140	150	160
_						ATCTAGTTCCG		
ACCC W			GCGCGACGAG A L L	- · · · ·		PAGATCAAGGC	CTCCATCTG	GAAAGCA
			FLT1 SS_			>		
						S	G>	
							> GR	P F V>
							<b>G</b>	31
								>
	170	180	190	200	210	220	230	240
AGAG						CGTCATTCCC		
						AGCAGTAAGGG		
E	MYS	EIPI	EIIH	MTE	GREI	LVIP	C R V	T S> 57
				_HFLT1 D2_				>
	050							
	250	0.00	220	202	200	200	210	320
СТАА	CATCACTGTT	260 'ACTTTAAAA	270 AAGTTTCCACT	280 TGACACTTTC		300 Gaaaacgcati	310	320 CAGTAGA
		ACTITAAAA	AAGTTTCCACT	TGACACTTTC	ATCCCTGAT	300 KGAAAACGCATY CCTTTTGCGTA	AATCTGGGA	CAGTAGA
	GTAGTGACAA	ACTITAAAA	AAGTTTCCACT TTCAAAGGTGA	TGACACTTTC	ATCCCTGAT	GAAAACGCAT	AATCTGGGA PTAGACCCT	CAGTAGA CTCATCT ) S R>
GATT	GTAGTGACAA	ACTTTAAAA TGAAA <b>TTT</b> T	AAGTTTCCACT TTCAAAGGTGA	TGACACTTTO ACTGTGAAAC	ATCCCTGATO TAGGGACTAO	GAAAACGCATI CTTTTGCGTA	AATCTGGGA PTAGACCCT	CAGTAGA CTCATCT
GATT	GTAGTGACAA	ACTTTAAAA TGAAA <b>TTT</b> T	AAGTTTCCACT	TGACACTTTO ACTGTGAAAC DT L _HFLT1 D2_	ATCCCTGATC TAGGGACTAC I P D	GGAAAACGCAT; CCTTTTGCGTA; G K R I	AATCTGGGA PTAGACCCT I W I	CAGTAGA CGTCATCT S R> 84
GATT P N	GTAGTGACAA I T V 330	CACTITAAAAA ATGAAATITI T L K	AAGTTTCCACT TTCAAAGGTGA K F P I	TGACACTTTC ACTGTGAAAC D T L _HFLT1 D2_ 360	ATCCCTGATC TAGGGACTAC I P D	GAAAACGCATY CTTTTGCGTA' G K R I	AATCTGGGA PTAGACCCT I W I	CAGTAGA CAGTAGT CATCATCT CATCATCT CATCATCT CATCATCT CATCATCATCT CATCATCATCATCATCATCATCATCATCATCATCATCATC
GATTO P N	GTAGTGACAA I T V 330 GCTTCATCAT	TACTTTAAAA TGAAATTTT T L K 340 TATCAAATGC	AAGTTTCCACT TTCAAAGGTGZ K F P I 350 AACGTACAAA	TGACACTTTC ACTGTGAAAC DT L _HFLT1 D2_ 360 BAAATAGGGCT	ATCCCTGATC TAGGGACTAC I P D  370 TCTGACCTG	GGAAAACGCATA CCTTTTGCGTA G K R I 380 IGAAGCAACAG	AATCTGGGA TTAGACCCT I W I 390 TCAATGGG	CAGTAGA CAGTAGA CAGTCATCT CAGTCATCT ACCORDANCE ACCORDAN
GATTO P N AAGG	GTAGTGACAA I T V 330 GCTTCATCAT CGAAGTAGTA	TACTTTAAAAAT T L K  340 TACAAATGCI TAGTTTACGTTACGTTACGTTTACGTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACGTTACACGTTACGTTACGTTACGTTACGTTACGTTACGTTACACGTTACACGTTACACGTTACACACAC	AAGTTTCCACT PTCAAAGGTGA K F P I  350 AACGTACAAAC	TGACACTTTO ACTGTGAAAC DT L _HFLT1 D2_ 360 AAATAGGGCTTTTATCCCGA	ATCCCTGATC TAGGGACTAC I P D  370 TCTGACCTGA	GAAAACGCATY CTTTTGCGTA' G K R I	AATCTGGGA PTAGACCCT I W I  390 PCAATGGGC	CAGTAGA CAGTAGTA TA CAGTAGTA C
GATTO P N AAGG	GTAGTGACAA I T V 330 GCTTCATCAT CGAAGTAGTA	TACTTTAAAAAATTTTTTTTTTTTTLKK  340 TATCAAATGCI TAGTTTACGI	AAGTTTCCACT	TGACACTTTC ACTGTGAAAC DT L HFLT1 D2  360 SAAATAGGGCT TTTATCCCGA	ATCCCTGATC TAGGGACTAC I P D  370 TCTGACCTG AGACTGGACI	GAAAACGCATA CCTTTTGCGTA G K R I 380 GAAGCAACAG ACTTCGTTGTC E A T	AATCTGGGA ITAGACCCT I W I  390 ICAATGGGC AGTTACCCG	CAGTAGA CAGTAGA CATCT S R> 84 400 CATTIGTA FTAAACAT H L Y> 11:
GATTO P N AAGG	GTAGTGACAA I T V 330 GCTTCATCAT CGAAGTAGTA	TACTTTAAAAAATTTTTTTTTTTTTLKK  340 TATCAAATGCI TAGTTTACGI	AAGTTTCCACT	TGACACTTTC ACTGTGAAAC DT L HFLT1 D2  360 SAAATAGGGCT TTTATCCCGA	ATCCCTGATC TAGGGACTAC I P D  370 TCTGACCTG AGACTGGACI	GAAAACGCATA CTTTTGCGTA G K R I 380 GAAGCAACAG	AATCTGGGA ITAGACCCT I W I  390 ICAATGGGC AGTTACCCG	CAGTAGA CAGTAGA CATCT S R> 84 400 CATTIGTA FTAAACAT H L Y> 11:
GATTO P N AAGG	GTAGTGACAA I T V 330 GCTTCATCAT CGAAGTAGTA	TACTTTAAAAATTTTTTTTTTTTTTTTTTTTTTTTTTT	AAGTTTCCACT	TGACACTTTC ACTGTGAAAC D T L _HFLT1 D2_ 360 BAAATAGGGCT TTTATCCCGA E I G L _HFLT1 D2_	ATCCCTGATC TAGGGACTAC I P D  370 TCTGACCTG AGACTGGAC	GAAAACGCATA CCTTTTGCGTA G K R I 380 GAAGCAACAG ACTTCGTTGTC E A T	AATCTGGGA ITAGACCCT I W I  390 ICAATGGGC AGTTACCCG	CAGTAGA CAGTAGA CATCT S R> 84 400 CATTIGTA FTAAACAT H L Y> 11:
AAGG TTCC K TAAG	GTAGTGACAA I T V  330 GCTTCATCAT CGAAGTAGTA G F I I  410 ACAAACTATC	T L K  340 PATCAAATGC: ATGATTACG: S N A  420 PATCACACATCC	AAGTTTCCACT PTCAAAGGTGA K F P I  350 AACGTACAAAC PTGCATGTTTC T Y K  430 GACAAACCAAT	TGACACTTTC ACTGTGAAAC DT L _HFLT1 D2_ 360 BAAATAGGGCT TTTATCCCGA E I G I _HFLT1 D2_ 440 PACAATCATAG	ATCCCTGATC TAGGGACTAC I P D  370 TCTGACCTGA AGACTGGACA AGACTGCACA AGACTCACA AGACTGCACA AGACTGCACA AGACTGCACA AGACTGCACA AGACTGCACA AGACTCACA AGACTGCACA AGACTGCACA AGACTCACACA AGACTCACACA AGACTCACACACA AGACTCCACACA AGACTCACACACA AGACTCACACACACA AGACTCACACACACACACAC	GGAAAACGCATA CCTTTTGCGTA G K R I 380 GGAAGCAACAG ACTTCGTTGTC E A T 1	AATCTGGGA ITAGACCCT I W I  390 ICAATGGGC AGTTACCCG V N G  470 CATGGAATT	CAGTAGA CAGTAGA CAGTAGA CAGTAGA  84  400 CATTTGTA FTAAACAT H L Y> 111  480 CGAACTAT
AAGG TTCC K TAAG	GTAGTGACAA I T V  330 GCTTCATCAT CGAAGTAGTA G F I I  410 ACAAACTATC	TACTTTAAAA TGAAATTTT T L K  340 PATCAAATGCI TAGTTTACG' S N A  420 PATCACACATCC	AAGTTTCCACT PTCAAAGGTGA K F P I  350 AACGTACAAAC PTGCATGTTTC T Y K  430 GACAAACCAAT	TGACACTTTC ACTGTGAAAC D T L _HFLT1 D2_ 360 BAAATAGGGCT TTTATCCCGA E I G I _HFLT1 D2_ 440 PACAATCATAG	ATCCCTGATC TAGGGACTAC I P D  370 TCTGACCTGAC AGACTGGAC L T C  450 ATGTGGTTC TACACCAAG	GGAAAACGCATA CCTTTTGCGTA G K R I 380 GGAAGCAACAG ACTTCGTTGTCA E A T 1	AATCTGGGA ITAGACCCT I W I  390 ICAATGGGC AGTTACCCG V N G  470 CATGGAATT	CAGTAGA CAGTAGA CAGTAGA CAGTAGA  84  400 CATTTGTA FTAAACAT H L Y> 111  480 CGAACTAT
AAGG TTCC K TAAG	GTAGTGACAA  I T V  330  GCTTCATCAT  CGAAGTAGTA  G F I I  410  ACAAACTATC  TGTTTGATAG  T N Y	TACTTTAAAA TGAAATTTT T L K  340 PATCAAATGCI TAGTTTACG' S N A  420 PTCACACATCC PAGTGTGTAGC	AAGTTTCCACT PTCAAAGGTGA K F P I  350 AACGTACAAAC PTGCATGTTTC T Y K  430 GACAAACCAAT	TGACACTTTC ACTGTGAAAC D T L _HFLT1 D2_ 360 SAAATAGGGCT TTTATCCCGA E I G I _HFLT1 D2_ 440 FACAATCATAG T I I	ATCCCTGATC TAGGGACTAC I P D  370 TCTGACCTGAC AGACTGGACI AGACTGGACI TCTGACCCAAG	GGAAAACGCATA CCTTTTGCGTA G K R I 380 GGAAGCAACAG ACTTCGTTGTC E A T 1	AATCTGGGA ITAGACCCT I W I  390 ICAATGGGC AGTTACCCG V N G  470 CATGGAATT	CAGTAGA CAGTAGA CAGTAGA CAGTAGA  84  400 CATTTGTA FTAAACAT H L Y> 111  480 CGAACTAT
AAGG TTCC K TAAG	GTAGTGACAA  I T V  330  GCTTCATCAT  CGAAGTAGTA  G F I I  410  ACAAACTATC  TGTTTGATAG  T N Y	TACTTTAAAA TGAAATTTT T L K  340 PATCAAATGCI TAGTTTACG' S N A  420 PTCACACATCC PAGTGTGTAGC	AAGTTTCCACT PTCAAAGGTGA K F P I  350 AACGTACAAAC PTGCATGTTTC T Y K  430 GACAAACCAAT CTGTTTGGTTA	TGACACTTTC ACTGTGAAAC D T L _HFLT1 D2_ 360 SAAATAGGGCT TTTATCCCGA E I G I _HFLT1 D2_ 440 FACAATCATAG T I I	ATCCCTGATC TAGGGACTAC I P D  370 TCTGACCTGAC AGACTGGACI AGACTGGACI TCTGACCCAAG D>	GGAAAACGCATA CCTTTTGCGTA G K R I 380 GGAAGCAACAG ACTTCGTTGTC E A T 1	AATCTGGGA PTAGACCCT I W I  390 PCAATGGGC AGTTACCCG W N G  470 PATGGAATT GTACCTTAA	CAGTAGA CAGTAGA CATCT O S R> 84  400 CATTIGTA FTAAACAT H L Y> 11: 480 CGAACTAT CCTTGATA E L>
AAGG TTCC K TAAG	GTAGTGACAA  I T V  330  GCTTCATCAT  CGAAGTAGTA  G F I I  410  ACAAACTATC  TGTTTGATAG  T N Y	TACTTTAAAA TGAAATTTT T L K  340 PATCAAATGCI TAGTTTACG' S N A  420 PTCACACATCC PAGTGTGTAGC	AAGTTTCCACT PTCAAAGGTGA K F P I  350 AACGTACAAAC PTGCATGTTTC T Y K  430 GACAAACCAAT CTGTTTGGTTA	TGACACTTTC ACTGTGAAAC D T L _HFLT1 D2_ 360 SAAATAGGGCT TTTATCCCGA E I G I _HFLT1 D2_ 440 FACAATCATAG T I I	ATCCCTGATO TAGGGACTAC I P D  370 TCTGACCTGA AGACTGGACI AGACTGGACI AGACTGGACI AGACTGGACI AGACTGGACI AGACTGGACI AGACTGGACI AGACTGACI AGACT	GGAAAACGCATA CCTTTTGCGTA G K R I 380 IGAAGCAACAG ACTTCGTTGTC E A T ' 460 IGAGTCCGTCTA	AATCTGGGA PTAGACCCT I W I  390 PCAATGGGC AGTTACCCG W N G  470 PATGGAATT PATG	CAGTAGA CAGTAGA CATCT O S R> 84  400 CATTIGTA FTAAACAT H L Y> 11: 480 CGAACTAT CCTTGATA E L> 137

HIR LINGS CAR TOWN

Fig.21B.





Fig.21C. 1100 1080 1090 1070 1060 1050 CTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAA  ${\tt GACTTACCGTTCCTCATGTTCACGTTCCAGAGGTTGTTTCGGGAGGGTCGGGGGTAGCTCTTTTGGTAGAGGTTTCGGTT}$ LNGKEYKCKVSNKALPAPIEKTISKAK> FC\(\Delta\) (A) >A>C_A_allotype >G>T_A_allotype 1180 1190 1170 1150 1160 1130 1140 G Q P R E P Q V Y T L P P S R D E L T K N Q V S L T> FCΔC1 (A)___ 1260 1250 1230 1240 1210 1220 GCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC C L V K G F Y P S D I A V E W E S N G Q P E N N Y K T> FCAC1(A)_ >T>C 1330 1320 1310 1290 1300 TPPVLDSDGSFFLYSKLTVDKSRWQQG> __FCΔC1 (A) ___ 1420 1410 1400 1380 1390 GAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTA NVFSCSVMHEALHNHYTQKSLSPG> 457 _FCΔC1 (A) __ >NotI_site 1450 **AATGAGCGGCCGC** TTACTCGCCGGCG K *> 458

Fig	g.22A			>EcoR]	_site		
10	20	30	40	50	60	70	80
AAGCTTGGGCTGCA(							
TTCGAACCCGACGTC	CAGCTAGCT	GAGATCTCCT	AGCTAGGGGC	CCGCTCGAGC	TTAAGCGTTG		CGATG S Y>
						1	4
							>
					>BspEI_bri	dge	
90	100	110	120	130	140	150	160
TGGGACACCGGGGT							
ACCCTGTGGCCCCAC						CTCCATCTGGA	AAGCA
WDTGV		ALL		LTG	S S> >		
	FLT1	SIGNAL SEC	OFIACE			G>	
						>	
						G R P	F V>
							31
							>
170	100	190	200	210	220	230	240
170 AGAGATGTACAGTG	180						
TCTCTACATGTCAC							
	EIPE			GREI		C R V T	
							57
		FL	ri ig domai	IN 2			>
250	260	270	280	290	300	310	320
CTAACATCACTGTT						AATCTGGGACA	GTAGA
GATTGTAGTGACAA'							
P N I T V	T L K	KFPI	DTL	I P D	G K R I	IWD	S R>
						•	84
		FL/	ri ig Domai	IN 2			
330	340	350	360	370	380	390	400
AAGGGCTTCATCAT				-	IGAAGCAACAG	TCAATGGGCAT	TTGTA
TTCCCGAAGTAGTA	TAGTTTACGT	TGCATGTTTY	CTTTATCCCG/	AAGACTGGAC	ACTTCGTTGTC	AGTTACCCGTA	AACAT
K G F I I	S N A	T Y K	EIGI	LLTC	E A T	V M G H	L Y>
					÷		11
		FL	ri ig doma:	IN 2			>
410	420	420	440	450	460	470	480
410 TAAGACAAACTATC	420 TCACACATCO	טכ <del>ני</del> מראמממחמי	ህድድ አፈጥልንምልልግልባ	ODACCOPATAT	TGTTGCCCAG	AAGTCGCTGGA	GCTGC
ATTCTGTTTGATAG	AGTGTGTAGC	TGTTTGGTT	ATGTTAGTAT	CTATAGGTCG	ACAACGGGTC	CTTCAGCGACCT	CGACG
KTNY							
				>			
				I Q	LLPR	K S L E	E L> 137
				T/FC	१४ए.ए४) १९५५	IG DOMAIN 3	


# Fig.22B.

	490			500			51	LO		5	20			530	0		54	.0		:	550			560
GGTAG																								
CCATC				CAG V						CACC W														
	J E	v	ב	٧	ъ	14	C		•	**	A		•	**	٦	Ŭ	•	•	•	_	••	_	•	16
							VE	GFR	3	(FLI	4)	IG	DO	MAII	<b>1</b> 3					_				
	570			580			59	90		6	00			610	0		62	0		(	630			640
GGAAG																								
CCTTC																								
G K	Q Z	A E	E	₹ G	·	K	W	<i>j</i>	? ]	E R	l I	₹ :	S	Q (	2	T ł	1 1	· •	L		5 :	. i	Li	 [
							VI	EGFR	83	(FLI	4)	IG	DO	MAII	<b>N</b> 3									
	CE 0			660			6-	70		6	:00			601	n		70	ın			710			720
ATCCA	650 ממר	בייונים	יכרנ			GAC																		
PAGGTY																								
I H	N	V	s	Q	Н	D	L	G	s	Y	V	С	K	A	N	N	G	I	Q	R	F	R	E	
									_															21
							VI	egff	3	(FLI	4)	IG	DO	MALI	N J									
	730			740	)		79	50		7	60			77	0		78	30			790			80
CGAGG'			CA'												CCC	ACC	TGC	CCZ	AGCA	CC'	TGA	ACTY	CCTY	3GG
									D	K	T	H	T	С	P	P	С	P	A	P	E	L	L	G: 24
														FCΔ	C1	- A	ALI	LOT	YPE_					
	810			820	,		83	30		٤	340			85	0		86	50			870			880
GACCG																								
CTGGC																							CGC	
G P	S	V I	7 ]	L F	'	P	P 1	KI	2	K I	, (	T	L	M	T	S I	R :	ו ז	? E	5	V	1 '	•	•
							_	FC	CΔC	1 -	A	ALL	ОТУ	PE_										
	890			900				10		-	920			93	-		_	10			950			96
GTGGA																								
CACCT			FTG( H							aag: F														
V D	V	5	п	£	ט	P	E,	V		F	14	٧v	_	٧	ט	•	٠	_	٠	••				29
								F	CAC	1 -	Α	ALI	OTY	PE_										
																				_				
	970			980	-			90			000			101			10:		~~~	_	1030			104
22222																								
CGGCG										ACA V						V ?						V L		
-		_	×	-		_	•	_		-	•	-	•			•			-					3
								FY	CAC	1 -	А	AT.T	ATO.	/PE										

### Fig.22C.



TOOL DEG AN GOOD TOWN



- Flt1D2Flk1D3.FcdeltaC1(a)
- △Flt1D2VEGFR3D3.FcdeltaC1(a)
- **▽ TIE2-Fc**
- Flt1(1-3)-Fc

Fig.24A.

			1 1	y.4	_+	八.													
		1	.0			20			30				* 10			50 *			60 *
באמע	כוזיי	AGC	* ጥልቦ	ukaz	GAC	* 200	æ	CITY	*	CIIG	TGC			CTC			CTG	CTT	
TAC	CAG	TCG	ATG	ACC	CIG	TGG	$\alpha$	CAG	GAC	GAC	ACG	CGC	GAC	GAG	TCG	ACA	GAC	GAA	GAG
M	V	s	Y	W	D	$\mathbf{T}$	G	V	L	L	С	A	L	L	S	C	L	L	L>
_1				5			hFL/I	ri si	GNAI	SEX	QUENC	E		15_					_20>
		_							-00			10	00		-	L10			120
		1	70 *			80 *			90			10	*		-	*			*
ACA	GGA	TCT	AGT	TCC	GGA	AGT	GAT	ACC	GGT	AGA	CCT	TTC	GTA	GAG	ATG	TAC	AGT	GAA	ATC
TGT	CCT	AGA	TCA	AGG	CCT	TCA	CTA	TGG	CCA	TCT	GGA	AAG	CAT	CTC	TAC	ATG	TCA	CTT	TAG
${f T}$		S	s		G>														
21_l	FLT1	LSIG	NAL	SEQ	_26>		_	_	_	_	_	_		_		17	_		<b>T</b> .
						S					P m1 3				M		5	E	I> 40>
						_2/_			_30		411 1	IG D	ודאויע	v <u>z</u> _					
		13	30		1	L <b>4</b> 0			150			10	50		:	170			180
			*			*			*				*			*			*
CCC	GAA	ATT	ATA	CAC	ATG	ACT	GAA	GGA.	AGG	GAG	CTC	GIC	ATT	ccc	TGC	CGG	GTT	ACG	TCA
		TAA								CIC	GAG	CAG	TAA	GGG	ACG C	GCC	CAA	TGC	AGT C>
	E			H	M	T	E	G ਪਦਾਗਾ	R	DOM:	L TNT 2	, v	Τ.	55		K	V	•	60>
41_		<u></u>		_45				т. т.т.	1 10	1000	2224			00.					
		19	90		2	200			210			2:	20			230			240
			*			*			*							*			*
CCT	AAC	ATC	ACT	GTT	ACT	TTA	AAA	AAG	TTT	CCA	CTT	GAC	ACT	TIG	ATC	CCT	GAT	GGA	AAA
GGA	TIG	TAG I	TGA	CAA	TGA	AAT	TTT	TIC	AAA	GGT	GAA.	CIG	'IGA	AAC T.	TAG	GGA P	D	G	K>
P 61	N	T	T	V 65	T	יד	hi hi	A. PT/P1	TG 1	OMA:	TN 2	ט	•	75	-	•			80>
01_				05_							_,								
		2	50		:	260			270			2				290			300
			*			*			*				*			*		~~~	* 3/03
CGC	ATA	ATC	TGG	GAC	AGT	AGA	AAG	GGC	TTC	ATC	ATA	TCA	TAA	GCA	ACG	TAC	AAA	GAA	ATA TAT
		TAG I									TAT	AGT C	N	Z CG1	T	A	K	E	TAT <i< td=""></i<>
К 91	1		W	85	5	ĸ	hi hi	ਚ ਜਾ.ਸਾ1	IG :									_	_100>
0																			
		3:	10		:	320			330			3	40			350			360
			*			*		~~~	*	~~~			* *	330		* *		CITC	מים י
GGG	CTT	CIG	ACC	TGT	GAA	GCA	ACA	GIC	MT/X	GGG	CAT	AVC.	AUD TAT	THE STATE S	י אלייאי	י שאני	ATA	GAG	ACA
œ	GAA	.GAC L	TGG m	ACA	CIT	CGT	ψ. 191	77	N.	G	H H	L	Y	K	T	N	Y	L	T>
101	ם		•	105			h	FLT1	IG	DOMA				_115					_120>
		3	70			380						4				410 *			420 *
			*					~~	*				*	. ग्रा			ריים .	ממם י	
CAT	CGA	CAA	ACC	AAT	ACA ACA	TAIC	ጥልጥ የ	מידים .	CYC	CVD	GAC	LCA	GGC	: AGA	GTA	CCI	TAZ	CII	CTA GAT
	R			N		I	I	D>											
		hF							_>										_
		_							V	V	L	, s	P	S	H	G	I	E	L> 140>
									130			_nFI	wr ]	G D	ILAM	<u> </u>			

PCT/US00/14142

40/55


Fig.24B.

470 480 430 440 450 460 TCT GTT GGA GAA AAG CTT GTC TTA AAT TGT ACA GCA AGA ACT GAA CTA AAT GTG GGG ATT AGA CAA CCT CTT TTC GAA CAG AAT TTA ACA TGT CGT TCT TGA CTT GAT TTA CAC CCC TAA S V G E K L V L N C T A R T E L N V G I> ____145____hFLK1 IG DOMAIN 3_____ 155 520 530 490 500 510 GAC TTC AAC TGG GAA TAC CCT TCT TCG AAG CAT CAG CAT AAG AAA CTT GTA AAC CGA GAC CTG AAG TTG ACC CTT ATG GGA AGA AGC TTC GTA GTC GTA TTC TTT GAA CAT TTG GCT CTG D F N W E Y P S S K H Q H K K L V N R D> ____165_____hFLK1 IG DOMAIN 3_____175__ 590 560 570 580 CTA AAA ACC CAG TCT GGG AGT GAG ATG AAG AAA TTT TTG AGC ACC TTA ACT ATA GAT GGT GAT TIT TGG GTC AGA CCC TCA CTC TAC TTC TTT AAA AAC TCG TGG AAT TGA TAT CTA CCA L K T Q S G S E M K K F L S T L T I D G> ______185_____hFLK1 IG DOMAIN 3_____195__ 200> 650 660 620 630 640 610 GTA ACC CGG AGT GAC CAA GGA TTG TAC ACC TGT GCA GCA TCC AGT GGG CTG ATG ACC AAG CAT TGG GCC TCA CTG GTT CCT AAC ATG TGG ACA CGT CGT AGG TCA CCC GAC TAC TGG TTC 720 700 710 680 690 670 AAG AAC AGC ACA TIT GIC AGG GIC CAT GAA AAG GAC AAA ACT CAC ACA TGC CCA CCG TGC TTC TTG TCG TGT AAA CAG TCC CAG GTA CTT TTC CTG TTT TGA GTG TGT ACG GGT GGC ACG K N S T F V R V H E K> 231> 221 hflk1 ig domain 3_ H T C P P C> D K T hFCAC1 A 232___ 780 770 730 740 750 760 CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC GGT CGT GGA CTT GAG GAC CCC CCT GGC AGT CAG AAG GAG AAG GGG GGT TTT GGG TTC CTG PAPELLGGPSVFLFPPKD> 260> __hFCAC1 A ___ 255 _245__ 820 830 800 810 * ACC CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA TOG GAG TAC TAG AGG GCC TOG GGA CTC CAG TGT ACG CAC CAC CAC CTG CAC TCG GTG CTT T L M I S R T P E V T C V V V D V S H E>
261_____265____hFCAC1 A _____275_____280: 900 870 880 890 850 860 GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA CTG GGA CTC CAG TTC AAG TTG ACC ATG CAC CTG CCG CAC CTC CAC GTA TTA CGG TTC TGT DPEVKFNWYVDGVEVHNAKT> _____hFCAC1 A ______300> _____285___


Fig.24C.

		9:	LO *		9											950 *			
					CAG														
					GIC														
					Q														
301_				_305_				n	CACI	. A _				212_					_320>
		97	°0 *			80 *			990 *			100	0 *		10	10		1	020 *
CAC	CAG	GAC	TGG	CTG	AAT	GGC	AAG	GAG	TAC	AAG	TGC	AAG	GTC	TCC	AAC	AAA	GCC	CIC	CCA
GTG	GTC	CTG	ACC	GAC	ATT	CCG	TIC	CIC	ATG	TTC	ACG	TTC	CAG	AGG	TIG	TTT	CGG	GAG	GGT
H	Q	D	W	L	N	G	K	Ε,	Y	K	С	K	V	S	N	K	A	L	P>
321_				_325_					IF CAC	ΊA				_335_					_340>
		103	30 *		10	)40 *		:	L050 *			106	50 *		10	070 *		-	* 1080
GCC	ccc	ATC	GAG	AAA	ACC	ATC	TCC	AAA	GCC	AAA	GGG	CAG	CCC	CGA	GAA	CCA	CAG	GTG	TAC
CGG	GGG	TAG	CTC	TTT	TGG	TAG	AGG	TTT	CGG	TTT	CCC	GTC	GGG	GCT	CTT	GGT	GTC	CAC	ATG
A	P	I	E	K	T	I	S	K	A	K	G	Q	P	R	E	P	Q	V	Y>
341_				_345_				hl	CAC1	. A _				_355_					_360>
					1.1							112						:	L140 *
					CGG														
TGG	GAC	GGG	GGT	AGG	GCC	CTA	CIC	GAC	TGG	TTC	TTG	GTC	CAG	TCG	GAC	TGG	ACG	GAC	CAG
T	L	P	P	S	R	D	E	L	T	K	N	Q	V	S	L	T	С	L	200×
361_				365				h	CVC	A				_3 /5_					_>0U>
		115			11	L60		•					30			190		:	
AAA	GGC	115	50 * TAT	ccc	11 AGC	L60 * GAC	ATC	ecc:	1170 * GIG	GAG	TGG	118 GAG	30 * AGC	ААТ	1: GGG	190 * CAG	ccs	GAG	1200 * AAC
$\mathbf{TTT}$	$\infty$	119 TTC AAG	50 * TAT ATA	CCC	11 AGC TCG	L60 * GAC CTG	ATC TAG		1170 * GIG CAC	GAG CTC	TGG ACC	118 GAG CTC	30 * AGC TCG	AAT TTA	1. GGG CCC	190 * CAG GTC	CCC	GAG CTC	1200 * AAC TTG
TTT K	CCG G	115 TTC AAG F	50 * TAT ATA Y	CCC GGG P	AGC TCG S	L60 * GAC CIG D	ATC TAG I	GCC CGG A	1170 * GIG CAC V	GAG CTC E	TGG ACC W	118 GAG CTC E	BO * AGC TCG S	AAT TTA N	1: GGG CCC G	190 * CAG GTC Q	CCG GGC P	GAG CTC E	1200 * AAC TIG N>
TTT K	CCG G	115 TTC AAG F	50 * TAT ATA Y	CCC GGG P	AGC TCG S	L60 * GAC CIG D	ATC TAG I	GCC CGG A	1170 * GIG CAC V	GAG CTC E	TGG ACC W	118 GAG CTC E	BO * AGC TCG S	AAT TTA N	1: GGG CCC G	190 * CAG GTC Q	CCG GGC P	GAG CTC E	1200 * AAC TTG
TTT K	CCG G	119 TTC AAG F	TAT ATA Y	CCC GGG P _385_	AGC TCG S	GAC CTG D	ATC TAG I	GCC CGG A h	1170 * GIG CAC V FCAC1	GAG CTC E A	TGG ACC W	GAG CTC E	AGC TCG S	aat tta n _395_	GGG CCC G	190 * CAG GTC Q 250	CCG GGC P	GAG CTC E	1200 * AAC TTG N> _400>
TTT K 381_	CCG G TAC	TTC AAG F	TAT ATA Y  10 * ACC	CCC GGG P _385_	AGC TCG S	GAC CTG D	ATC TAG I	GCC CGG A hi	GIG CAC V FCAC1	GAG CTC E A	TGG ACC W	GAG CTC E	AGC TCG S	AAT TTA N _395_	GGG CCC G	190  CAG GTC Q 250  CTC	CCG GGC P	GAG CTC E	1200 * AAC TTG N> _400> 1260 * AAG
TTT K 381_ AAC TTG	CCG G TAC ATG	TTC AAG F 12:	TAT ATA Y  10 * ACC TGG	CCC GGG P _385_ ACG TGC	AGC TCG S	GAC CTG D	ATC TAG I	GCC CCG A hi	GIG CAC V FCACI 1230 * GAC CIG	GAG CTC E A _	TGG ACC W	GAG CTC E 124 GGC CCG	AGC TCG S  10 * TCC AGG	AAT TTA N _395_ TTC AAG	GGG CCC G	CAG GTC Q 250 *	CCG GGC P TAC	GAG CTC E AGC TCG	1200 * AAC TTG N> _400> 1260 * AAG TTC
TTT  K  381  AAC TTG  N	CCG G TAC ATG Y	TTC AAG F 12:	TAT ATA Y  10 * ACC TGG	CCC GGG P _385_ ACG TGC T	AGC TCG S	GAC CTG D 220 * CCC GGG	ATC TAG I GIG CAC V	GCC CGG A hi hi CTG GAC L	GIG CAC V FCACI 1230 GAC CIG D	GAG CTC E A _	TGG ACC W GAC CTG	GAG CTC E 124 GGC CCG G	AGC TCG S  40  * TCC AGG S	AAT TTA N _395_ TTC AAG F	GGG CCC G 11 TTC AAG	CAG GTC Q 250 * CTC GAG L	CCG GGC P TAC ATG	GAG CTC E AGC TCG S	1200 * AAC TTG N> _400>  1260     * AAG TTC K>
TTT  K  381  AAC TTG  N	CCG G TAC ATG Y	TTC AAG F 12:	TAT ATA Y  10 * ACC TGG	CCC GGG P _385_ ACG TGC T	AGC TCG S	GAC CTG D 220 * CCC GGG	ATC TAG I GIG CAC V	GCC CGG A hi hi CTG GAC L	GIG CAC V FCACI 1230 GAC CIG D	GAG CTC E A _	TGG ACC W GAC CTG	GAG CTC E 124 GGC CCG G	AGC TCG S  40  * TCC AGG S	AAT TTA N _395_ TTC AAG F	GGG CCC G 11 TTC AAG	CAG GTC Q 250 * CTC GAG L	CCG GGC P TAC ATG	GAG CTC E AGC TCG S	1200 * AAC TTG N> _400> 1260 * AAG TTC
TTT  K  381  AAC TTG  N	CCG G TAC ATG Y	TTC AAG F 12:	TAT ATA Y  10 * ACC TGG	CCC GGG P _385_ ACG TGC T	AGC TCG S	GAC CTG D	ATC TAG I GIG CAC V	GCC CCG A hi CTG GAC L	GIG CAC V FCACI 1230 * GAC CIG D	GAG CTC E A _ TCC AGG S L A _	TGG ACC W GAC CTG D	GAG CTC E 124 GGC CCG G	AGC TCG S 10 * TCC AGG S	AAT TTA N 395_ TTC AAG F 415_	GGG CCC G 1: TTC AAG	CAG GTC Q 250 * CTC GAG L	CCG GGC P TAC ATG	GAG CTC E AGC TCG	1200 * AAC TTG N> _400>  1260     * AAG TTC K>
AAC TTG N 401_	TAC ATG	TTC AAG F 12: AAG TTC K 12: GTG	TAT ATA Y  10 * ACC TGG T	CCC GGG P _385_ ACG TGC T _405_	AGC TCG S  12 CCT GGA P  13 AGC	GAC CTG D  2220 * CCC GCG P  280 * AGG	ATC TAG I GIG CAC V	CTG GAC L ht	GIG CAC V FCACI 1230 * GAC CIG D FCACI 1290 * CAG	GAG CTC E TCC AGG S I A GGGG	TGG ACC W GAC CTG D	GAG CTC E 12-4 GGC CCG G 130 GTC	AGC TCG S TCC AGG S TTCC AGG TTCC TTCC TTCC TTCC	AAT TTA N 395 TTC AAG F 415	11 GGG CCC G TTC AAG F 1 TGC	CAG GTC Q 250 * CTC GAG L 310 *	CCG GGC P TAC ATG Y	GAG CTC E AGC TCG S	1200 * AAC TTG N> _400> 1260 * AAG TTC K> _420> 1320 * CAT
AAC TTG N 401_CTC GAG	TAC ATG Y	TTC AAG F  12: AAG TTC K  12: GTG CAC	TAT ATA Y  10 * ACC TGG T  70 * GAC CTG	CCC GGG P _385_ ACG TGC T _405_	AGC TCG S  12  CCT GGA P  12  AGC TCG	GAC CTG D  2200 * CCC GCG P  280 * AGG TCC	ATC TAG I GTG CAC V	GCC CGG A hi CTG GAC L h	1170  * GIG CAC V FCACI 1230  * GAC CIG D FCACI 1290  * CAG GIC	GAG CTC E AGG S L A GGG CCC	TGG ACC W GAC CTG D	GAG CTC E 124 GGC CCG G 134 GTC CAG	AGC TCG S TCG AGG AGG TCC AGG AGG AAG	AAT TTA N 395 TTC AAG F 415	11: GGG CCC G TTC AAG F 1: TGC ACG ACG	CAG GTC Q 250 * CTC GAG L 310 * TCC AGG	CCG GGC P TAC ATG Y	GAG CTC E AGC TCG S	1200  * AAC TTG N> 400> 1260  * AAG TTC K> 420> 1320  * CAT
AAC TTG N 401_CTC GAG L	TAC ATG Y	TTC AAG F  12: AAG TTC K  12: GTG CAC V	TAT ATA Y  10 * ACC TGG T  70 * GAC CTG D	CCC GGG P _385_ ACG TGC T _405_	AGC TCG S  12 CCT GGA P  12 AGC TCG S	GAC CTG D 2220 * CCC GCG P 280 * AGG TCC R	ATC TAG I GTG CAC V TGG ACC W	GCC CGG A hi CTG GAC L h	1170  * GIG CAC V FCACI 1230  * GAC CIG D FCACI 1290  * CAG GIC Q	GAG CTC E AGG S L A GGG CCC G	TGG ACC W GAC CTG D	GAG CTC E 124 GGC CCG G 134 GTC CAG V	AGC TCG S TCC AGG S TTCC AGG TTCC AGG TTCC AAGG TTCC AAGG TTCC	AAT TTA N 395 TTC AAG F 415 AGT S	11: GGG CCC G TTC AAG F 1: TGC ACG C	CAG GTC Q 250 * CTC GAG L 310 * TCC AGG S	CCG GGC P TAC ATG Y	GAG CTC E AGC TCG S	1200  * AAC TTG N> 400> 1260  * AAG TTC K> 420> 1320  * CAT GTA H>
AAC TTG N 401_CTC GAG L	TAC ATG Y	TTC AAG F  12: AAG TTC K  12: GTG CAC V	TAT ATA Y  10 * ACC TGG T  70 * GAC CTG D	CCC GGG P _385_ ACG TGC T _405_	AGC TCG S  12 CCT GGA P  12 AGC TCG S	GAC CTG D 2220 * CCC GCG P 280 * AGG TCC R	ATC TAG I GTG CAC V TGG ACC W	GCC CGG A hi CTG GAC L h	1170  * GIG CAC V FCACI 1230  * GAC CIG D FCACI 1290  * CAG GIC Q	GAG CTC E AGG S L A GGG CCC G	TGG ACC W GAC CTG D	GAG CTC E 124 GGC CCG G 134 GTC CAG V	AGC TCG S TCC AGG S TTCC AGG TTCC AGG TTCC AAGG TTCC AAGG TTCC	AAT TTA N 395 TTC AAG F 415 AGT S	11: GGG CCC G TTC AAG F 1: TGC ACG C	CAG GTC Q 250 * CTC GAG L 310 * TCC AGG S	CCG GGC P TAC ATG Y	GAG CTC E AGC TCG S	1200  * AAC TTG N> 400> 1260  * AAG TTC K> 420> 1320  * CAT
AAC TTG N 401_CTC GAG L	TAC ATG Y	TTC AAG F 12: AAG TTC K 12' GTG CAC V 13:	TAT ATA Y  10 * ACC TGG T  70 * GAC CTG D	CCC GGG P _385_ ACG TGC T _405_	AGC TCG S  12 CCT GGA P  12 AGC TCG S	GAC CTG D 2220 * CCC GGG P AGG TCC R	ATC TAG I GIG CAC V TGG ACC W	GCC CGG A hi CTG GAC L h	1170  * GIG CAC V FCACI 1230  * GAC CIG D FCACI 1290  * CAG GIC Q FFCACI	GAG CTC E A TCC AGG S LA CCC G LA	TGG ACC W GAC CTG D	GAG CTC E 124 GGC CCG G 134 GTC CAG V	AGC TCG S TCC AGG S TTCC AGG AAG F	AAT TTA N 395 TTC AAG F 415 TCA AGT S 435	GGG CCCC G TTC AAG F 1 TGC ACG C	CAG GTC Q 250 * CTC GAG L 310 * TCC AGG S	CCG GGC P TAC ATG Y	GAG CTC E AGC TCG S	1200  * AAC TTG N> 400> 1260  * AAG TTC K> 420> 1320  * CAT GTA H>
AAC TIG N 401_CTC GAG L 421_	TAC ATG Y  ACC TGG T	TTC AAG F 12: AAG TTC K 12' GTG CAC V 13: CTG	TAT ATA Y  10 * ACC TGG T  70 * GAC CTG D  30 *	CCC GGG P _385_ ACG TGC T _405_ AAG TTC K _425_	AGC TCG S  CCT GGA P  AGC TCG S  CAC	L60 * GAC CTIG D 220 * CCC GGG P 280 * AGG TCC R TAC	ATC TAG I GTG CAC V TGG ACC	CTG CAG CAG CAG CAG CAG CAG CAG	GIG CAC V FCACI 12300 ** GAC CIG D FCACI 1290 ** CAG GIC Q FCACI 1350 ** AAG	GAG CTC E A A A A A A A A A A A A A A A A A A A	TGG ACC W GAC CTG D AAC TTG N	GAG CTC E  124 GGC CCG G  130 GTC CAG V	AGC TCG S 40 * TCC AGG S TTCC AAGG C TTCC C TCC TC	AAT TTA N 395 TTC AAG F 415 TCA AGT S 435	11: GGG CCC G TTCC AAG F 1: TGC ACG C 1: CCG	CAG GTC Q 250 * CTC GAG L 310 * TCC AGG S 370 *	CCG GGC P TAC ATG Y GTG CAC V	GAG CTC E AGC TCG S ATG TAC M	1200  * AAC TTG N> _400>  1260  * AAG TTC K> _420>  1320  * CAT GTA H> _440>
AAC TIG N 401_CIC GAG L 421_	TAC ATG Y  ACC TGG T  GCT CGA	TTC AAG F 12: AAG TTC K 12: CAC V 13: CTG GAC	TAT ATA Y  10 * ACC TGG T  70 * GAC CTG D  30 * CAC GTG	CCC GGG P _385_ ACG TGC T _405_ AAC TTC K _425_	AGC TCG S  12 CCT GGA P  13 AGC TCG S  14 CAC GTG	GAC CTIG D 2220 * CCC GGG P 280 * TCC R 340 * TAC ATG	ATC TAG I GTG CAC V TGG ACC W	CTG A hi CTG GAC L h CAG GTC Q h	GIG CAC V FCACI 12300 * GAC CIG D FCACI 1290 CAG GIC Q FCACI 1350 * AAG TIC	GAG CTC E A A A A A A A A A A A A A A A A A A A	TGG ACC W GAC CTG D AAC TTG N	GAG CTC E  124 GGC CCG G  130 GTC CAG V  137 TCC AGG	AGC TCG S TCC AGG S TTCC AGG TTCC AGG CTG AAG F	AAT TTA N 395 TTC AAG F 415 TCA AGT S 435	11: GGG CCC G TTCC AAG F 1: TGC ACG C C CGGGGGGGGGGGGGGGGGGGGGGGGGG	CAG GTC Q 250 * CTC GAG L 310 * TCC AGG S 370 *	CCG GGC P TAC ATG Y GTG CAC V	GAG CTC E AGC TCG S ATG TAC M	1200  * AAC TTG N> _400>  1260  * AAG TTC K> _420>  1320  * CAT GTA H> _440>
AAC TIG N 401_CTC GAG L 421_CTC E	CCG G TAC ATG Y ACC TGG T CGA A	TTC AAG F 12: AAG TTC K 12: CAC V 13: CTG GAC L	TAT ATA Y  10 * ACC TGG T  CTG D  30 * CAC GTG H	CCC GGG P _385_ ACG TGC T _405_ AAC TTC K _425_ N	AGC TCG S  CCT GGA P  AGC TCG S  CAC	L60  * GAC CTIG D  220  * CCC GGG P  280  * AGG TCC R  TAC ATG Y	ATC TAG I GTG CAC V TGG ACC W ACG TGC	CTG A hi CTG GAC L h CAG GTC Q CAG GTC Q	GIG CAC V FCACI 12300 * GAC CIG D FCACI 1290 CAG GIC Q FCACI 1350 * AAG TIC K	GAG CTC E A A C AGG S L A C AGC TCG S	TGG ACC W GAC CTG D AAC TTG N	GAG CTC E  124 GGC CCG G  130 GTC CAG V  137 TCC AGG S	AGC TCG S TCC AGG S TTCC AGG C TTCC AGG C TTCC AGG L	AAT TTA N 395 TTC AAG F 415 TCA AGT S 435	11: GGG CCC G TTCC AAG F 1: TGC ACG C C CCG GGC P	CAG GTC Q 250 * CTC GAG L 310 * TCC AGG S 370 * GGT CCA G	CCG GGC P TAC ATG Y GTG CAC V	GAGC CTC E  AGCC TCG ATGC TACC M  TGA ACT *>	1200  * AAC TTG N> _400>  1260  * AAG TTC K> _420>  1320  * CAT GTA H> _440>


## Fig.25A.



## Fig.25B.




**SUBSTITUTE SHEET (RULE 26)** 




44/55

## Fig.26A.



45/55



SUBSTITUTE SHEET (RULE 26)


-ig.28.


Binding S	Binding Stoichiometry of hVEGF165 to Flt1	hVEGF165 to Fit1D2Fik1D3.FcΔC1(a) & VEGFR1R2-FcΔC1(a)
hVEGF165 (nM)	hVEGF165 (nM) VEGF/Flt1D2Flk1D3.FcΔC1(a)	VEGF/VEGFR1R2-FcΔC1(a)
•	0.93	0.98
10	0.97	0.94
50	-	0:39
Average ± StDev	0.96 ± 0.03	0.97 ± 0.02


46/55

SUBSTITUTE SHEET (RULE 26)


MARCH BUT THE DECIMENT









7 1










Fig.36.

KRIIWDSRKGFIIS<u>N</u>ATYKEIGLLT<u>C</u>EATVNGHLYKTNYLTHRQTNTIII GRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDG


VVLSPSHGIELSVGEKLVL<u>NC</u>TARTELNVGIDFNWEYPSSKHQHKKLVNR


SHEDPEVKFNWYVDGVEVHNAKTKPREEQY<u>N</u>STYRVVSVLTVLHQDWLN DLKTQSGSEMKKFLSTLTIDGVTRSDQGLYT<u>C</u>AASSGLMTKK<u>N</u>STFVRVH EKGPGDKTHT<u>C</u>PP<u>C</u>PAPELLGGPSVFLFPPKPKDTLMISRTPEVT<u>C</u>VVVD


51/55


350 GKEYK<u>C</u>KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS

RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK











SUBSTITUTE SHEET (RULE 26)

ini.





#### **DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) of an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES AND METHODS OF MAKING AND USING THEREOF, which is the United States national stage filing of International Application PCT/US00/14142 filed May 23, 2000.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to in the oath or declaration.

I acknowledge the duty to disclose information of which I am aware that is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PCT/US00/14142 filed May 23, 2000

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States Application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) that occurred between the filing date of the prior application and the national or PCT international filing date of this application:

USSN 60/138,133 filed June 8, 1999

And I hereby appoint Joseph M. Sorrentino (Registration No. 32,598), Gail M. Kempler (Registration No. 32,143), and Linda O. Palladino (Registration No. 45,636) each of them my attorneys and agent, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International

5

Att. Docket No.REG 710-A-US

USSN: Not Yet Known

US File Date: Filed Herewith Int'l File No.: PCT/US00/14142 Int'l File Date: May 23, 2000 Declaration and Power of Attorney

Page 2

Applications that are based thereon under the provisions of the Patent Cooperation Treaty.

Please address all communications, and direct all telephone calls, regarding this application to:

Linda O. Palladino
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
Tel. (914-345-7400)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 12/06/01

Inventor: NICHOLAS J. PAPADOPOULOS

Signature:

Citizenship: <u>United States of America</u>

Residence: 59 Heritage Lane

Lagrangeville, New York 12540

Post Office Address: same as residence

Att. Docket No.REG 710-A-US

USSN: Not Yet Known

US File Date: Filed Herewith
Int'l File No.: PCT/US00/14142
Int'l File Date: May 23, 2000
Declaration and Power of Attorney

Page 3

200

Inventor: SAMUEL DAVIS

Signature: Xamul Lam'

Date: 12/6/0/

12-6.01

Date:

Citizenship: United States of America

Residence: 332 W. 88th Street, #B2

New York, New York 10024

Post Office Address: same as residence

Inventor: GEORGE D. YANCOPOULOS

Signature:

Citizenship: United States of America

Residence: 1519 Baptist Church Road

Yorktown Heights, New York 10598

Post Office Address: same as residence

#### SEQUENCE LISTING

<110> Nicholas J. Papadopoulos et al.

<120> MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES AND METHODS OF MAKING AND USING THEREOF

<130> REG 710-A-US

<140> Not Yet Known

<141> Filed Herewith

<150> PCT/US00/14142

<151> 2000-05-23

<150> 60/138,133

<151> 1999-06-08

<160> 38

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1704

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(1701)

<400> 1

atg	gtc	agc	tac	tgg	gac	acc	ggg	gtc	ctg	ctg	tgc	gcg	ctg	ctc	agc	48
Met	Val	Ser	${\tt Tyr}$	Trp	Asp	Thr	Gly	Val	Leu	Leu	Cys	Ala	Leu	Leu	Ser	
1				5					10					15		

tgt ctg ctt ctc aca gga tct agt tca ggt tca aaa tta aaa gat cct 96 Cys Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro 20 25 30

gaa ctg agt tta aaa ggc acc cag cac atc atg caa gca ggc cag aca 144 Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr 40

ctg cat ctc caa tgc agg ggg gaa gca gcc cat aaa tgg tct ttg cct 192 Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro
50 60

gaa atg gtg agt aag gaa agc gaa agg ctg agc ata act aaa tct gcc
Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala
70
70
80

tgt gga aga aat ggc aaa caa ttc tgc agt act tta acc ttg aac aca

288

Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr

gct caa gca aac cac act ggc ttc tac agc tgc aaa tat cta gct gta
Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val

			_	-	aag Lys	_		_		-						384
_	-			-	cct Pro		-		-		_	_				432
			_		gaa Glu 150					-			_		_	480
_					act Thr	-				_				_		528
_			-		aaa Lys	-				-	-	-	-			576
				_	acg Thr			_				_		_	-	624
_		-			cat His	-										672
					ata Ile 230											720
					cat His											768
					gtt Val											816
	_	-	-		gta Val		-	_		-						864
-					agt Ser	-				-		_				912
_					act Thr 310	-	-									960
					gtg Val											1008
				-	aaa Lys				-		_					1056

														ccc Pro		110	4
			_							-		_		gtg Val	-	115	2
		_		-	-			-	-					gtg Val	-	120	0
														cag Gln 415		124	8
														cag Gln		129	6
														gcc Ala		134	4
														ccc Pro		139	2
														acc Thr		144	0
	_	_	_	_		_	_	-						agc Ser 495		148	8
Ile	Ala	Val	Glu 500	Trp	Glu	Ser	Asn	Gly 505	Gln	Pro	Glu	Asn	Asn 510	tac Tyr	Lys	153	6
														tac Tyr		158	4
														ttc Phe		163	2
														aag Lys		168	0
		ctg Leu		_	~ ~		tga									170	4

<210> 2 <211> 567 <212> PRT <213> Homo sapiens

<400> 2 Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser 1.0 Cys Leu Leu Thr Gly Ser Ser Gly Ser Lys Leu Lys Asp Pro 25 Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr 40 Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro 55 60 Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala 70 75 Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr 85 90 Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val 100 105 Pro Thr Ser Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile 120 125 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 135 140 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 150 155 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 165 170 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 185 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 200 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 215 Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val 230 235 Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr 245 250 Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys 265 260 Asn Lys Arg Ala Ser Val Arg Arg Ile Asp Gln Ser Asn Ser His 280 285 Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys Met Gln Asn Lys 300 295 Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys 315 310 Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Gly Pro Gly Glu 325 330 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 345 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 360 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 375 380 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 390 395 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 405 410 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 420 425 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 440 445 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 455 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys

465 Asr	Gln	Val	Ser		470 Thr	Cys	Leu	Val		475 Gly	Phe	Tyr	Pro		480 Asp	
Il $\epsilon$	Ala	Val	Glu 500	485 Trp	Glu	Ser	Asn	Gly 505	490 Gln	Pro	Glu	Asn	Asn 510	495 Tyr	Lys	
Thr	Thr	Pro 515	Pro	Val	Leu	Asp	Ser 520	Asp	Gly	Ser	Phe	Phe 525	Leu	Tyr	Ser	
Lys	Leu 530		Val	Asp	Lys	Ser 535		Trp	Gln	Gln	Gly 540		Va1	Phe	Ser	
Cys 545	Ser	Val	Met	His	Glu 550		Leu	His	Asn	His 555		Thr	Gln	Lys	Ser 560	
Leu	Ser	Leu	Ser	Pro 565	Gly	Lys										
	<: <:	210> 211> 212> 213>	1674 DNA		piens	5										
	<:	220> 221> 222>		(1	1671)	1										
		400>														
	gtc Val															48
_	ctg Leu						_									96
-	ctg Leu															144
	cat His 50															192
-	atg Met		Ser	Lys		Ser	Glu	Arg	Leu	Ser	Ile	Thr	Lys		Ala	240
	gga Gly															288
	caa Gln															336
	act Thr							-								384
	gat Asp 130															432
att	ata	cac	atg	act	gaa	gga	agg	gag	ctc	gtc	att	ccc	tgc	cgg	gtt	480

Ile 145	Ile	His	Met	Thr	Glu 150	Gly	Arg	Glu	Leu	Val 155	Ile	Pro	Cys	Arg	Val 160	
_						gtt Val				_				-		528
			-			cgc Arg	_	_		_	_	-	_			576
				-	_	tac Tyr		_				~		-	_	624
_		_				ttg Leu 215		_							-	672
						gat Asp	-			_			-		-	720
			-			act Thr		-			_		_			768
	-		-	_	-	caa Gln	_			-						816
_		_				gcc Ala					_	-		_	_	864
						gac Asp 295										912
_	~ ~					tct Ser	~								_	960
						ccc Pro										1008
	-					gaa Glu		_			-					1056
						gac Asp			_							1104
						gac Asp 375										1152
						ggc Gly										1200

385					390					395					400	
_	cgg Arg			-			-									1248
	gtc Val	-		-	-		_			_						1296
_	tcc Ser			-			-									1344
	aaa Lys 450															1392
	gat Asp															1440
	ttc Phe			-	_		_				-				_	1488
	gag Glu															1536
	ttc Phe															1584
	ggg Gly 530															1632
	tac Tyr			_	_			_		_	~ -		tga			1674
	<2 <2	210> 211> 212> 213>	557 PRT	sag	piens	5										
Met	<4 Val	100> Ser		Trp	Asp	Thr	Gly	Val	Leu	Leu	Cys	Ala	Leu	Leu	Ser	
1	Leu		-	5	_			Ser	10					15		
Glu	Leu		20 Leu	Lys	Gly	Thr		25 His	Ile	Met	Gln		30 Gly	Gln	Thr	
Leu	His 50	35 Leu	Gln	Cys	Arg	Gly 55	40 Glu	Ala	Ala	His	Lys 60	45 Trp	Ser	Leu	Pro	
Glu 65	Met	Val	Ser	Lys	Glu 70		Glu	Arg	Leu	Ser 75	-	Thr	Lys	Ser	Ala 80	
	Gly	Arg	Asn	Gly 85		Gln	Phe	Cys	Ser 90		Leu	Thr	Leu	Asn 95		

Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val 105 Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile 120 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 135 140 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 150 155 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 170 165 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 180 190 185 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 200 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 215 220 Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val 230 235 Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr 250 245 Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Ile 260 265 Asp Gln Ser Asn Ser His Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile 275 280 Asp Lys Met Gln Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg 295 300 Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His Ile Tyr Asp 310 315 Lys Ala Gly Pro Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 335 325 330 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 340 345 350 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 360 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 375 380 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 390 395 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 405 410 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 420 425 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 440 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 455 460 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 470 475 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 485 490 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 500 505 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 520 525 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 535 540 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 550

<210> 5 <211> 1359

			212> 213>	DNA Homo	o saj	piens	S										
		<2	220> 221> 222>	CDS	(3	1356)	)										
÷		gtcVal		tac													48
	_	ctg Leu										_					96
	_	tac Tyr	_	-			_				_		-				144
		gtc Val 50			_		_	_									192
		aag Lys															240
		gac Asp															288
		GJA aaa		_		_	_	-		_							336
		aac Asn					_							-	_		384
	Ile	agc Ser 130	Thr	Pro	Arg		Val	Lys		Leu	Arg	Gly	His			-	432
		aat Asn	_		-				-		-	_	_		_		480
		agt Ser			-	-		_									528
		tac Tyr															576
		tat Tyr		-	-	-		_									624
	acc	tca	gtg	cat	ata	tat	gat	aaa	gca	ggc	ccg	ggc	gag	CCC	aaa	tct	672

Thr	Ser 210	Val	His	Ile	Tyr	Asp 215	Lys	Ala	Gly	Pro	Gly 220	Glu	Pro	Lys	Ser	
-	_					tgc Cys		_	_				-			720
		_		_		ctc Leu										768
_						gag Glu	-		_				_		_	816
						aag Lys										864
						aag Lys 295										912
	_	-				ctc Leu		-								960
						aag Lys										1008
						aaa Lys	-			_			_			1056
			_			tcc Ser		-		_		_			_	1104
_	_		_	_	-	aaa Lys 375					_	_	_		_	1152
			_			cag Gln	_					-				1200
		_	_		_	ggc Gly										1248
						cag Gln										1296
_			-	_		aac Asn			-	-	-	-				1344
	ccg Pro		aaa Lys	tga												1359

```
<210> 6
<211> 452
<212> PRT
<213> Homo sapiens
```

<400> 6 Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser 5 Cys Leu Leu Thr Gly Ser Ser Gly Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu 40 Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu 55 Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile 70 75 Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu 90 Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys 100 105 Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Val Gln 115 120 125 Ile Ser Thr Pro Arg Pro Val Lys Leu Leu Arg Gly His Thr Leu Val 140 135 Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr Arg Val Gln Met Thr 155 150 Trp Ser Tyr Pro Asp Glu Ile Asp Gln Ser Asn Ser His Ala Asn Ile 165 170 Phe Tyr Ser Val Leu Thr Ile Asp Lys Met Gln Asn Lys Asp Lys Gly 185 180 Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys Ser Val Asn 200 195 205 Thr Ser Val His Ile Tyr Asp Lys Ala Gly Pro Gly Glu Pro Lys Ser 220 215 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 230 235 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 295 300 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 310 315 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 330 325 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 345 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 360 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 375 380 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro

410

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

390

405

395

Val	Asp	Lys	Ser 420	Arg	Trp	Gln	Gln	Gly 425	Asn	Val	Phe	Ser	Cys 430	Ser	Val	
	His Pro	435	Ala	Leu	His	Asn	His 440	Tyr	Thr	Gln	Lys	Ser 445	Leu	Ser	Leu	
	450															
	<2 <2	212>	1389 DNA		piens	3			÷							
	<2	220> 221> 222>		(	L386)											
atg Met 1	<4 gtc Val	100> agc Ser	tac	tgg Trp 5	gac Asp	acc Thr	Gly aaa	gtc Val	ctg Leu 10	ctg Leu	tgc Cys	gcg Ala	ctg Leu	ctc Leu 15	agc Ser	48
tgt Cys	ctg Leu	ctt Leu	ctc Leu 20	aca Thr	gga Gly	tct Ser	agt Ser	tcc Ser 25	gga Gly	ggt Gly	aga Arg	cct Pro	ttc Phe 30	gta Val	gag Glu	96
atg Met	tac Tyr	agt Ser 35	gaa Glu	atc Ile	ccc Pro	gaa Glu	att Ile 40	ata Ile	cac His	atg Met	act Thr	gaa Glu 45	gga Gly	agg Arg	gag Glu	144
ctc Leu	gtc Val 50	att Ile	ccc Pro	tgc Cys	cgg Arg	gtt Val 55	acg Thr	tca Ser	cct Pro	aac Asn	atc Ile 60	act Thr	gtt Val	act Thr	tta Leu	192
aaa Lys 65	aag Lys	ttt Phe	cca Pro	ctt Leu	gac Asp 70	act Thr	ttg Leu	atc Ile	cct Pro	gat Asp 75	gga Gly	aaa Lys	cgc Arg	ata Ile	atc Ile 80	240
tgg Trp	gac Asp	agt Ser	aga Arg	aag Lys 85	Gly	ttc Phe	atc Ile	ata Ile	tca Ser 90	aat Asn	gca Ala	acg Thr	tac Tyr	aaa Lys 95	gaa Glu	288
ata Ile	Gly gaa	ctt Leu	ctg Leu 100	acc Thr	tgt Cys	gaa Glu	gca Ala	aca Thr 105	Val	aat Asn	Gly	cat His	ttg Leu 110	tat Tyr	aag Lys	336
aca Thr	aac Asn	tat Tyr 115	ctc Leu	aca Thr	cat His	cga Arg	caa Gln 120	acc Thr	aat Asn	aca Thr	atc Ile	ata Ile 125	Asp	gtc Val	caa Gln	384
ata Ile	agc Ser 130	Thr	cca Pro	cgc Arg	cca Pro	gtc Val 135	Lys	tta Leu	. ctt . Leu	aga Arg	ggc Gly 140	His	act Thr	ctt Leu	gtc Val	432
ctc Leu 145	Asn	tgt Cys	act Thr	gct Ala	acc Thr 150	Thr	ccc	ttg Leu	aac Asn	acg Thr 155	Arg	gtt Val	caa Gln	atg Met	acc Thr 160	480
tgg Trp	agt Ser	tac Tyr	cct Pro	gat Asp 165	Glu	aaa Lys	aat Asn	aag Lys	aga Arg 170	r Ala	tcc Ser	gta Val	agg Arg	cga Arg 175	cga Arg	528

att Ile	gac Asp	caa Gln	agc Ser 180	aat Asn	tcc Ser	cat His	gcc Ala	aac Asn 185	ata Ile	ttc Phe	tac Tyr	agt Ser	gtt Val 190	ctt Leu	act Thr	576
att Ile	gac Asp	aaa Lys 195	atg Met	cag Gln	aac Asn	aaa Lys	gac Asp 200	aaa Lys	gga Gly	ctt Leu	tat Tyr	act Thr 205	tgt Cys	cgt Arg	gta Val	624
agg Arg	agt Ser 210	gga Gly	cca Pro	tca Ser	ttc Phe	aaa Lys 215	tct Ser	gtt Val	aac Asn	acc Thr	tca Ser 220	gtg Val	cat His	ata Ile	tat Tyr	672
gat Asp 225	aaa Lys	gca Ala	ggc Gly	ccg Pro	ggc Gly 230	gag Glu	ccc Pro	aaa Lys	tct Ser	tgt Cys 235	gac Asp	aaa Lys	act Thr	cac His	aca Thr 240	720
tgc Cys	cca Pro	ccg Pro	tgc Cys	cca Pro 245	gca Ala	cct Pro	gaa Glu	ctc Leu	ctg Leu 250	Gly ggg	gga Gly	ccg Pro	tca Ser	gtc Val 255	ttc Phe	768
ctc Leu	ttc Phe	ccc Pro	cca Pro 260	aaa Lys	ccc Pro	aag Lys	gac Asp	acc Thr 265	ctc Leu	atg Met	atc Ile	tcc Ser	cgg Arg 270	acc Thr	cct Pro	816
gag Glu	gtc Val	aca Thr 275	tgc Cys	gtg Val	gtg Val	gtg Val	gac Asp 280	gtg Val	agc Ser	cac His	gaa Glu	gac Asp 285	cct Pro	gag Glu	gtc Val	864
aag Lys	ttc Phe 290	aac Asn	tgg Trp	tac Tyr	gtg Val	gac Asp 295	ggc Gly	gtg Val	gag Glu	gtg Val	cat His 300	aat Asn	gcc Ala	aag Lys	aca Thr	912
aag Lys 305	ccg Pro	cgg Arg	gag Glu	gag Glu	cag Gln 310	tac Tyr	aac Asn	agc Ser	acg Thr	tac Tyr 315	cgt Arg	gtg Val	gtc Val	agc Ser	gtc Val 320	960
ctc Leu	acc Thr	gtc Val	ctg Leu	cac His 325	cag Gln	gac Asp	tgg Trp	ctg Leu	aat Asn 330	ggc Gly	aag Lys	gag Glu	tac Tyr	aag Lys 335	tgc Cys	1008
aag Lys	gtc Val	tcc Ser	aac Asn 340	Lys	gcc Ala	ctc Leu	cca Pro	gcc Ala 345	ccc Pro	atc Ile	gag Glu	aaa Lys	acc Thr 350	Ile	tcc Ser	1056
aaa Lys	gcc Ala	aaa Lys 355	Gly	cag Gln	ccc Pro	cga Arg	gaa Glu 360	cca Pro	cag Gln	gtg Val	tac Tyr	acc Thr 365	ctg Leu	ccc Pro	cca Pro	1104
tcc Ser	cgg Arg 370	Asp	gag Glu	ctg Leu	acc Thr	aag Lys 375	Asn	cag Gln	gtc Val	agc Ser	ctg Leu 380	Thr	tgc Cys	ctg Leu	gtc Val	1152
aaa Lys 385	Gly	ttc Phe	tat Tyr	ccc Pro	ago Ser 390	Asp	ato Ile	gcc Ala	gtg Val	gag Glu 395	Trp	gag Glu	agc Ser	aat Asn	ggg Gly 400	1200
cag Glr	r ccg Pro	gag Glu	aac Asn	aac Asn 405	ı Tyr	aag Lys	acc Thr	acg Thr	cct Pro 410	Pro	gtg Val	ctg Leu	gac Asp	tco Ser 415	gac Asp	1248
ggc	tcc	: ttc	ttc	cto	tac	ago	aag	gctc	acc	gtg	gac	aag	g ago	agg	, tgg	1296

```
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
                                425
            420
cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac
                                                                    1344
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
                           440
                                                                    1386
aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
                        455
                                                                    1389
tga
      <210> 8
      <211> 462
      <212> PRT
      <213> Homo sapiens
     <400> 8
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
                5
                                    10
Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Gly Arg Pro Phe Val Glu
                                25
Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu
                                                45
                            40
Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu
                        55
Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile
                                        75
                    70
Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu
                                    90
                85
Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys
                                105
            100
Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Val Gln
                           120
                                               125
Ile Ser Thr Pro Arg Pro Val Lys Leu Leu Arg Gly His Thr Leu Val
                                           140
                       135
Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr Arg Val Gln Met Thr
                                       155
                    150
Trp Ser Tyr Pro Asp Glu Lys Asn Lys Arg Ala Ser Val Arg Arg Arg
                                   170
                                                        175
                165
Ile Asp Gln Ser Asn Ser His Ala Asn Ile Phe Tyr Ser Val Leu Thr
                               185
Ile Asp Lys Met Gln Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val
                                                205
                           200
Arg Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His Ile Tyr
                                           220
                        215
Asp Lys Ala Gly Pro Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr
                                        235
                    230
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
                                                       255
                                    250
                245
 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
                                                   270
                                265
            2.60
 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
                                                285
         275
                            280
 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
                                            300
                        295
 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
                                        315
                    310
 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
```

330

325

```
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
                                345
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
                                                365
                            360
        355
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
                        375
                                            380
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
                                        395
                    390
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
                                    410
                                                         415
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
            420
                                425
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
        435
                            440
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
                        455
    450
      <210> 9
      <211> 1704
      <212> DNA
      <213> Homo sapiens
      <220>
      <221> CDS
      <222> (1) ... (1701)
      <400> 9
atg gtc agc tac tgg gac acc ggg gtc ctg ctg tgc gcg ctg ctc agc
                                                                       48
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
                                                                       96
tgt ctg ctt ctc aca gga tct agt tca ggt tca aaa tta aaa gat cct
Cys Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro
             20
                                                                      144
gaa ctg agt tta aaa ggc acc cag cac atc atg caa gca ggc cag aca
Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr
         35
ctg cat ctc caa tgc agg ggg gaa gca gcc cat aaa tgg tct ttg cct
                                                                      192
Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro
     50
                         55
                                                                      240
gaa atg gtg agt aag gaa agc gaa agg ctg agc ata act aaa tct gcc
Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala
 65
tgt gga aga aat ggc aaa caa ttc tgc agt act tta acc ttg aac aca
                                                                      288
Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr
gct caa gca aac cac act ggc ttc tac agc tgc aaa tat cta gct gta
                                                                      336
Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val
            100
                                                                      384
cct act tca aag aag aag gaa aca gaa tct gca atc tat ata ttt att
Pro Thr Ser Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile
        115
                            120
                                                                      432
agt gat aca ggt aga cct ttc gta gag atg tac agt gaa atc ccc gaa
Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu
```

130 135 140

att Ile 145	ata Ile	cac His	atg Met	act Thr	gaa Glu 150	gga Gly	agg Arg	gag Glu	ctc Leu	gtc Val 155	att Ile	ccc Pro	tgc Cys	cgg Arg	gtt Val 160		480
acg Thr	tca Ser	cct Pro	aac Asn	atc Ile 165	act Thr	gtt Val	act Thr	tta Leu	aaa Lys 170	aag Lys	ttt Phe	cca Pro	ctt Leu	gac Asp 175	act Thr		528
ttg Leu	atc Ile	cct Pro	gat Asp 180	gga Gly	aaa Lys	cgc Arg	ata Ile	atc Ile 185	tgg Trp	gac Asp	agt Ser	aga Arg	aag Lys 190	ggc Gly	ttc Phe		576
atc Ile	ata Ile	tca Ser 195	aat Asn	gca Ala	acg Thr	tac Tyr	aaa Lys 200	gaa Glu	ata Ile	ggg Gly	ctt Leu	ctg Leu 205	acc Thr	tgt Cys	gaa Glu		624
gca Ala	aca Thr 210	gtc Val	aat Asn	Gly ggg	cat His	ttg Leu 215	tat Tyr	aag Lys	aca Thr	aac Asn	tat Tyr 220	ctc Leu	aca Thr	cat His	cga Arg		672
caa Gln 225	acc Thr	aat Asn	aca Thr	atc Ile	ata Ile 230	gat Asp	gtc Val	caa Gln	ata Ile	agc Ser 235	aca Thr	cca Pro	cgc Arg	cca Pro	gtc Val 240		720
aaa Lys	tta Leu	ctt Leu	aga Arg	ggc Gly 245	cat His	act Thr	ctt Leu	gtc Val	ctc Leu 250	aat Asn	tgt Cys	act Thr	gct Ala	acc Thr 255	act Thr		768
ccc Pro	ttg Leu	aac Asn	acg Thr 260	aga Arg	gtt Val	caa Gln	atg Met	acc Thr 265	tgg Trp	agt Ser	tac Tyr	cct Pro	gat Asp 270	gaa Glu	aaa Lys		816
aat Asn	aag Lys	aac Asn 275	gct Ala	tcc Ser	gta Val	agg Arg	cga Arg 280	cga Arg	att Ile	gac Asp	caa Gln	agc Ser 285	aat Asn	tcc Ser	cat His		864
gcc Ala	aac Asn 290	ata Ile	ttc Phe	tac Tyr	agt Ser	gtt Val 295	ctt Leu	act Thr	att Ile	gac Asp	aaa Lys 300	atg Met	cag Gln	aac Asn	aaa Lys		912
gac Asp 305	aaa Lys	gga Gly	ctt Leu	tat Tyr	act Thr 310	tgt Cys	cgt Arg	gta Val	agg Arg	agt Ser 315	gga Gly	cca Pro	tca Ser	ttc Phe	aaa Lys 320		960
tct Ser	gtt Val	aac Asn	acc Thr	tca Ser 325	gtg Val	cat His	ata Ile	tat Tyr	gat Asp 330	aaa Lys	gca Ala	ggc Gly	ccg Pro	ggc Gly 335	gag Glu	-	1008
ccc Pro	aaa Lys	tct Ser	tgt Cys 340	gac Asp	aaa Lys	act Thr	cac His	aca Thr 345	tgc Cys	cca Pro	ccg Pro	tgc Cys	cca Pro 350	gca Ala	cct Pro		1056
gaa Glu	ctc Leu	ctg Leu 355	Gly	gga Gly	ccg Pro	tca Ser	gtc Val 360	Phe	ctc Leu	ttc Phe	ccc Pro	cca Pro 365	aaa Lys	ccc Pro	aag Lys		1104
gac Asp	acc Thr 370	ctc Leu	atg Met	atc Ile	tcc Ser	cgg Arg 375	acc Thr	cct Pro	gag Glu	gtc Val	aca Thr 380	Суз	gtg Val	gtg Val	gtg Val		1152

gac Asp 385	gtg Val	agc Ser	cac His	gaa Glu	gac Asp 390	cct Pro	gag Glu	gtc Val	aag Lys	ttc Phe 395	aac Asn	tgg Trp	tac Tyr	gtg Val	gac Asp 400	1200
ggc Gly	gtg Val	gag Glu	gtg Val	cat His 405	aat Asn	gcc Ala	aag Lys	aca Thr	aag Lys 410	ccg Pro	cgg Arg	gag Glu	gag Glu	cag Gln 415	tac Tyr	1248
aac Asn	agc Ser	acg Thr	tac Tyr 420	cgt Arg	gtg Val	gtc Val	agc Ser	gtc Val 425	ctc Leu	acc Thr	gtc Val	ctg Leu	cac His 430	cag Gln	gac Asp	1296
tgg Trp	ctg Leu	aat Asn 435	Gly ggc	aag Lys	gag Glu	tac Tyr	aag Lys 440	tgc Cys	aag Lys	gtc Val	tcc Ser	aac Asn 445	aaa Lys	gcc Ala	ctc Leu	1344
cca Pro	gcc Ala 450	ccc Pro	atc Ile	gag Glu	aaa Lys	acc Thr 455	atc Ile	tcc Ser	aaa Lys	gcc Ala	aaa Lys 460	Gly ggg	cag Gln	ccc Pro	cga Arg	1392
gaa Glu 465	cca Pro	cag Gln	gtg Val	tac Tyr	acc Thr 470	ctg Leu	ccc Pro	cca Pro	tcc Ser	cgg Arg 475	gat Asp	gag Glu	ctg Leu	acc Thr	aag Lys 480	1440
aac Asn	cag Gln	gtc Val	agc Ser	ctg Leu 485	acc Thr	tgc Cys	ctg Leu	gtc Val	aaa Lys 490	ggc Gly	ttc Phe	tat Tyr	ccc Pro	agc Ser 495	gac Asp	1488
atc Ile	gcc Ala	gtg Val	gag Glu 500	tgg Trp	gag Glu	agc Ser	aat Asn	ggg Gly 505	cag Gln	ccg Pro	gag Glu	aac Asn	aac Asn 510	tac Tyr	aag Lys	1536
acc Thr	acg Thr	cct Pro 515	ccc Pro	gtg Val	ctg Leu	gac Asp	tcc Ser 520	gac Asp	ggc Gly	tcc Ser	ttc Phe	ttc Phe 525	ctc Leu	tac Tyr	agc Ser	1584
aag Lys	ctc Leu 530	acc Thr	gtg Val	gac Asp	aag Lys	agc Ser 535	agg Arg	tgg Trp	cag Gln	cag Gln	ggg Gly 540	aac Asn	gtc Val	ttc Phe	tca Ser	1632
tgc Cys 545	Ser	gtg Val	atg Met	cat His	gag Glu 550	gct Ala	ctg Leu	cac His	aac Asn	cac His 555	tac Tyr	acg Thr	cag Gln	aag Lys	agc Ser 560	1680
		_		_	ggt Gly											1704

<210> 10

<211> 567

<212> PRT

<213> Homo sapiens

<400> 10

Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val Pro Thr Ser Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys Asn Lys Asn Ala Ser Val Arg Arg Ile Asp Gln Ser Asn Ser His Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys Met Gln Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Gly Pro Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 

	530		Val			535					540					
Cys 545	Ser	Val	Met		Glu 550	Ala	Leu	His	Asn	His 555	Tyr	Thr	Gln	Lys	Ser 560	
	Ser	Leu	Ser	Pro 565	Gly	Lys										
	<2 <2	212>	1453		oiens	i.										
	<2	220> 221> 222>	CDS (69)	(	1442	:)										
aago	ttac	ato	gcag	ago	: tac	: tgg	g gad	c acc	ggg	ggto	ctg	g cto ı Lei	, tga	geg	aattcg g ctg a Leu	60 110
ctc Leu 15	agc Ser	tgt Cys	ctg Leu	ctt Leu	ctc Leu 20	aca Thr	gga Gly	tct Ser	agt Ser	tcc Ser 25	gga Gly	ggt Gly	aga Arg	cct Pro	ttc Phe 30	158
gta Val	gag Glu	atg Met	tac Tyr	agt Ser 35	gaa Glu	atc Ile	ccc Pro	gaa Glu	att Ile 40	ata Ile	cac His	atg Met	act Thr	gaa Glu 45	gga Gly	206
agg Arg	gag Glu	ctc Leu	gtc Val 50	att Ile	ccc Pro	tgc Cys	cgg Arg	gtt Val 55	acg Thr	tca Ser	cct Pro	aac Asn	atc Ile 60	act Thr	gtt Val	254
act Thr	tta Leu	aaa Lys 65	aag Lys	ttt Phe	cca Pro	ctt Leu	gac Asp 70	act Thr	ttg Leu	atc Ile	cct Pro	gat Asp 75	gga Gly	aaa Lys	cgc Arg	302
Ile	atc Ile 80	Trp	gac Asp	Ser	Arg	Lys	Gly	Phe	atc Ile	Ile	Ser	Asn	gca Ala	acg Thr	tac Tyr	350
aaa Lys 95	gaa Glu	ata Ile	Gly	ctt Leu	ctg Leu 100	acc Thr	tgt Cys	gaa Glu	gca Ala	aca Thr 105	gtc Val	aat Asn	Gl ^A aaa	cat His	ttg Leu 110	398
tat Tyr	aag Lys	aca Thr	aac Asn	tat Tyr 115	ctc Leu	aca Thr	cat His	cga Arg	caa Gln 120	Thr	aat Asn	aca Thr	atc Ile	ata Ile 125	gat Asp	446
gtg Val	gtt Val	ctg Leu	agt Ser 130	ccg Pro	tct Ser	cat His	gga Gly	att Ile 135	Glu	cta Leu	tct Ser	gtt Val	gga Gly 140	Glu	aag Lys	494
ctt Leu	gtc Val	tta Leu 145	Asn	tgt Cys	aca Thr	gca Ala	aga Arg 150	Thr	gaa Glu	cta Leu	aat Asn	gtg Val 155	g1y ggg	att Ile	gac Asp	542
ttc Phe	aac Asn 160	Trp	gaa Glu	tac Tyr	cct Pro	tct Ser 165	Ser	aag Lys	cat His	cag Gln	cat His	Lys	aaa Lys	ctt Leu	gta Val	590

	_	gac Asp				_			_						638
_		tta Leu			_		_			-	-			-	686
		gca Ala													734
-		gtc Val 225		-	_		_		_					_	782
		cca Pro													830
		aaa Lys													878
		gtg Val													926
	-	tac Tyr		-	-										974
		gag Glu 305	-			-	_		-		_	-	-		1022
_	-	cac His		_		_			_			-	-		1070
		aaa Lys				_									1118
		cag Gln													1166
		ctg Leu		-		_	_	-	_		_	_			1214
		ccc Pro 385													1262
		aac Asn													1310

		ctc Leu			-				_	_	_			_	_	135	8
		gtc Val			-		_									140	6
	_	cag Gln	_	_			_		_			tga	gegg	ccg		145	2
C																145	3
	<br </td <td>210&gt; 211&gt; 212&gt; 213&gt;</td> <td>458 PRT</td> <td>o sap</td> <td>piens</td> <td>3</td> <td></td>	210> 211> 212> 213>	458 PRT	o sap	piens	3											
	<	400>	12														
Met 1	Val	Ser	Tyr	Trp 5	Asp	Thr	Gly	Val	Leu 10	Leu	Cys	Ala	Leu	Leu 15	Ser		
	Leu	Leu	Leu 20	Thr	Gly	Ser	Ser	Ser 25	Gly	Gly	Arg	Pro	Phe		Glu		
Met	Tyr	Ser 35		Ile	Pro	Glu	Ile 40		His	Met	Thr	Glu 45		Arg	Glu		
Leu	Val 50	Ile	Pro	Сув	Arg	Val 55		Ser	Pro	Asn	Ile 60		Val	Thr	Leu		
Lys 65		Phe	Pro	Leu	Asp 70		Leu	Ile	Pro	Asp 75		Lys	Arg	Ile	Ile 80		
	Asp	Ser	Arg	Lys 85		Phe	Ile	Ile	Ser 90		Ala	Thr	Tyr	Lys 95			
Ile	Gly	Leu	Leu 100		Cys	Glu	Ala	Thr 105		Asn	Gly	His	Leu 110		Lys		
Thr	Asn	Tyr 115		Thr	His	Arg	Gln 120		Asn	Thr	Ile	Ile 125		Val	Val		
Leu	Ser 130	Pro	Ser	His	Gly	Ile 135		Leu	Ser	Val	Gly 140		Lys	Leu	Val		
Leu 145		Сув	Thr	Ala	Arg 150		Glu	Leu	Asn	Val 155		Ile	Asp	Phe	Asn 160		
	Glu	Tyr	Pro			Lys	His	Gln			Lys	Leu	Val				
Asp	Leu	Lys		165 Gln	Ser	Gly	Ser		170 Met	Lys	Lys	Phe		175 Ser	Thr		
Leu	Thr	Ile	180 Asp	Gly	Val	Thr	Arg 200	185 Ser	Asp	Gln	Gly	Leu 205	190 Tyr	Thr	Суз		
Ala	Ala 210	195 Ser	Ser	Gly	Leu	Met 215		Lys	Lys	Asn	Ser 220		Phe	Val	Arg		
Val		Glu	Lvs	Glv	Pro		Asp	īvs	Thr	His		Cvs	Pro	Pro	Cvs		
225		~	~	1	230	1		-1 -		235		-10			240		
Pro	Ala	Pro	Glu	Leu 245	Leu	Gly	Gly	Pro	Ser 250	Val	Phe	Leu	Phe	Pro 255	Pro		
Lys	Pro	Lys	Asp 260	Thr	Leu	Met	Ile	Ser 265	Arg	Thr	Pro	Glu	Val 270	Thr	Cys		
Val	Val	Val 275	Asp	Val	Ser	His	Glu 280	Asp	Pro	Glu	Val	Lys 285	Phe	Asn	Trp		
Tyr	Val 290	Asp	Gly	Val	Glu	Val 295		Asn	Ala	Lys	Thr 300		Pro	Arg	Glu		
Glu 305		Tyr	Asn	Ser	Thr	_	Arg	Val	Val	Ser		Leu	Thr	Val	Leu 320		

305 310 315 320 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn

				325					330					335		
Lys	Ala	Leu	Pro 340	Ala	Pro	Ile	Glu	Lys 345	Thr	Ile	Ser	Lys	Ala 350	Lys	Gly	
Gln	Pro	Arg 355	Glu	Pro	Gln	Val	Tyr 360	Thr	Leu	Pro	Pro	Ser 365	Arg	Asp	Glu	
Leu	Thr 370	Lys	Asn	Gln	Val	Ser 375	Leu	Thr	Cys	Leu	Val 380	Lys	Gly	Phe	Tyr	
Pro 385	Ser	Asp	Ile	Ala	Val 390	Glu	Trp	Glu	Ser	Asn 395	Gly	G1n	Pro	Glu	Asn 400	
	Tyr	Lys	Thr	Thr 405	Pro	Pro	Va1	Leu	Asp 410		Asp	Gly	Ser	Phe 415		
Leu	Tyr	Ser	Lys 420	Leu	Thr	Val	Asp	Lys 425	Ser	Arg	Trp	Gln	Gln 430	Gly	Asn	
Val	Phe	Ser 435	Cys	Ser	Val	Met	His 440	Glu	Ala	Leu	His	Asn 445	His	Tyr	Thr	
Gln	Lys 450	Ser	Leu	Ser	Leu	Ser 455	Pro	Gly	Lys							
		210> 211>		1												
	<2	212>	DNA		piens	5										
		220>														
		221> 222>			(1433	3)										
		100>														<b>C</b> 0
=	rttgg	ggc t	gcag	ggtcg	ga to	gact	cctaq	g ago	gateg	gatc	cccc	igaco	gag d	ctega	attcg	60
_	ccaco														g ctg	110
_	ccaco											ı Lei			g ctg a Leu	110
caac	agc	Met 1 tgt	: Va] ctg	l Sei	r Tyı ctc	Try 5 aca	As <u>r</u> gga	Thi tct	Gly agt	v Val	L Lei 10 gga	Lei ) ggt	ı Cys	s Ala	a Leu ttc	110
caac	agc	Met 1 tgt	: Va] ctg	l Sei	с Туі	Try 5 aca	As <u>r</u> gga	Thi tct	Gly agt	v Val	L Lei 10 gga	Lei ) ggt	ı Cys	s Ala	a Leu ttc	
ctc Leu 15	agc Ser gag	Met 1 tgt Cys atg	ctg Leu tac	ctt Leu	ctc Leu 20 gaa	Try 5 aca Thr	gga Gly ccc	tct Ser gaa	agt Ser	tcc Ser 25	gga Gly cac	ggt Gly atg	aga Arg act	cct Pro gaa	ttc Phe 30 gga	
ctc Leu 15	agc Ser gag	Met 1 tgt Cys atg	ctg Leu tac	ctt Leu	ctc Leu 20	Try 5 aca Thr	gga Gly ccc	tct Ser gaa	agt Ser	tcc Ser 25	gga Gly cac	ggt Gly atg	aga Arg act	cct Pro gaa	ttc Phe 30 gga	158
ctc Leu 15 gta Val	agc Ser gag Glu	Met 1 tgt Cys atg Met	ctg Leu tac Tyr	ctt Leu agt Ser 35	ctc Leu 20 gaa Glu	aca Thr atc Ile	gga Gly ccc Pro	tct Ser gaa Glu	agt Ser att Ile 40	tcc Ser 25 ata Ile	gga Gly cac His	ggt Gly atg Met	aga Arg act Thr	cct Pro gaa Glu 45	ttc Phe 30 gga Gly	158
ctc Leu 15 gta Val	agc Ser gag Glu	Met 1 tgt Cys atg Met	ctg Leu tac Tyr	ctt Leu agt Ser 35	ctc Leu 20 gaa Glu	aca Thr atc Ile	gga Gly ccc Pro	tct Ser gaa Glu	agt Ser att Ile 40	tcc Ser 25 ata Ile	gga Gly cac His	ggt Gly atg Met	aga Arg act Thr	cct Pro gaa Glu 45	ttc Phe 30 gga Gly	158 206
ctc Leu 15 gta Val agg Arg	agc Ser gag Glu gag Glu	Met 1 tgt Cys atg Met ctc Leu aaa	ctg Leu tac Tyr gtc Val 50	ctt Leu agt Ser 35 att Ile	ctc Leu 20 gaa Glu	aca Thr atc Ile tgc Cys ctt	gga Gly ccc Pro cgg Arg	tct Ser gaa Glu gtt Val 55	agt Ser att Ile 40 acg Thr	tcc Ser 25 ata Ile tca Ser	gga Gly cac His cct Pro	ggt Gly atg Met aac Asn	aga Arg act Thr atc Ile 60	cct Pro gaa Glu 45 act Thr	ttc Phe 30 gga Gly gtt Val	158 206
ctc Leu 15 gta Val agg Arg	agc Ser gag Glu gag Glu	Met 1 tgt Cys atg Met ctc Leu aaa	ctg Leu tac Tyr gtc Val 50	ctt Leu agt Ser 35 att Ile	ctc Leu 20 gaa Glu ccc Pro	aca Thr atc Ile tgc Cys ctt	gga Gly ccc Pro cgg Arg	tct Ser gaa Glu gtt Val 55	agt Ser att Ile 40 acg Thr	tcc Ser 25 ata Ile tca Ser	gga Gly cac His cct Pro	ggt Gly atg Met aac Asn	aga Arg act Thr atc Ile 60	cct Pro gaa Glu 45 act Thr	ttc Phe 30 gga Gly gtt Val	158 206 254
ctc Leu 15 gta Val agg Arg act Thr	agc Ser gag Glu gag Glu tta Leu	Met 1 tgt Cys atg Met ctc Leu aaa Lys 65 tgg	ctg Leu tac Tyr gtc Val 50 aag Lys	ctt Leu agt Ser 35 att Ile ttt Phe	ctc Leu 20 gaa Glu ccc Pro	aca Thr atc Ile tgc Cys	gga Gly ccc Pro cgg Arg gac Asp 70	tct Ser gaa Glu gtt Val 55 act Thr	agt Ser att Ile 40 acg Thr ttg Leu	tcc Ser 25 ata Ile tca Ser atc Ile	gga Gly cac His cct Pro	ggt Gly atg Met aac Asn gat Asp 75	aga Arg act Thr atc Ile 60 gga Gly	cct Pro gaa Glu 45 act Thr aaa Lys	ttc Phe 30 gga Gly gtt Val cgc Arg	158 206 254
ctc Leu 15 gta Val agg Arg act Thr	agc Ser gag Glu gag Glu tta Leu	Met 1 tgt Cys atg Met ctc Leu aaa Lys 65 tgg	ctg Leu tac Tyr gtc Val 50 aag Lys	ctt Leu agt Ser 35 att Ile ttt Phe	ctc Leu 20 gaa Glu ccc Pro	aca Thr atc Ile tgc Cys	gga Gly ccc Pro cgg Arg gac Asp 70	tct Ser gaa Glu gtt Val 55 act Thr	agt Ser att Ile 40 acg Thr ttg Leu	tcc Ser 25 ata Ile tca Ser atc Ile	gga Gly cac His cct Pro	ggt Gly atg Met aac Asn gat Asp 75	aga Arg act Thr atc Ile 60 gga Gly	cct Pro gaa Glu 45 act Thr aaa Lys	ttc Phe 30 gga Gly gtt Val cgc Arg	158 206 254 302
ctc Leu 15 gta Val agg Arg act Thr	agc Ser gag Glu gag Glu tta Leu atc Ile 80	Met 1 tgt Cys atg Met ctc Leu aaa Lys 65 tgg Trp	ctg Leu tac Tyr gtc Val 50 aag Lys gac Asp	ctt Leu agt Ser 35 att Ile ttt Phe agt Ser	ctc Leu 20 gaa Glu ccc Pro	aca Thr atc Ile tgc Cys ctt Leu aag Lys 85	gga Gly ccc Pro cgg Arg gac Asp 70 ggc Gly	tct Ser gaa Glu gtt Val 55 act Thr ttc Phe	agt Ser att Ile 40 acg Thr ttg Leu atc	tcc Ser 25 ata Ile tca Ser atc Ile ata Ile	gga Gly cac His cct Pro cct Pro	ggt Gly atg Met aac Asn gat Asp 75 aat	aga Arg act Thr atc Ile 60 gga Gly gca Ala	cct Pro gaa Glu 45 act Thr aaa Lys	ttc Phe 30 gga Gly gtt Val cgc Arg tac Tyr	158 206 254 302
ctc Leu 15 gta Val agg Arg act Thr	agc Ser gag Glu gag Glu tta Leu atc Ile 80	Met 1 tgt Cys atg Met ctc Leu aaa Lys 65 tgg Trp	ctg Leu tac Tyr gtc Val 50 aag Lys gac Asp	ctt Leu agt Ser 35 att Ile ttt Phe agt Ser	ctc Leu 20 gaa Glu ccc Pro cca Pro aga Arg	aca Thr atc Ile tgc Cys ctt Leu aag Lys 85	gga Gly ccc Pro cgg Arg gac Asp 70 ggc Gly	tct Ser gaa Glu gtt Val 55 act Thr ttc Phe	agt Ser att Ile 40 acg Thr ttg Leu atc	tcc Ser 25 ata Ile tca Ser atc Ile ata Ile	gga Gly cac His cct Pro cct Pro	ggt Gly atg Met aac Asn gat Asp 75 aat	aga Arg act Thr atc Ile 60 gga Gly gca Ala	cct Pro gaa Glu 45 act Thr aaa Lys	ttc Phe 30 gga Gly gtt Val cgc Arg tac Tyr	158 206 254 302 350
ctc Leu 15 gta Val agg Arg act Thr ata Ile aaa Lys 95 tat	agc Ser gag Glu gag Glu tta Leu atc Ile 80 gaa Glu aag	Met 1 tgt Cys atg Met ctc Leu aaa Lys 65 tgg Trp ata Ile aca	ctg Leu tac Tyr gtc Val 50 aag Lys gac Asp	ctt Leu agt Ser 35 att Ile ttt Phe agt Ser ctt Leu	ctc Leu 20 gaa Glu ccc Pro cca Pro aga Arg	aca Thr atc Ile tgc Cys ctt Leu aag Lys 85 acc Thr aca	gga Gly ccc Pro cgg Arg gac Asp 70 ggc Gly tgt Cys	tct Ser gaa Glu gtt Val 55 act Thr ttc Phe gaa Glu	agt Ser att Ile 40 acg Thr ttg Leu atc Ile gca Ala	tcc Ser 25 ata Ile tca Ser atc Ile ata Ile aca Thr 105 acc	gga Gly cac His cct Pro cct Pro tca Ser 90 gtc Val	ggt Gly atg Met aac Asn gat Asp 75 aat Asn aat	aga Arg act Thr atc Ile 60 gga Gly gca Ala	cct Pro gaa Glu 45 act Thr aaa Lys acg Thr	ttc Phe 30 gga Gly gtt Val cgc Arg tac Tyr ttg Leu 110 gat	158 206 254 302 350

										-	-	gta Val				4	194
												tca Ser 155					542
	_		-				_	_	_			ggt Gly	_			c.	590
												tcc Ser	-			6	538
					-	_		_	_		-	tat Tyr		_		€	86
-					_					_		gag Glu	-			7	734
	-			_		-					_	cca Pro 235	_	-		7	82
												ttc Phe				8	30
	-	-			_							gtc Val		-	-	8	378
				_		_	_			_		ttc Phe				9	26
				Glu	Val		Asn	Ala	Lys	Thr	Lys	ccg Pro				9	74
												acc Thr 315				10	22
_	-		_			_			-	_	_	gtc Val				10	70
-												gcc Ala			_	11	.18
Pro	Arg	Glu	Pro	Gln 355	Val	Tyr	Thr	Leu	Pro 360	Pro	Ser	cgg Arg	Asp	Glu 365	Leu		.66
acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	CCC	12	14

Thr	Lys	Asn	Gln 370	Val	Ser	Leu	Thr	Cys 375	Leu	Val	Lys	Gly	Phe 380	Tyr	Pro	
														aac Asn		1262
	_		_				_	_		_				ttc Phe		1310
	_	_				_	_	-			-	-		aac Asn	-	1358
		_			-			_	-					acg Thr 445		1406
_	_		tcc Ser 450	_		_			tgag	gegge	ccg o	2				1444
	<2 <2	210> 211> 212> 213>	455	sa <u>r</u>	piens	5										
		£00>														
Met 1	Val	Ser	Tyr	Trp 5	Asp	Thr	Gly	Val	Leu 10	Leu	Cys	Ala	Leu	Leu 15	Ser	
Cys	Leu	Leu	Leu 20	Thr	Gly	Ser	Ser	Ser 25	Gly	Gly	Arg	Pro	Phe 30	Va1	Glu	
Met	Tyr	Ser 35		Ile	Pro	Glu	Ile 40		His	Met	Thr	Glu 45	Gly	Arg	Glu	
Leu			Pro	Cys	Arg	Val 55		Ser	Pro	Asn	Ile 60		Val	Thr	Leu	
_	50 Lys	Phe	Pro	Leu	_		Leu	Ile	Pro	-		Lys	Arg	Ile		
65 Trp	Asp	Ser	Arg		70 Gly	Phe	Ile			75 Asn	Ala	Thr	Tyr	Lys	80 Glu	
Ile	Gly	Leu		85 Thr	Cys	Glu	Ala	Thr	90 Val	Asn	Gly	His		95 Tyr	Lys	
Thr	Asn		100 Leu	Thr	His	Arg		105 Thr	Asn	Thr	Ile		110 Asp	Ile	Gln	
Leu		115 Pro	Arg	Lys	Ser		120 Glu	Leu	Leu	Val		125 Glu	Lys	Leu	Val	
Leu	130 Asn	Cys	Thr	Val	Trp	135 Ala	Glu	Phe	Asn	Ser	140 Gly	Val	Thr	Phe	Asp	
145 Trp	Asp	Tyr	Pro	Gly	150 Lys	Gln	Ala	Glu	Arg	155 Gly	Lys	Trp	Val	Pro	160 Glu	
				165					170					175 Thr		
			180					185					190	Ala		
		195					200					205		His		
	210					215					220					
Asn 225	Gly	Pro	Gly	Asp	Lys 230	Thr	His	Thr	Cys	Pro 235	Pro	Cys	Pro	Ala	Pro 240	
222																
	Leu	Leu	Gly,	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	

					245					250					255		
	Asp	Thr	Leu	Met 260	Ile	Ser	Arg	Thr	Pro 265	Glu	Val	Thr	Cys	Val 270	Val	Val	
	Asp	Val	Ser 275	His	Glu	Asp	Pro	Glu 280	Val	Lys	Phe	Asn	Trp 285	Tyr	Val	Asp	
	Gly	Val 290	Glu	Val	His	Asn	Ala 295	Lys	Thr	Lys	Pro	Arg 300	Glu	Glu	Gln	Tyr	
	Asn 305	Ser	Thr	Tyr	Arg	Val 310	Val	Ser	Val	Leu	Thr 315	Val	Leu	His	Gln	Asp 320	
	Trp	Leu	Asn	Gly	Lys 325	Glu	Tyr	Lys	Сув	Lys 330	Val	Ser	Asn	Lys	Ala 335	Leu	
	Pro	Ala	Pro	Ile 340	Glu	Lys	Thr	Ile	Ser 345	Lys	Ala	Lys	Gly	Gln 350	Pro	Arg	
	Glu	Pro	Gln 355	Val	Tyr	Thr	Leu	Pro 360	Pro	Ser	Arg	Asp	Glu 365	Leu	Thr	Lys	
,	Asn	Gln 370	Val	Ser	Leu	Thr	Cys 375	Leu	Val	Lys	Gly	Phe 380	Tyr	Pro	Ser	Asp	
	Ile 385	Ala	Val	Glu	Trp	Glu 390	Ser	Asn	Gly	Gln	Pro 395	Glu	Asn	Asn	Tyr	Lys 400	
	Thr	Thr	Pro	Pro	Val 405	Leu	Asp	Ser	Asp	Gly 410	Ser	Phe	Phe	Leu	Tyr 415	Ser	
	Lys	Leu	Thr	Val 420	Asp	Lys	Ser	Arg	Trp 425	Gln	Gln	Gly	Asn	Val 430	Phe	Ser	
	Cys	Ser	Val 435	Met	His	Glu	Ala	Leu 440	His	Asn	His	Tyr	Thr 445	Gln	Lys	Ser	
	Leu	Ser 450	Leu	Ser	Pro	Gly	Lys 455										
		<2	210>	15													
			211> 212>	1377 DNA	7												
		<2	213>	Homo	sa <u>r</u>	piens	5										
			220>	CDS													
		<2	222		/ 1	13741											
				(1).	( )	13/4)											
	ato	<4	400>	15				aaa	atc	cta	cta	tac	aca	cta	ctc	agc	48
		<4 gtc	100> agc	15 tac	tgg	gac Asp	acc										48
	Met 1 tgt	<4 gtc Val	100> agc Ser	15 tac Tyr	tgg Trp 5	gac Asp	acc Thr	Gly agt	Val tcc	Leu 10 gga	Leu agt	Cys gat	Ala acc	Leu ggt	Leu 15 aga	Ser	48 96
	Met 1 tgt	<4 gtc Val	100> agc Ser	15 tac Tyr	tgg Trp 5	gac Asp	acc Thr	Gly agt	Val tcc	Leu 10 gga	Leu agt	Cys gat	Ala acc	Leu ggt	Leu 15 aga	Ser	
	Met 1 tgt Cys	<4 gtc Val ctg Leu	100> agc Ser ctt Leu	15 tac Tyr ctc Leu 20	tgg Trp 5 aca Thr	gac Asp gga Gly	acc Thr tct Ser	Gly agt Ser	Val tcc Ser 25	Leu 10 gga Gly gaa	Leu agt Ser att	Cys gat Asp ata	Ala acc Thr	ggt Gly 30 atg	Leu 15 aga Arg	Ser cct Pro	
	Met 1 tgt Cys	<4 gtc Val ctg Leu	100> agc Ser ctt Leu	15 tac Tyr ctc Leu 20	tgg Trp 5 aca Thr	gac Asp gga Gly	acc Thr tct Ser	Gly agt Ser	Val tcc Ser 25	Leu 10 gga Gly gaa	Leu agt Ser att	Cys gat Asp ata	Ala acc Thr	ggt Gly 30 atg	Leu 15 aga Arg	Ser cct Pro	96
	Met 1 tgt Cys ttc Phe	gtc Val ctg Leu gta Val	agc Ser Ctt Leu gag Glu 35	15 tac Tyr ctc Leu 20 atg Met	tgg Trp 5 aca Thr tac Tyr	gac Asp gga Gly	acc Thr tct Ser gaa Glu	agt Ser atc Ile 40	tcc Ser 25 ccc Pro	Leu 10 gga Gly gaa Glu	agt Ser att Ile	Cys gat Asp ata Ile	acc Thr cac His 45	ggt Gly 30 atg Met	Leu 15 aga Arg act Thr	Ser cct Pro gaa Glu act	96
	Met 1 tgt Cys ttc Phe	gtc Val ctg Leu gta Val	agc Ser Ctt Leu gag Glu 35	15 tac Tyr ctc Leu 20 atg Met	tgg Trp 5 aca Thr tac Tyr	gac Asp gga Gly agt Ser	acc Thr tct Ser gaa Glu	agt Ser atc Ile 40	tcc Ser 25 ccc Pro	Leu 10 gga Gly gaa Glu	agt Ser att Ile	Cys gat Asp ata Ile	acc Thr cac His 45	ggt Gly 30 atg Met	Leu 15 aga Arg act Thr	Ser cct Pro gaa Glu act	96 144
	Met 1 tgt Cys ttc Phe gga Gly gtt	gtc Val ctg Leu gta Val agg Arg 50	agc Ser Ctt Leu gag Glu 35 gag Glu	15 tac Tyr ctc Leu 20 atg Met ctc Leu	tgg Trp 5 aca Thr tac Tyr gtc Val	gac Asp gga Gly agt Ser	acc Thr tct Ser gaa Glu ccc Pro 55	agt ser atc ile 40 tgc Cys	tcc Ser 25 ccc Pro cgg Arg	Leu 10 gga Gly gaa Glu gtt Val act	Leu agt Ser att Ile acg Thr	gat Asp ata Ile tca Ser 60 atc	Ala acc Thr cac His 45 cct Pro	ggt Gly 30 atg Met aac Asn	Leu 15 aga Arg act Thr atc Ile	cct Pro gaa Glu act Thr	96 144
	Met 1 tgt Cys ttc Phe gga Gly gtt	gtc Val ctg Leu gta Val agg Arg 50	agc Ser Ctt Leu gag Glu 35 gag Glu	15 tac Tyr ctc Leu 20 atg Met ctc Leu	tgg Trp 5 aca Thr tac Tyr gtc Val	gac Asp gga Gly agt Ser att Ile	acc Thr tct Ser gaa Glu ccc Pro 55	agt ser atc ile 40 tgc Cys	tcc Ser 25 ccc Pro cgg Arg	Leu 10 gga Gly gaa Glu gtt Val act	Leu agt Ser att Ile acg Thr	gat Asp ata Ile tca Ser 60 atc	Ala acc Thr cac His 45 cct Pro	ggt Gly 30 atg Met aac Asn	Leu 15 aga Arg act Thr atc Ile	cct Pro gaa Glu act Thr	96 144 192
	Met 1 tgt Cys ttc Phe gga Gly gtt Val 65 cgc	gtc Val ctg Leu gta Val agg Arg 50 act Thr	l00> agc Ser  ctt Leu  gag Glu 35  gag Glu  tta Leu  atc	15 tac Tyr  ctc Leu 20 atg Met  ctc Leu aaa Lys	tgg Trp 5 aca Thr tac Tyr gtc Val aag Lys	gac Asp gga Gly agt Ser att Ile	acc Thr tct Ser gaa Glu ccc Pro 55 cca Pro	agt ser atc ile 40 tgc Cys	tcc Ser 25 ccc Pro cgg Arg	Leu 10 gga Gly gaa Glu gtt Val act Thr	agt Ser att Ile acg Thr ttg Leu 75	Cys gat Asp ata Ile tca Ser 60 atc Ile ata	Ala acc Thr cac His 45 cct Pro cct	ggt Gly 30 atg Met aac Asn gat Asp	Leu 15 aga Arg act Thr atc Ile gga Gly gca	cct Pro gaa Glu act Thr aaa Lys 80 acg	96 144 192

		-				ctg Leu										336
_		_				ctc Leu			-							384
						tct Ser 135										432
_		-			-	aca Thr	_	-		_						480
-				-		cct Pro		_	_							528
_		_	-			acc Thr	-			_						576
_	_					gat Asp		-			-	-			_	624
		-	-	-		agt Ser 215		_	-					_		672
	_	_				aag Lys	_					_				720
	-				_	Gly ggg		-		_						768
		-	-			atg Met	Ile						-		-	816
		-	-		_	cac His	_	_			-					864
						gtg Val 295										912
_	_			-	_	tac Tyr	_			_	-			-	_	960
				-		ggc Gly	-	_								1008

	_			-	ccc Pro							_		10	56
					cag Gln									11	04
					gtc Val									11	52
					gtg Val 390									12	00
		_		_	cct Pro			_	_		-			12	48
					acc Thr									12	96
-			-		gtg Val	_								13	44
_	_	_			ctg Leu		_			tga				13	77

<210> 16 <211> 458 <212> PRT

<213> Homo sapiens

<400> 16

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser 1 5 10 Cys Leu Leu Thr Gly Ser Ser Ser Gly Ser Asp Thr Gly Arg Pro 25 Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu 40 Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr 50 55 60 Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys 65 70 75 80 Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr 85 90 95 Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His 100 105110 Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile 115 120 125 Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu 135 Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile 150 155 Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu 170 165 175

Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe 185 Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu 195 200 Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr 215 220 Phe Val Arg Val His Glu Lys Asp Lys Thr His Thr Cys Pro Pro Cys 230 235 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 245 250 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 265 270 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 280 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 295 300 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 315 310 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 330 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 345 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 360 365 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 375 380 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 390 395 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 405 410 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 420 425 430 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 435 440 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455

<210> 17

<211> 430

<212> PRT

<213> Homo sapiens

<400> 17

Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His 1.0 Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro 25 Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro 40 Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val 70 75 Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn 85 90 Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser 100 105 Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn 120 125 Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His 135

```
Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met
                   150
                                       155
Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp
                                  170
               165
Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys
           180
                               185
Asn Ser Thr Phe Val Arg Val His Glu Lys Gly Pro Gly Asp Lys Thr
                           200
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
                       215
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
                   230
                                      235
Thr Pro Glu Val Thr Cys Val Val Asp Val Ser His Glu Asp Pro
                                  250
               245
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
                               265
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
                           280
                                               285
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
                       295
                                           300
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
                   310
                                       315
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
               325
                                   330
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
           340
                              345
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
       355
                           360
                                               365
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
                       375
                                           380
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
                   390
                                      395
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
              405
                               410
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Pro Gly Lys
           420
                               425
     <210> 18
      <211> 36
      <212> DNA
      <213> Artificial Sequence
     <220>
     <223> primer
     <400> 18
                                                                      36
gactagcagt ccggaggtag acctttcgta gagatg
      <210> 19
      <211> 33
      <212> DNA
      <213> Artificial Sequence
      <223> primer
      <400> 19
cggactcaga accacatcta tgattgtatt ggt
                                                                      33
     <210> 20
```

<211> 7

<212> P <213> H	RT omo sapiens	
<400> 2 Gly Arg Pro Pi	0 he Val Glu Met 5	
<210> 2 <211> 3 <212> DI <213> A	5	
<220> <223> p:	rimer	
<400> 2 acaatcatag at	1 gtggttet gagteegtet eatgg	35
<210> 2: <211> 3: <212> Di <213> A:	8	
<220> <223> p:	rimer	
<400> 23 gataatgccc ggg	2 gccctttt catggaccct gacaaatg	38
<210> 23 <211> 6 <212> PI <213> Ho		
<400> 23 Val Arg Val H		
<210> 24 <211> 30 <212> DI <213> A	6	
<220> <223> ps	rimer	
<400> 24 gactagcagt ccg	4 ggaggtag acctttcgta gagatg	36
<210> 2! <211> 38 <212> DI <213> A:	8	
<220> <223> p:	rimer	
<400> 29 ttcctgggca aca	5 agctggat atctatgatt gtattggt	38
<210> 26	6	

```
<211> 4
      <212> PRT
      <213> Homo sapiens
      <400> 26
Ile Gln Leu Leu
      <210> 27
      <211> 39
      <212> DNA
      <213> Artificial Sequence
      <220>
      <223> primer
      <400> 27
                                                                         39
atccagctgt tgcccaggaa gtcgctggag ctgctggta
      <210> 28
      <211> 39
      <212> DNA
      <213> Artificial Sequence
      <220>
      <223> primer
      <400> 28
                                                                         39
attttcatgc acaatgacct cggtgctctc ccgaaatcg
      <210> 29
      <211> 38
      <212> DNA
      <213> Artificial Sequence
      <220>
      <223> primer
      <400> 29
tcatagatat ccagctgttg cccaggaagt cgctggag
                                                                         38
      <210> 30
      <211> 39
      <212> DNA
      <213> Artificial Sequence
      <220>
      <223> primer
      <400> 30
                                                                         39
gataatgccc gggccatttt catgcacaat gacctcggt
      <210> 31
      <211> 6
      <212> PRT
      <213> Homo sapiens
      <400> 31
Val Ile Val His Glu Asn
                 5
```

```
<210> 32
      <211> 10
      <212> PRT
      <213> Artificial Sequence
      <220>
      <223> modified Flt1 receptor
      <400> 32
Lys Asn Lys Arg Ala Ser Val Arg Arg Arg
               5
      <210> 33
      <211> 8
      <212> PRT
      <213> Artificial Sequence
      <220>
      <223> modified Flt1 receptor
      <400> 33
Asn Ala Ser Val Asn Gly Ser Arg
      <210> 34
       <211> 10
       <212> PRT
       <213> Artificial Sequence
       <220>
       <223> modified Flt1 receptor
       <400> 34
 Lys Asn Lys Cys Ala Ser Val Arg Arg Arg
                  5
  1
       <210> 35
       <211> 4
       <212> PRT
       <213> Homo sapiens
       <400> 35
 Ser Lys Leu Lys
  1
       <210> 36
       <211> 9
        <212> PRT
        <213> Homo sapiens
        <400> 36
 Lys Asn Lys Arg Ala Ser Val Arg Arg
                   5
        <210> 37
        <211> 4
        <212> PRT
        <213> Homo sapiens
        <400> 37
```

```
Thr Ile Ile Asp

1

<210> 38
<211> 4
<212> PRT
<213> Homo sapiens
<400> 38

Val Val Leu Ser
1
```